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Prostate cancer is the most prevalent type of cancer in men. However, there is no cure 
for relapsed androgen withdrawal-refractory prostate cancer which is fatal due to 
metastasis. Many studies have demonstrated the existence of cancer cells with stem 
cell properties (aka cancer propagating cells (CPCs)) within the cancer cell population. 
CPCs may cause cancer recurrence due to resistence to conventional therapies. 
Understanding molecular and cellular mechanisms governing normal prostate stem 
cells and CPCs may improve our understanding and provide new opportunities for the 
design of therapeutics acting specifically on CPCs. Two of such mechanisms, 
p53/microRNA-34/Met network and neuroendocrine (NE) signaling are the topic of my 
dissertation.  
microRNA-34 (miR-34) family has been proposed to play a tumor suppressor role 
in various cancers, including the prostate cancer. However, direct genetic evidence for 
the tumor suppressor functions of miR-34 under physiologically relevant settings has 
been lacking. By using newly generated mice carrying conditional alleles of mir-34, we 
have shown that miR-34 cooperates with p53 in suppression of prostate carcinogenesis 
by joint control of MET-dependent prostate stem/progenitor cells. Thus, therapeutic 
targeting of MET is likely to affect CPCs, particularly in p53 and miR-34 deficient 
patients. 
NE signaling has been shown to be one of the features in advanced prostate 
cancer. However, the roles of NE cells in prostate carcinogenesis and development are 
insufficiently elucidated. By using bacterial artificial chromosome (BAC) we have 
generated a mouse model for conditional NE cell ablation, and shown that prostate 
epithelium-specific ablation of NE cells results in prostate hypotrophy, suggesting NE 
cells play an important role in prostate development. Moreover, we have studied effects 
of neuropeptide in membrane metallo-endopeptidase (Mme) null mice, and shown that 
Mme cooperates with Pten to suppress prostate carcinogenesis in the control of 
prostate stem/progenitor cells. Gastrin-releasing peptide (GRP), a substrate of MME, 
showed similar effects on mouse prostate stem/progenitor cells and human prostate 
CPCs. These effects were effectively abrogated by GRP receptor (GRPR) antagonist or 
knockdown of GRPR expression. Taken together, these findings show critical role of NE 
signaling in prostate development and carcinogenesis and GRPR is a potential 
therapeutics targeting prostate CPCs. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Prostate Cancer 
 
Prostate cancer is the most frequently diagnosed cancer with an estimated annual 
incidence of 233,000 new cases and is only excelled by lung cancer as a leading cause 
of cancer-related death with an estimated incidence of 29,480 deaths in men for the 
United States in 2014 (Siegel et al., 2014). The clinical progression of prostate cancer is 
correlated with aging (Shen and Abate-Shen, 2010). Early in the course of the disease, 
prostate cancer grows slowly and is sensitive to androgens, proceeding after a long 
period of dormancy, from the normal prostate epithelium to prostatic intraepithelial 
neoplasia (PIN). This is followed by organ-confined prostate cancer and eventually 
metastatic prostate cancer (Abate-Shen and Shen, 2000). The major type of prostate 
cancer is adenocarcinoma. Other types of prostate cancer, such as small cell carcinoma 
and carcinoid tumors, are rare (di Sant'Agnese, 1992; Sun et al., 2009). The 5-year 
relative survival rate for men diagnosed in the United States from 2003 to 2009 with 
local or regional disease was 100%, and the rate for distant disease was 28%; a 99% 
survival rate was observed for all stages combined (American Cancer Society, 2014). 
Prostate cancer, like most other solid malignancies, can metastasize to distant organs, 
such as the liver, lung, brain, and bone with high propensity. Approximately 80% of the 
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men who had died from prostate cancer possessed bone metastases (Bubendorf et al., 
2000; Li and Tang, 2011). 
Generally, early localized disease can be cured by radical prostatectomy and 
radiation therapy with good prognosis (Cooperberg et al., 2005; Li and Tang, 2011). The 
androgen deprivation therapy is most commonly used against advanced disease, such 
as metastatic disease, recurrence after radical prostatectomy or radiotherapy and as 
neoadjuvant therapy. In general, prostate cancer has an initial response rate of 85-90%. 
However, most patients eventually relapse with castration-resistant prostate cancer 
after around 18 to 36 months, which turns into a more aggressive and ultimately fatal 
stage of disease (Cooperberg et al., 2005; Debes and Tindall, 2004; Harris et al., 2009; 
Li and Tang, 2011; Shen and Abate-Shen, 2010). Chemotherapy is another therapeutic 
option for treating castration-resistant prostate cancer. However, chemotherapy seems 
to have no benefit on survival even if it can significantly palliate pain (Buchler and 
Harland, 2007). No treatment has been proved effective on curing progressive hormone 
withdrawal-refractory prostate cancer. Moreover, the underlying mechanisms of prostate 
cancer carcinogenesis, recurrence, and metastasis are not well-understood (Bok and 
Small, 2002; Feldman and Feldman, 2001; Shen and Abate-Shen, 2010; Sun et al., 
2009). 
  
1.2 Stem Cells and Prostate Cancer 
 
1.2.1 Prostate stem cells  
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The prostate epithelium consists of three differentiated cell types: luminal cells, basal 
cells, and a smaller number of NE cells (Abrahamsson, 1999; Isaacs, 2008). The adult 
mouse prostate regresses after castration and the prostate can be regenerated when 
androgen is restored. Such regression/regeneration manipulations can be cycled 
multiple times, suggesting the presence of prostate stem cells resistant to castration 
(English et al., 1987). Accumulating reports since this finding further indicate the 
existence of prostate stem cells. For example, stem cell antigen 1-positive (Sca-1+) 
prostate basal cells are quiescent, are also positive for other stem cell markers, such as 
integrin α6 (CD49f) (Shinohara et al., 1999; Suzuki et al., 2000; Tani et al., 2000) and 
anti-apoptotic factor Bcl-2 (Domen et al., 2000; Potten et al., 1997; Tiberio et al., 2002), 
and are able to reconstitute the prostate gland by an in vivo renal capsule tissue 
regeneration assay, unlike the corresponding Sca-1− cells (Burger et al., 2005; Xin et al., 
2005). Lin−Sca-1+CD49fhi stem/basal cells (LSCs) can form prostate spheres and 
colonies in cell culture as well as reconstitute the prostate gland in vivo (Lawson et al., 
2007). Tumor-associated calcium signal transducer 2 (Trop2) has been shown to be a 
marker to identify a subpopulation of mouse and human prostate basal cells with stem 
cell characteristics. Mouse prostate stem cells can be further enriched by sorting for 
Trop2hiLSC cells (Goldstein et al., 2008). Moreover, CD117 is found to be expressed in 
mouse and human prostate basal cells, and generation of a prostate from a single adult 
mouse Lin−Sca-1+CD133+CD44+CD117+ stem cell has been done after transplantation 
in vivo (Leong et al., 2008). Previous studies indicated that prostate stem cells are 
preferentially localized in the proximal regions of prostatic ducts (Leong et al., 2008; 
Salm et al., 2005; Tsujimura et al., 2002; Wang et al., 2007), and the relative 
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quiescence of the mouse prostate stem cells is likely maintained by a positive reciprocal 
regulatory loop formed from Notch and TGFβ signaling pathways (Salm et al., 2005; 
Valdez et al., 2012). 
Using genetic lineage tracing experiments in mice with different promoters, several 
lines of evidence have indicated that the prostate stem/progenitor cells may also reside 
among the luminal cells. For example, luminal cells expressing Nkx3-1 (castration-
resistant Nkx3-1-expressing cells, CARNs) are bipotential (give rise to both basal and 
luminal cells during regeneration), can self-renew in vivo in a regression/regeneration 
assay, and can reconstitute the intact prostate ducts (basal, luminal, and NE cells) in 
renal grafts by transplantation assay (Wang et al., 2009a). Lineage-restricted unipotent 
prostate progenitor cells have been shown to reside in both basal and luminal cell 
populations by using K14-CreER and K8-CreERT2 transgenic lines, respectively (Choi et 
al., 2012). Furthermore, by using the prostate-specific antigen PSA-CreERT2 mouse 
model prostate stem cells residing in luminal cells can survive, proliferate and 
regenerate in a regression/regeneration assay (Liu et al., 2011b). Last but not least, a 
recent study shows that prostate basal cells are a source of multipotent stem cells that 
can differentiate into all epithelial prostate cells (basal, luminal, and NE cells) as well as 
unipotent basal and luminal progenitors, which together contribute to the prostate 
postnatal development (Ousset et al., 2012; Wang et al., 2013). 
As for the origin of human prostate stem cells, they seem to be localized in basal 
cell populations with expression of integrin α2β1 (Collins et al., 2001), CD133 
(Richardson et al., 2004), breast cancer resistance protein (BCRP/ABCG2) (Huss et al., 
2005), and Trop2 (Goldstein et al., 2008) based on findings so far. 
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1.2.2 Prostate cancer propagating cells 
 
Cancer propagating cells (CPCs, aka cancer stem cells) are a subset of cancer cells 
which are capable of regenerating tumors, and may be involved in metastasis and 
therapy resistance (Clevers, 2011; Magee et al., 2012; Nguyen et al., 2012; Shackleton 
et al., 2009; Valent et al., 2012; Visvader and Lindeman, 2012). Various populations of 
human prostate CPCs have been reported. For example, CD44 expression was also 
shown to identify prostate cancer cells with CPC features. In prostate cancer cell lines 
(DU145) and xenograft models (LAPC9, LAPC4), the CD44+ prostate cancer cells are 
relatively quiescent, more tumorigenic and metastatic than CD44− prostate cancer cells, 
express “stemness” genes, and are capable of undergoing asymmetric cell division. 
(Patrawala et al., 2007; Patrawala et al., 2006). In addition to CD44+ prostate CPCs, 
CD133+ (Miki et al., 2007; Vander Griend et al., 2008), CXCR4+ (Dubrovska et al., 2012; 
Miki et al., 2007), TRA-1-60+/CD151+/ CD166+ (Rajasekhar et al., 2011), PSA−/lo (Qin et 
al., 2012), HLA class I (HLAI) antigen-negative (HLAI-) (Domingo-Domenech et al., 
2012), side population (SP), (Patrawala et al., 2005), and aldehyde dehydrogenase-
positive (ALDH+) (Li et al., 2010b; van den Hoogen et al., 2010) prostate cancer cells 
have been uncovered as potential human prostate CPCs. Several reports point out the 
mechanisms in regulating prostate CPCs. Nanog (Jeter et al., 2009; Jeter et al., 2011), 
Pten/PI3K/ AKT pathway (Dubrovska et al., 2009), NFκB pathway (Rajasekhar et al., 
2011), and miR-34a (Liu et al., 2011a) have been shown to be regulators of human 
prostate CPCs. Moreover, human prostate CPCs lacking differentiation markers 
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(CK18−/ CK19−) and HLA class I (HLAI-) antigens show high activities for the Notch and 
Hedgehog signaling pathways and are resistant to docetaxel treatment (Domingo-
Domenech et al., 2012). 
As for the mouse CPCs, the Sca-1+ prostate cells initiate PIN formation upon 
lentiviral-mediated overexpression of AKT1, suggesting that Sca-1+ cells could be the 
potential CPCs (Xin et al., 2005). Lin−Sca-1+CD49fhi cells show properties of CPCs such 
as high sphere forming and tumorigenic potential in Pten-deficient prostate cancer 
model (Mulholland et al., 2009). Likewise, some potential regulators, such as AKT and 
androgen receptor (AR) (Abou-Kheir et al., 2010), Bmi-1 (Lukacs et al., 2010b), and 
Trop2 (Stoyanova et al., 2012) have been addressed in regulating mouse prostate 
CPCs. 
Finding the prostate CPCs in castration-resistant prostate cancer has drawn 
enormous attention. A previous report indicates that N-cadherin+ cells may be involved 
in castration-resistant prostate cancer development and prostate cancer metastasis 
(Tanaka et al., 2010). Another report shows that PSA−/lo prostate cancer cells are more 
clonogenic in androgen-deficient conditions in cell culture and more tumorigenic in 
castrated mice than the PSA+ prostate cancer cells, suggesting that the PSA−/lo cell 
population could be the prostate CPCs in castration-resistant prostate cancer and might 
become the therapeutic targets for castration-resistant prostate cancer (Qin et al., 2012). 
In addition, it is noteworthy that NE cells are suggested to be a cell origin of 
prostate CPCs (Palapattu et al., 2009; Sotomayor et al., 2009). Expression of CD44 has 
been shown to be positively associated with cells of NE phenotype in human prostate 
cancer cell lines and is selectively displayed in NE tumor cells in vivo (Palapattu et al., 
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2009). Furthermore, Oct4A, a stemness marker, is also expressed by a subpopulation 
of prostate chromogranin A (CgA) or synaptophysin (SYP) positive NE cells (Sotomayor 
et al., 2009). Thus, it is likely that prostate NE cells could transform into the CPCs while 
acquiring epigenetic modifications or genetic mutations. 
 
1.2.3 Cell origin of prostate cancer  
 
The major type of prostate cancer is adenocarcinoma, which is composed 
predominantly of luminal cells and sparsely of basal cells (Abate-Shen and Shen, 2000; 
Shen and Abate-Shen, 2010). Thus, prostate luminal cells are hypothesized to be the 
cell origin of prostate cancer after oncogenic transformation. This hypothesis has been 
supported by studies of lineage tracing in some mouse models. For example, targeted 
deletion of the Pten in CARNs of castrated male mice (Nkx3-1CreERT2/+; Ptenflox/flox) 
results in carcinoma formation after androgen-mediated regeneration (Wang et al., 
2009a). By using luminal cell-specific inducible Cre mice (K8-CreERT2Tg/wt; mTmG Tg/wt) 
and K8-CreERT2Tg/wt;Ptenflox/flox mice, luminal cells are shown to be more responsive to 
Pten null-induced prostate cancer formation. In contrast, basal cells are reluctant to be 
transformed directly upon Pten deleton, as evidenced by basal cell-specific inducible 
Cre mice (K14-CreERTg/Tg;mTmGTg/Tg) and K14-CreERTg/Tg; Ptenflox/flox mice (Choi et al., 
2012). Similar results was observed between Nkx3.1CreERT2/+; Ptenflox/flox; R26R-YFP/+ 
(luminal cells) and CK5-CreERT2; Ptenflox/flox; R26R-YFP/+ (basal cells) mice (Wang et 
al., 2013). Deletion of Pten in luminal cells by PSA-CreERT2 transgenic mice leads to 
prostate cancer, which also supports this notion (Ratnacaram et al., 2008). 
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On the other hand, some studies suggest that basal cells are the cell origin of 
prostate cancer by using tissue recombination/transplantation assay. For example, 
overexpression of AKT and AR in basal cells can lead to prostate cancer, whereas 
luminal cells fail to respond (Lawson et al., 2010). Similarly, co-expression of AKT, ETS-
family transcription factor ERG, and AR in human prostate basal cells (CD49fhiTrop2hi) 
can cause these cells to undergo malignant transformation and initiate prostate cancer 
in immunodeficient mice, but co-expression of these genes in human luminal cells 
(CD49floTrop2hi) cannot (Goldstein et al., 2010). It is worth noting that the tissue 
recombination/transplantation assay does not exactly reflect physiological conditions. 
Therefore, whether functions of prostate stem cells or CPCs by using this method are 
obligate or facultative is still controversial.   
 
1.3 p53/miR-34 Network 
 
1.3.1 miR-34 in cancers 
 
MicroRNAs (miRNAs) are about 20 to 24 nucleotides and are a non-coding subset of 
RNAs which control gene expression post-transcriptionally. In general, miRNAs bind to 
the 3’ untranslated regions (UTRs) of messenger RNAs (mRNAs) and recruit the RNA-
induced silencing complex (RISC), which causes the inhibition of translation and the 
degradation of the targeted mRNA (Hermeking, 2012; Winter et al., 2009). After the 
discovery of first and second miRNAs: lin-4 (Lee et al., 1993; Wightman et al., 1993) 
and let-7 (Reinhart et al., 2000), in Caenorhabditis elegans, significant advances and 
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explosive discovery of new miRNAs have been made in the past decade. Of which, 
miR-34 draws extensive attention because it is directly trans-activated by tumor 
suppressor p53 (Bommer et al., 2007; Chang et al., 2007; Corney et al., 2007; He et al., 
2007; Raver-Shapira et al., 2007; Tarasov et al., 2007) and is considered to be an 
important component of the p53 network, being a surrogate of p53 in processes such as 
cell proliferation, survival, and senescence (Hermeking, 2010, 2012). 
miR-34 comprises three family members: miR-34a (human: chr. 1, mouse: chr. 4), 
miR-34b (human: chr. 11, mouse: chr. 9), and miR-34c (human: chr. 11, mouse: chr. 9). 
miR-34a is encoded by its own transcript, whereas miR-34b and miR-34c come from a 
polycistronic transcript. Due to the high homology of the sequence, the miR-34 family 
may control an overlapping set of target genes and be functionally redundant (He et al., 
2007). In human tissues, detectable levels of miR-34a are detected in the majority of 
organs, while, miR-34b/c expression levels are generally low except in lung, ovary, 
testes, and trachea (Hsu et al., 2008). In mouse tissues, miR-34a is detectable, albeit at 
lower levels, also in a variety of organs, whereas, miR-34b and miR-34c expression 
seems largely restricted to testis, brain, and lung (Concepcion et al., 2012). 
mir-34a and mir-34b/c are located in the genomic sites that are frequently deleted 
in cancers (Calin et al., 2004; Cole et al., 2008). In addition, epigenetic modification 
such as hypermethylation in the promoter region of mir-34 family often occurs in 
cancers (Lodygin et al., 2008; Lujambio et al., 2008; Vogt et al., 2011). Loss or down-
regulation of miR-34 family in cancers suggests that miR-34 family is a potential tumor 
suppressor, such as in lung cancer (Bommer et al., 2007; Gallardo et al., 2009; Lodygin 
et al., 2008; Mudduluru et al., 2011; Wang et al., 2011; Wiggins et al., 2010), prostate 
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cancer (Fujita et al., 2008; Lodygin et al., 2008; Sethi et al., 2013), ovarian cancer 
(Corney et al., 2010; Kuo et al., 2009; Vogt et al., 2011), brain cancer (Cole et al., 2008; 
Feinberg-Gorenshtein et al., 2009; Li et al., 2009b; Wei et al., 2008; Welch et al., 2007; 
Yin et al., 2013), breast cancer (Lodygin et al., 2008; Mackiewicz et al., 2011; 
Mudduluru et al., 2011; Vogt et al., 2011), pancreas cancer (Chang et al., 2007; Lodygin 
et al., 2008; Vogt et al., 2011), colon cancer (Lodygin et al., 2008; Mudduluru et al., 
2011; Roy et al., 2012; Tazawa et al., 2007; Toyota et al., 2008; Vogt et al., 2011), 
kidney cancer (Lodygin et al., 2008; Vogt et al., 2011), liver cancer (Li et al., 2009a; 
Tryndyak et al., 2009), bladder cancer (Lodygin et al., 2008), gastric cancer (Suzuki et 
al., 2010), pleural mesothelioma (Kubo et al., 2011), skin cancer (Lodygin et al., 2008), 
esophagus cancer (Chen et al., 2012), cervical cancer (Li et al., 2010a; Wang et al., 
2009b), and leukemia and lymphoma (Chim et al., 2010; Mraz et al., 2009). 
 
1.3.2 Tumor suppressor function of miR-34 
 
Ectopic expression of miR-34 has been shown to inhibit different aspects of cancer-
associated traits in various cancer cell types by regulating target genes, such as cell 
growth, metastasis, and cancer cell stemness (Hermeking, 2010, 2012; Siemens et al., 
2013). 
Ectopic expression of miR-34 may inhibit cell proliferation by leading to G1/G2 
arrest, the decrease of cell doubling rates, and BrdU incorporation (Corney et al., 2007; 
He et al., 2007; Lodygin et al., 2008; Wiggins et al., 2010) and induce senescence 
(Christoffersen et al., 2010; He et al., 2007; Lodygin et al., 2008; Maes et al., 2009; 
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Tazawa et al., 2007) in cancer cells via repressing downstream targets, such as cyclin 
D1 (Sun et al., 2008), cyclin E2 (He et al., 2007), cyclin-dependent kinases 4 (He et al., 
2007) and 6 (Sun et al., 2008), as well as mitogen-activated protein kinase kinase 1 
(MEK1) (Ichimura et al., 2010), R-Ras (RRAS) (Kaller et al., 2011), platelet-derived 
growth factor receptor (PDGFRA) (Silber et al., 2012), hepatocyte growth factor 
receptor (MET) (Corney et al., 2010; He et al., 2007; Hwang et al., 2011), and MYC 
(Christoffersen et al., 2010). In addition, miR-34a has the pro-apoptotic function to 
repress BCL2 (Bommer et al., 2007; Cole et al., 2008) and survivin (Chen et al., 2010; 
Shen et al., 2012). Moreover, miR-34a can promote apoptosis by stimulating p53 
activity in a positive feedback-loop by targeting SIRT1 (silent information regulator 1), a 
NAD-dependent deacetylase that deactivates p53 (Yamakuchi et al., 2008), and YY1 
(Yin Yang 1), a transcriptional factor which interacts with p53 to promote p53 
ubiquitination and degradation (Chen et al., 2011; Sui et al., 2004). Collectively, miR-34 
is able to inhibit cell proliferation and induce apoptosis and senescence in cancer cells. 
miR-34 downregulates the metastasis-associated genes, such as MET (Corney et 
al., 2010; He et al., 2007; Hwang et al., 2011), AXL (Kaller et al., 2011; Mudduluru et al., 
2011), MTA2 (Kaller et al., 2011), and Notch1 (Du et al., 2012). Furthermore, miR-34 
has been shown to regulate Wnt signaling pathway which is involved in metastasis 
(Malanchi et al., 2012; Nguyen et al., 2009; Oskarsson et al., 2011; Yook et al., 2005; 
Yook et al., 2006). miR-34 directly represses WNT1 and WNT3, as well as LRP6, a co-
receptor of Frizzled that binds to Wnt ligands. miR-34 also represses downstream 
transcriptional mediators of Wnt signaling pathway, LEF1 and beta-catenin. Accordingly, 
miR-34 decreases Wnt-dependent, tissue-invasive activity of colorectal cancer cells 
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(Kim et al., 2011). 
Another function ascribed to miR-34 is to regulate CPCs. miR-34a levels are lower 
in CD44-expressing prostate CPCs purified from xenograft and primary tumors. Ectopic 
expression of miR-34a in bulk or purified CD44+ prostate cancer cells inhibited their 
abilities of clonogenic expansion, tumor regeneration, and metastasis in vivo (Liu et al., 
2011a). miR-34 is suggested to be involved in suppressing pancreatic CPC self-renewal, 
potentially via the direct modulation of downstream targets Bcl-2 and Notch (Ji et al., 
2009). miR-34a is also suggested to impair propagation properties of CD15+/CD133+ 
CPCs via targeting Notch ligand delta-like 1 and supports neural differentiation in 
medulloblastoma (de Antonellis et al., 2011). Moreover, Notch 1-targeting miR-34a is a 
cell-fate determinant of colon CPCs, helping to determine between self-renewal and 
differentiation (Bu et al., 2013). It is also worth noting that miR-34 may prevent induced 
pluripotent stem (iPS) cell reprogramming by directly inhibiting pluripotency genes, 
including NANOG, SOX2, and MYCN (Choi et al., 2011). 
The tumor suppressor function of miR-34 was also tested in various animal models 
of cancer, such as xenografts of melanoma (Chen et al., 2010), non-small lung cancer 
(Trang et al., 2011; Wiggins et al., 2010), prostate cancer (Liu et al., 2011a), pancreatic 
cancer (Pramanik et al., 2011), and lymphoma (Craig et al., 2012). miR-34 leads to a 
significant reduction in cell proliferation and an increase in apoptosis for inhibiting the 
tumor burden, or enhances survival or substantial decrease in metastasis in mice. Thus, 
miR-34 has its therapeutic potential based on the studies above, and recently has 
become the first miRNA mimic to reach the clinic (Bouchie, 2013). 
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1.3.3 Function of miR-34 in vivo  
 
The biological activities of miR-34 identified in cell cultures and animal models of cancer 
suggest that miR-34 is a promising tumor suppressor. However, contrary to 
expectations, no carcinogenesis except some minor developmental defects has been 
reported in studies of mice with targeted inactivating mutations of mir-34 (Agostini et al., 
2011; Boon et al., 2013; Concepcion et al., 2012; Wei et al., 2012). Such defects 
included reduction of proliferating cells in the dentate gyrus of the brain (Agostini et al., 
2011), and mitigation of age-associated decline in cardiac function (Boon et al., 2013) in 
mir-34a-/- mice. Mice with osteoblast-specific inactivation of mir-34b/c have increase in 
osteoblast proliferation and differentiation (Wei et al., 2012). Furthermore, mice lacking 
all three mir-34 genes have slight increase in the proliferation rate of early passage 
embryonic fibroblasts (Concepcion et al., 2012), but did not show impairment of the p53 
response in a variety of ex vivo and in vivo assays (Concepcion et al., 2012). Most 
surprisingly, no increase in spontaneous or irradiation-induced carcinogenesis has been 
observed in mice lacking all mir-34 genes by 18 month of age (Concepcion et al., 2012). 
Absence of all mir-34 genes also did not facilitate B-cell lymphomagenesis in mice 
overexpressing c-Myc under the control of Eμ-promoter (Concepcion et al., 2012). 
Taken together, these observations are contradictory with previous reports showing 
tumor suppressive function of miR-34 based on experiments performed in settings that 
were not physiologically relevant. Consequently, dissecting the precise role of miR-34 in 
carcinogenesis in vivo is critical and essential for clinical therapeutics. 
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1.3.4 p53-independent regulation of miR-34  
 
Although the canonical signaling pathway of miR-34 activation is p53-dependent 
(Bommer et al., 2007; Chang et al., 2007; Corney et al., 2007; He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007), emerging evidence suggests that p53 is not 
an exclusive regulator for miR-34 activation. For example, miR-34a can be up-regulated 
to repress MYC during oncogene-induced senescence in human TIG3 fibroblasts 
(Christoffersen et al., 2010) and contributes to megakaryocytic differentiation of K562 
cells (Navarro et al., 2009) in a p53-independent fashion. miR-34a repression 
upregulates expression of its target PDGFRA in proneural malignant gliomas, which is 
likely p53-independent (Silber et al., 2012). Within the samples of human glioblastoma, 
miR-34a levels are lower in mutant p53 tumors than in wild-type p53 tumors but the 
difference in miR-34a levels was smaller than the one measured between tumors and 
normal human brain. This also suggests that p53 mutations do not completely account 
for the decrease in miR-34a expression (Li et al., 2009b). SNAIL, ZEB1 (Siemens et al., 
2011), and FoxO3a (Kress et al., 2011) might bypass p53 to regulate miR-34. It also 
suggests that p21 can be induced indirectly by miR-34 through repression of histone 
deacetylase 1 (HDAC1), irrespective of p53 status (Zhao et al., 2013). In wild-type p53 
breast cancer samples, neither hypermethylation of the miR-34a promoter nor genetic 
variations of the p53-binding site were detected with downregulated miR-34a, providing 
evidence that miR-34a expression could be affected independent of p53 (Javeri et al., 
2013). 
Epigenetically, hypermethylation of miR-34 occurs in various cancers with p53-
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deficient status (Corney et al., 2010; Lodygin et al., 2008; Lujambio et al., 2008; Vogt et 
al., 2011). For example, p53-null PC3 (Scott et al., 2003) and p53-mutated LAPC-4 
(Klein et al., 1997) human prostate cancer cells both show downregulation of miR-34 by 
methylation (Fujita et al., 2008; Lodygin et al., 2008). These results suggest that 
existence of p53-independent regulation on tumor suppressive functions of miR-34. 
However, the evidence showing existence of p53-independent regulation of miR-34 in 
vivo has been lacking. 
 
1.4 Prostate Neuroendocrine Regulation 
 
1.4.1 Prostate neuroendocrine cells  
 
Neuroendocrine (NE) cells are so named due to their dual endocrine and neural 
properties, acting in the autocrine/paracrine fashions. NE cells are scattered sparsely 
throughout the prostate epithelium. Although very little is known about the presence of 
NE cells in the developing prostate, recent studies have indicated that NE cells originate 
from the prostate epithelium stem/progenitor cells (Cheng et al., 2010; Huss et al., 
2004a; Kurita et al., 2004; Leong et al., 2008; Liao et al., 2007; Litvinov et al., 2006; 
Nikitin et al., 2007; Ousset et al., 2012; Wang et al., 2009a; Wang et al., 2001; Wang et 
al., 2013; Zhou et al., 2007). An entire prostate gland with NE cells can be generated 
from prostate basal epithelium stem cells (Leong et al., 2008; Ousset et al., 2012; Wang 
et al., 2013) or luminal epithelium stem cells (Wang et al., 2009a). Other evidence, 
however, suggests that NE cells are of neurogenic origin (Aumuller et al., 1999). NE 
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cells were present in the surrounding mesenchyme and paraganglia, but not in UGS 
epithelium of 10-week-old human embryos. Proceeding to week 12, chromogranin A-
positive cells (marker for NE cells) were present within the epithelial buds that ultimately 
develop into prostate glandular components. This suggests that NE cells are of 
neurogenic origin instead of prostate epithelium stem cells. However, this evidence 
could be circumstantial because the data were not based on lineage tracing 
experiments.  
Prostatic NE cells contain dense-core cytoplasmic granules that store peptide 
hormones and pro-hormones. These granules contain either a single product or a mix of 
different products such as chromogranin A (CgA), neuron specific enolase (NSE), 
serotonin, neuropeptide Y, calcitonin gene family (calcitonin, katacalcin, and calcitonin 
gene-related peptide, CGRP), bombesin, gastrin-releasing peptide, somatostatin, 
vasoactive intestinal peptide, endothelin-1, human chorionic gonadotropin, thyroid-
stimulating hormone, parathyroid hormone-related protein, neurotensin, and a number 
of other neuropeptides and proteins (Abrahamsson, 1999; Sun et al., 2009). Common 
markers for NE cells include CgA (Gazdar et al., 1988), NSE (Schmechel et al., 1978), 
neural cell adhesion molecules (NCAMs, so-called CD56) (Jin et al., 1991), CGRP 
(Cadieux et al., 1986), and SYP (Wiedenmann et al., 1986). NE cells do not proliferate 
(Ki67-), and do not express p63 protein or PSA (Vashchenko and Abrahamsson, 2005) 
and lack AR expression (Krijnen et al., 1993), indicating that NE cells are androgen 
insensitive (Bang et al., 1994). Neuropeptides secreted by NE cells, acting as autocrine 
and paracrine growth factors, are suggested to be involved in facilitating the 
development and secretion of the prostate since receptors for some of the NE products 
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have been found to be expressed in the normal prostate (Abrahamsson, 1999; 
Vashchenko and Abrahamsson, 2005). However, the physiological role of prostatic NE 
cells is still not well understood. 
 
1.4.2 Neuroendocrine cell differentiation in prostate cancer  
 
NE cell differentiation is one of the features in prostate carcinogenesis (Bonkhoff and 
Berges, 2010; Debes and Tindall, 2004; Hansson and Abrahamsson, 2001, 2003; Sun 
et al., 2009). It is often identified by scattered clusters of differentiated NE cells among a 
predominant population of adenocarinoma, except for infrequent cases of small cell 
carcinoma or carcinoid (Komiya et al., 2009). NE cell differentiation and neuropeptides 
released by NE cells were suggested to be positively correlated with tumor progression, 
Gleason score, androgen deprivation therapy failure, and poor prognosis (Berruti et al., 
2005; Grobholz et al., 2005; Kamiya et al., 2008; McWilliam et al., 1997; Sun et al., 
2009; Taplin et al., 2005; Vashchenko and Abrahamsson, 2005). 
Androgen ablation therapy is the main option for treating metastatic prostate cancer; 
however, patients who received a longer course of androgen ablation therapy have 
been found to have higher levels of NE cell differentiation (Hirano et al., 2004; Ismail et 
al., 2002; Ito et al., 2001). In addition to clinical specimens, androgen withdrawal-
induced NE cell differentiation is also seen in prostate cancer cell culture and in vivo 
animal model studies. LNCaP cells (androgen dependent) without NE cell differentiation 
are able to be trans-differentiated into an NE-like phenotype in response to androgen 
deprivation and begin to express the NE cell markers (Shen et al., 1997; Yuan et al., 
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2006; Zelivianski et al., 2001). The NE trans-differentiation induced by androgen 
deprivation can be reversed by the addition of dihydrotestosterone (DHT) and then can 
be restored by Casodex, an androgen antagonist. Moreover, androgen receptor (AR) 
knockdown in LNCaP cells also induces NE trans-differentiation (Wright et al., 2003). 
Collectively, it suggests that androgen-activated AR signaling suppresses NE 
differentiation. Similarly, in animal models, castration promotes NE differentiation of 
xenograft tumors formed by androgen dependent PC-295, PC-310 (Jongsma et al., 
1999, 2000), LNCaP (Burchardt et al., 1999), or CWR22 cells (Huss et al., 2004b) cell 
lines. Taken together, cell culture, in vivo studies, as well as clinical observations, 
suggest that androgen ablation may enhance NE cell differentiation of prostate 
adenocarcinoma. 
Several reports show that increased intracellular 3'-5'-cyclic adenosine 
monophosphate (cAMP) leads to NE cell differentiation of prostate cancer cells. 
Elevation of cAMP, by cAMP analogs and phosphodiesterase (which degrades cAMP 
by breaking the phosphodiester bond) inhibitors (Bang et al., 1994), forskolin (adenylate 
cyclase activator), or epinephrine (β-adrenergic receptor agonist) (Cox et al., 1999), 
induces NE cell differentiation of prostate cancer cells and NE cell differentiation of 
prostate cancer cells are reversible after removal of cAMP-elevating agents (Cox et al., 
1999). 
Interleukin-6 (IL-6) has been suggested to be positively correlated with prostate 
cancer progression (Adler et al., 1999; Drachenberg et al., 1999; Shariat et al., 2001). 
IL-6 is also able to induce NE cell differentiation of LNCaP cells (Deeble et al., 2001; 
Qiu et al., 1998; Wang et al., 2004). Moreover, elevated expression of gp130, the signal 
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transduction subunit of the IL-6 receptor, induces NE cell differentiation in LNCaP cells, 
also suggesting IL-6-induced NE cell differentiation of prostate cancer cells (Palmer et 
al., 2005). In addition to IL-6, other cytokines, such as IL-1β, are suggested to play a 
role in NE cell differentiation of prostate cancer (Chiao et al., 1999; Diaz et al., 1998). 
NE cell differentiation of prostate cancer cells is suggested to be mediated by 
multiple signaling pathways in addition to the factors mentioned above. For example, 
heparin-binding epidermal growth factor (HB-EGF), an epidermal growth factor receptor 
(EGFR) ligand, can also promote NE cell differentiation (Adam et al., 2002; Humez et al., 
2006; Kim et al., 2002). Vasoactive intestinal peptide (VIP) is a neuropeptide and can 
also promote NE cell differentiation of LNCaP cells (Gutierrez-Canas et al., 2005; 
Juarranz et al., 2001). Moreover, calcium chelator BAPTA/AM inhibits VIP-induced NE 
phenotype in LNCaP cells, whereas increased expression of calcium channel proteins 
promotes NE cell differentiation, suggesting an association between intracellular 
calcium level and NE cell differentiation of prostate cancer cells (Collado et al., 2005; 
Mariot et al., 2002; Vanoverberghe et al., 2004).  
Although the roles of NE cells and their secreted neuropeptides in prostate cancer 
have been extensively studied in various cancer cell lines, mouse models of cancer, 
and human biopsies, the precise function and the mechanism of NE differentiation in 
prostate carcinogenesis in vivo are insufficiently elucidated so far. 
 
1.4.3 The role of membrane metallo-endopeptidase in neuropeptide processing 
and prostate cancer 
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Membrane metallo-endopeptidase (MME), also known as CD10, neutral endopeptidase, 
enkephalinase, neprilysin, or common acute lymphoblastic leukemia antigen (CALLA), 
is a zinc-dependent cell surface peptidase which may metabolize neuropeptides 
(Roques et al., 1993; Turner and Tanzawa, 1997). MME cleaves peptide bonds on the 
amino side of hydrophobic amino acids and inactivates a variety of physiologically 
active neuropeptides, including neuropeptide Y, atrial natriuretic factor, substance P, 
bradykinin, oxytocin, Leu- and Met-enkephalins, cholecystokinin, vasoactive intestinal 
peptide, neurotensin, bombesin, endothelin-1, and gastrin-releasing peptide (Erdos and 
Skidgel, 1989; Medeiros Mdos and Turner, 1996; Shipp and Look, 1993; Sumitomo et 
al., 2005; Turner and Tanzawa, 1997).  
Association of MME with various cancers has been observed (Maguer-Satta et al., 
2011; Sumitomo et al., 2005), including prostate cancer. MME expression is lost or 
altered in over 50% of primary and metastatic prostate cancers, independently 
predicting a poor prognosis (Freedland et al., 2003; Osman et al., 2004; Papandreou et 
al., 1998). Therefore, it has been suggested that the loss or decrease in MME 
expression may promote peptide-mediated proliferation by allowing an accumulation of 
neuropeptides at the cell surface and facilitate neoplastic transformation or progression.  
The tumor suppressive functions of MME have been extensively tested in various 
cell culture and ex vivo studies. The effects of MME on cell growth, cell motility, and cell 
survival are mediated through two major mechanisms: catalytic-dependent and 
catalytic-independent MME functions. The catalytic-dependent inactivation of MME 
substrates, such as neuropeptides which stimulate prostate cancer migration and 
invasion by bombesin-stimulated RhoA signaling (Zheng et al., 2006), and fibroblast 
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growth factor 2 which results in endothelial cell growth and angiogenesis by inducing 
Akt signaling (Goodman et al., 2006), has been reported. Catalytic-independent 
processes act via protein-protein interaction of MME’s cytoplasmic domain with other 
important cellular proteins. For example, MME associates with p85, a PI3K subunit, and 
Lyn kinase indirectly via glycosylphosphatidylinositol (GPI)-microdomains to prevent 
focal adhesion kinase (FAK) activation by PI3K and thereby decrease cell motility 
(Ganju et al., 1996; Sumitomo et al., 2005; Sumitomo et al., 2000). Moreover, MME 
competes with CD44 and decreases its binding to ezrin/radixin/moesin (ERM) proteins, 
resulting in increased cell adhesion and decreased migration (Iwase et al., 2004). MME 
also recruits and interacts directly with endogenous Pten at the cell membrane, leading 
to prolonged Pten protein stability and increased Pten phosphatase activity, resulting in 
downregulation of Akt activity (Sumitomo et al., 2004). However, cooperative functions 
of MME and PTEN in prostate cancer suppression in vivo have not been studied.  
Furthermore, the lentiviral and adenoviral delivery of MME has been shown to 
inhibit prostate cancer tumorigenicity in a xenograft model of human prostate cancer 
(Horiguchi et al., 2007; Iida et al., 2012). However, MME conventional knockout mice 
generated by Dr. Gerard’s group show no cancer-related phenotype (Lu et al., 1995), 
indicating MME deficiency is insufficient to induce cancer formation in vivo, which is 
contradictory with previous reports showing tumor suppressive function of MME. 
Consequently, dissecting the precise role of MME in carcinogenesis in vivo is critical 
and essential for clinical therapeutics. 
 
1.5 Concluding Remarks and Project Overview 
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miR-34 has been proposed to act as a tumor suppressor in various cell culture 
experiments and mouse models of cancer, which led to miR-34 becoming the first 
miRNA mimic to reach the clinic. However, no tumor phenotype was found in mouse 
models with conventional and conditional inactivation of mir-34. These findings placed 
the tumor suppressor function of miR-34 under suspicion, because previous finding of 
its functions were based on experiments performed in not physiologically relevant 
settings. Therefore, exploring the precise role of miR-34 in carcinogenesis will be vital to 
clinical therapy. In chapter 2, by using newly generated mice carrying conditional alleles 
of mir-34a and mir-34b/c, we have shown that miR-34 may cooperate with p53 in 
suppression of prostate carcinogenesis in addition to canonical activation of miR-34 by 
p53. Furthermore, we have shown that miR-34 and p53 jointly regulate MET-dependent 
growth, self-renewal, motility, and invasion of prostate epithelium stem cells, alterations 
of which may lead to cancer.  
To address the role of NE signaling in prostate development, in Chapter 3, we 
identified upstream promoter regions sufficient for accurate expression of SYP, a 
marker of NE cells. By using this region, we generated Tg(Syp-EGFPloxP-DTA)147Ayn 
(SypELDTA) transgenic mice suitable for flexible organ-specific ablation of NE cells. By 
crossing this line with the PB-Cre4 mouse line, which allows prostate epithelium-specific 
Cre-loxP mediated recombination, we showed a substantial decrease in the number of 
NE cells and associated prostate hypotrophy, suggesting that NE cells play an 
important role in prostate development. In Chapter 4, by using newly generated mice 
with prostate epithelium-specific inactivation of Pten and Mme null, we have shown that 
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unprocessed neuropeptides may enhance Pten-deficient prostate carcinogenesis by 
increase of stem cell activities, such as stem cell pool expansion, growth, and self-
renewal. We also showed that these effects can be recapitulated by GRP, a major 
substrate of MME, in mouse prostate stem cells and human prostate CPCs. Our results 
demonstrate that MME suppresses prostate cancer by controlling GRP-dependent 
prostate stem/progenitor cells, and suggest that GRPR antagonists may be an effective 
therapeutics targeting prostate CPCs.  
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2.1 Abstract 
 
The miR-34 family was originally found to be a direct target of p53 and is a group of 
putative tumor suppressors. Surprisingly, mice lacking all mir-34 genes show no 
increase in cancer formation by 18 months of age, hence placing the physiological 
relevance of previous studies in doubt. Here, we report that mice with prostate 
epithelium-specific inactivation of mir-34 and p53 show expansion of the prostate stem 
cell compartment and develop early invasive adenocarcinomas and high-grade prostatic 
intraepithelial neoplasia, whereas no such lesions are observed after inactivation of 
either the mir-34 or p53 genes alone by 15 months of age. Consistently, combined 
deficiency of p53 and miR-34 leads to acceleration of MET-dependent growth, self-
renewal, and motility of prostate stem/progenitor cells. Our study provides direct genetic 
evidence that mir-34 genes are bona fide tumor suppressors and identifies joint control 
of MET expression by p53 and miR-34 as a key component of prostate stem cell 
compartment regulation, aberrations in which may lead to cancer. 
 
2.2 Introduction 
 
The microRNA-34 (miR-34) is highly evolutionary conserved (Corney et al., 2007; He et 
al., 2007). In mammals, the miR-34 family is composed of three processed miRNAs that 
are encoded by two different genes: miR-34a is encoded by its own transcript, whereas 
miR-34b and miR-34c share a common primary transcript as a cluster. Due to the high 
homology among these three members, they have many similar targets and may be 
functionally redundant (He et al., 2007). miR-34 was the first miRNA reported to be 
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directly transactivated by tumor suppressor p53 (a.k.a Trp53/TP53), and is considered 
to be an important component of the p53 network (Hermeking, 2012).  
 In addition to transactivation-dependent decrease in expression levels in p53 
deficient tumors, mir-34 is also deleted or epigenetically down-regulated in multiple 
cancer cell lines and human malignancies (Bader, 2012; Hermeking, 2012). Ectopic 
expression of miR-34 has been shown to counteract various oncogenic processes by 
regulating target genes that function in cell cycle, apoptosis, senescence, cell migration, 
and invasion (Hermeking, 2012). Furthermore, treatment with miR-34 mimics inhibits 
cancer formation in transplantation experiments (Bader, 2012; Liu et al., 2011a).  
 Contrary to the expectations raised from experiments based on nonphysiological 
approaches, such as exogenous miR-34 introduction and miR-34 knockdown, only 
minor defects have been reported in studies of mice with targeted inactivating mutations 
of mir-34 (Concepcion et al., 2012; Park et al., 2002; Wei et al., 2012). Moreover, 
complete genetic inactivation of miR-34 did not impair the p53 response in a variety of 
ex vivo and in vivo assays (Concepcion et al., 2012). Most surprisingly, no increase in 
spontaneous or irradiation-induced carcinogenesis has been observed in mice lacking 
all mir-34 genes by 18 month of age (Concepcion et al., 2012). The absence of all mir-
34 genes also did not accelerate B-cell lymphomagenesis in mice overexpressing c-Myc 
under the control of Eμ promoter (Concepcion et al., 2012). These data question the 
native tumor-suppressive function of miR-34. Clarification of miR-34 role as a tumor 
suppressor is of particular importance because reintroduction of this miRNA into cancer 
cells has already reached phase 1 clinical trials (Bouchie, 2013). 
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 A number of recent studies have provided evidence of p53-independent 
expression of miR-34. For example, miR-34a can be up-regulated to repress MYC 
during oncogene-induced senescence in human TIG3 fibroblasts (Christoffersen et al., 
2010), and contributes to megakaryocytic differentiation of K562 cells (Navarro et al., 
2009) in a p53-independent fashion. Consistent with these observations, levels of all 
miR-34 family members remain high in the brains, testes, and lungs of mice lacking p53 
(Concepcion et al., 2012). 
 Methylation of mir-34a and mir-34b/c has been found in prostate cancers 
carrying mutant p53 (Fujita et al., 2008; Kojima et al., 2010; Liu et al., 2011a; Lodygin et 
al., 2008). Furthermore, frequent hypermethylation of mir-34 in cancers with high 
occurrence of p53 mutations, such as ovarian and mammary carcinomas and soft tissue 
sarcomas (Corney et al., 2010; Lodygin et al., 2008; Vogt et al., 2011), suggests the 
coexistence of both alterations in the same neoplasms. These findings, together with 
reports of p53-independent regulation of miR-34, suggest that p53 and miR-34 may 
cooperate in cancer suppression. This possibility is also supported by our observation 
that p53 and miR-34 may jointly regulate MET receptor tyrosine kinase as a part of 
coherent feedforward loop in primary ovarian surface epithelium cells (Hwang et al., 
2011). However, there is no direct experimental evidence for p53 and miR-34 
cooperation in MET regulation in animal models. By using newly generated mice 
carrying conditional alleles of mir-34a and mir-34b/c, we show that miR-34 cooperates 
with p53 in suppression of prostate carcinogenesis by joint MET-mediated control of 
stem cell compartment. 
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2.3 Materials and Methods 
 
Generation of mice with mir-34 conventional and conditional targeted mutations. All 
animal experiments were carried out in strict accordance with the recommendations of 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health. The protocol was approved by the Institutional Laboratory Animal Use and Care 
Committee at Cornell University. mir-34a and mir-34b/c gene-targeting vectors were 
introduced into embryonic stem cells and homologous recombinants were identified by 
positive/negative selection and by a quantitative approach, respectively. After germ line 
transmission of the targeted allele, a FRT-flanked Neo cassette was excised by crosses 
with FLPeR transgenic mice. The resulting mice carrying conditional (floxed) alleles 
were crossed to EIIa-Cre mice to obtain conventional null alleles (Figures 2.1A and 
2.1B). The lack of individual miR-34 family members was confirmed by qRT-PCR of the 
brain and the prostate of mir-34-/- mice (Figure 2.1C).  
 
Targeting mir-34a and mir-34b/c genes. The conditional gene-targeting vector was 
constructed using a recombineering approach as described elsewhere (Liu et al., 2003). 
BAC clones RP23-410P10 and RP23-318E9 (C57Bl/6 genomic DNA; BACPAC 
Resource Center at Children's Hospital Oakland Research Institute, California) 
containing mir-34a and mir-34b/c locus, respectively, were used to generate the mir-34a 
and mir-34b/c conditional (floxed) allele. We engineered the mir-34a targeting construct 
with a 5 kb and 4.6 kb homologous arm on both the 5’ and 3’ ends, which flanked one 
loxP site and a neomycin resistance cassette (Neo) flanked by FRT sites with a loxP 
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site in upstream and downstream of mir-34a, respectively. Linearized mir-34a targeting 
vector was electroporated into E14 mouse embryonic stem cells (ES) cells, and cultured 
on the top of feeder cells with G418 (200 µg/ml) and Ganciclovir (0.2 µM) for positive 
and negative selection, respectively. ES clones (n=293) were picked up, and screened 
for correct homologous recombination by Southern blotting. The mir-34b/c targeting 
construct contained a 114 kb and 83 kb homologous arm on both the 5’ and 3’ ends, 
which flanked two loxP sites and Neo flanked by FRT sites downstream of mir-34b/c. 
Linearized mir-34b/c targeting vector was electroporated into v6.5 ES cells, and cultured 
on the top of feeder cells with G418 (200 µg/ml). ES clones (n=333) were picked up, 
and screened for correct homologous recombination by a quantitative PCR assay due 
to extremely long arms of homology. Correctly targeted clones undergoing correct 
homologous recombination were injected into C57Bl/6 blastocysts, to generate chimeric 
mice. After germ-line transmission of the targeted allele, FRT flanked Neo was removed 
by crosses with FLPeR mice (129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP1)Dym/J, The 
Jackson Laboratory. Bar Harbor, ME, stock number #00396; Farley et al., 2000). 
Following Neo removal null mir-34a and mir-34b/c alleles were obtained by crossing to 
EIIa-Cre mice (FVB/N-Tg(EIIa-cre)C5379Lmgd/J; The Jackson Laboratory, stock 
number #003314; Lakso et al., 1996). In some experiments we have also used mir-34a-
/- and mir-34aloxP/loxP mice generated by Hermeking group (Nelson et al., 2006). Those 
mice were on SV/C57Bl6 background. The outcomes of experiments with all mouse 
strains have been very similar and are reported together. Compound mice carrying 
conventional (mir-34a-/-mir-34b/c-/-, mir-34-/-) and conditional (mir-34aloxP/loxPmir-
34b/cloxP/loxP, mir-34L/L) targeted alleles of all mir-34 genes were generated by crossing 
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mice with individual targeted alleles. To minimize the confounding effects of genetic 
background all mice were backcrossed to FVB/N for at least 10 generations, and all 
control experiments were performed on age and sex-matched mice of the same 
background.  
  
Generation of mice with prostate epithelium-specific inactivation of p53, mir-34 and/or 
Met. ARR2PB-Cre transgenic mice (PB-Cre4; Wu et al., 2001) and p53loxP/loxP mice 
(p53L/L`: Marino et al., 2000) were backcrossed to FVB/N background for 20 
generations. PB-Cre4 male mice were crossed to mir-34L/L, p53L/L, and p53L/Lmir-34L/L 
female mice. Resulting PB-Cre4mir-34L/L, PB-Cre4p53L/L, and PB-Cre4p53L/Lmir-34L/L 
male mice were designated as mice with prostate epithelium (PE)-specific gene 
inactivation, mir-34PE-/-, p53PE-/-, and p53PE-/-mir-34PE-/- mice, respectively. Mice with 
floxed Met (Huh et al., 2004) were crossed in a similar fashion to obtain p53PE-/-mir-34PE-
/-MetPE-/- mice.  
 
Pathologic assessment. Moribund mice, as well as those sacrificed according to 
schedule, were anesthetized with avertin and, if necessary, subjected to cardiac 
perfusion at 90 mm Hg with phosphate-buffered saline (PBS). After macroscopic 
evaluation during necropsy, brain, pituitary gland, Thyroid gland, lung, thymus, stomach, 
small and large intestine, liver, kidney, adrenal gland, gonads, spleen, pancreas, 
salivary gland, prostate or uterus, mammary gland, trigeminal nerve, thigh and cardiac 
muscle, humerus, tibia, femur, and lymph nodes were fixed in phosphate-buffered 4% 
paraformaldehyde tissues, embedded in paraffin and 4-µm-thick sections were stained 
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with Hematoxylin (Mayer's haemalum) and eosin. Mouse prostatic intraepithelial 
neoplasia (PIN) were defined according to earlier publications (Flesken-Nikitin et al., 
2013; Park et al., 2002; Shappell et al., 2004; Zhou et al., 2006). Briefly, distal PIN1 has 
1 or 2 layers of atypical cells; PIN2 has 3 or more layers of atypical cells, PIN3 occupies 
the near entire glandular lumen; and PIN4 fills and distorts the glandular profile, and is 
frequently marked by pronounced desmoplastic reaction. In agreement with the recent 
consensus report (Flesken-Nikitin et al., 2013), PIN1 and PIN2 represent low-grade PIN, 
and PIN3 and PIN4 represent high-grade PIN. Due to different architecture of the 
proximal regions of prostatic ducts, current PIN classification cannot be carefully applied 
to atypical proliferative lesions found in those structures. Thus we named those lesions 
as proximal duct dysplasia to stress their dissimilarity to PIN of distal regions of prostatic 
ducts. Given the complexity of the interpretation of mouse prostatic neoplastic lesions, 
we used term adenocarcinoma only for neoplasms with invasive growth confirmed by 
serial sections followed by 3D reconstruction.  
 
Immunohistochemistry and quantitative image analysis. Immunoperoxidase staining of 
paraffin sections of paraformaldehyde-fixed tissue was performed by a modified Elite 
avidin-biotin-peroxidase (ABC) technique (Nikitin and Lee, 1996). Antigen retrieval was 
done by boiling the slides in 10 mM citric buffer (pH 6.0) for 10 min. The primary 
antibodies to Ki67 (Leica Microsystems; Bannockburn, IL; NCL-Ki67p, 1:1000), MET 
(Santa Cruz; Dallas, TX, sc-162, 1:200), keratin 5 (CK5, Covance: Dallas, TX, #PRB-
160P, 1:1000), p63 (Santa Cruz, #sc-8431, 1:1000), EZH2 (Cell Signaling Technology; 
Danvers, MA; #5246, 1:200), and AMACR (Santa Cruz, #sc-107916, 1:100) were 
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incubated with deparaffinized sections at 4ºC overnight (Ki67, CK5, p63, EZH2, AMACR) 
or at room temperature (RT, MET) for 1 hour followed by incubation with secondary 
biotinylated antibody (1 hour, RT) and modified avidin-biotin-peroxidase (ABC) 
technique. Methyl green (Ki67, p63, EZH2) and hematoxylin (MET, CK5, AMACR) were 
used as the counterstain in immunoperoxidase stainings. Slides were scanned by 
ScanScope CS (Leica Biosystems, Vista, CA) with 40X objective followed by lossless 
compression. Quantitative analysis of IHC was performed with the ImageJ software (W. 
Rasband, National Institutes of Health, Bethesda, MD). 
 
MicroRNA in situ hybridization. In situ hybridization was performed as previously 
described (Corney et al., 2010; Krizhanovsky and Lowe, 2009). Briefly, 6 µm-thick 
paraffin sections of 13.5-day-old FVB/N mouse embryos were deparaffinized and 
dehydrated, followed by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) fixation 
(Meletis et al., 2006). Following pre-hybridization blocking, sections were incubated 
overnight at 55-56ºC with digoxigenin-labeled locked nucleic acid (LNA) modified miR-
34a or miR-34b oligo probe (Exiqon, Woburn, MA). After stringency washes, sections 
were incubated with anti-digoxigenin alkaline phosphatase-labeled secondary antibody 
(Roche, Indianapolis, IN) overnight at 4ºC followed by development of stain with 
NBT/BCIP (Promega, Fitchburg, WI). Sections were counterstained with methyl green 
or nuclear fast red, dehydrated, cleared in xylene, coverslipped and scanned by 
ScanScope CS. 
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Cell culture. Embryonic stem cells were cultured in undifferentiating conditions on 
mitotically inactivated feeder cells and in the presence of leukemia inhibitory factor (LIF) 
at 37ºC in 5% CO2. Briefly, medium used was Dulbecco’s Modified Eagle Medium (high 
glucose) containing 15% heat-inactivated ES cell qualified fetal bovine serum, 6 mM L-
glutamine, 1 mM sodium pyruvate, 1X Dulbecco’s non-essential amino acids (all 
purchased from Invitrogen, Carlsbad, CA) plus 10-4 M 2-mercaptoethanol (Sigma, St. 
Louis, MO), and 103 units/ml LIF (Millipore, Billerica, MA). For positive neomycin 
selection, cells were cultured in medium containing 200 µg/ml G418. Mouse embryonic 
fibroblast (MEF) cells were prepared from gestational day (GD) 13.5-15.5 embryos 
carrying Neo under the control of PGK promoter (C57BL/6J-Tg(pPGKneobpA)3Ems/J, 
The Jackson Laboratory, stock number 002356; Aubrecht et al., 2011). Prior to use as 
feeder MEF cells were mitotically inactivated by exposure to 10 µg/ml mitomycin C for 
one hour at 37ºC followed by three washes with PBS. ES cells were routinely passaged 
using 0.25% trypsin/EDTA prior to reaching confluence. Feeder cells were separated 
from ES cells by differential attachment to gelatinized plates for one hour at 37ºC.  
 Primary prostate epithelial cell, stem/basal cell, and luminal cell populations were 
isolated following described procedures (Lawson et al., 2010; Lukacs et al., 2010a). 
Lipofectamin 2000 reagent (Invitrogen, Carlsbad, CA) was used for the transfection 
following manufacturer’s recommendations. Control siRNA (Santa Cruz, #sc-37007) 
and two independent Met siRNAs (Santa Cruz, #sc-35924 and Life Technologies, 
#155340) were used for all knockdown experiments. Migration and invasion assays 
were performed as previously described (Corney et al., 2010). In experiments with 
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conditional gene inactivation, the efficiency of adenoviral infection followed by Cre-
mediated gene excision was over 90% according to PCR genotyping (Figure 2.4C).  
 For hypoxia experiments CD49fhi/Sca-1+ prostate stem cells were exposed for 24 
hours to either normoxic (20% O2) or hypoxic (0.2% O2) conditions immediately after 
fluorescence activated cell sorting. For mithramycin A experiments prostate stem cells 
were treated with 100 nM mithramycin A (Sigma, #M6891) for one hour. MET 
expression was detected by Western blot after 24-hour culture.  
 
Prostate sphere assay. Prostate sphere assays were performed as described previously 
(Lawson et al., 2010; Lukacs et al., 2010a). Briefly, 104 prostate stem cells or prostate 
luminal cells were resuspended in 120 µl of a 1:1 mixture of Matrigel (BD Biosciences, 
San Jose, CA, #354234) and PrEGM (Lonza, Allendale, NJ, #CC-3166), and plated 
around the rim of a well of a 12-well tissue culture plate. Matrigel mix was allowed to 
solidify at 37ºC for 15 min, and 1 ml of PrEGM was added per well. Media was changed 
every 3 days. To recover the spheres, each well was treated with enzyme mixture: 750 
µl Collagenase/Dispase 4 mg/ml (Roche, #10269638001), 30 mg BSA (Sigma, #A3311), 
1 µl DNase1 10 mg/ml (Sigma, #D4513), followed by Trypsin 0.25% EDTA (Cellgro, 
Manassas, VA, 25-052-Cl) to make cell suspensions, which were ready for passaging.    
 
Quantitative reverse transcription - PCR. qRT-PCR was performed as previously 
described (Corney et al., 2007; Corney et al., 2010) using Rnu6b and GAPDH 
amplification as housekeeping control for miR-34 and Met, respectively. 
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Western blot and coimmunoprecipitation analysis. For western blot cell lysates were 
prepared using RIPA buffer (50 mM Tris-HCl, (pH 7.4), 1% Nonidet P-40, 0.25% Na-
deoxicholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, Aprotinin, leupeptin, pepstatin: 
1 µg/ml each, 1 mM Na3VO4, 1 mM NaF), followed by sonication for 10 seconds 5 times 
on ice. Lysates were then separated by 12% SDS-PAGE and transferred to PVDF 
membrane (Millipore #IPVH00010). The membrane was incubated overnight at 4ºC with 
antibodies to detect MET (Santa Cruz, #sc-162, 1:500), p53 (Santa Cruz, #sc-6243, 
1:2000), SP1 (Millipore, #07-645, 1:2000), HIF1A (Santa Cruz, #sc-10790, 1:500), and 
GAPDH (Advanced Immunohistochemical Inc.; Long Beach, CA; #2-RGM2,1:5000), 
followed by incubation for 1 hour at room temperature with corresponding horseradish 
peroxidase-conjugated anti-rabbit secondary antibodies (Santa Cruz, #sc-2004, 1:2000) 
or anti-mouse secondary antibodies (Santa Cruz, #sc-2005, 1:2000) and developed 
using chemiluminescent substrate (Thermo Scientific, Rockford, IL, #34077).  
 For coimmunoprecipitation lysates were prepared in modified Lysis 250 buffer 
(50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM EDTA, 0.1% NP-40 100 mM). The 
antibodies used for immunoprecipitation were SP1 (Millipore, #07-645, 1:2000) and p53 
(Cell Signaling Technology, Danvers, MA, #2524, 1:2000). Cell extracts were incubated 
at 4ºC overnight with 2 µg of corresponding antibodies, followed by incubation with 20 µl 
of Protein A/G Plus UltraLink Resin (Thermo Scientific, #53135) for 2 hours at 4ºC. 
Immunoprecipitates were isolated by centrifugation and followed by 3 times washing 
with lysis buffer. Samples were resuspended in the 5X sample buffer, subjected to 10% 
SDS-polyacrylamide gel electrophoresis, transferred onto a PVDF membrane and the 
immunoprecipitated proteins were detected by Western blotting. 
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Met 3’UTR verification. Total RNA was isolated using mirVana miRNA Isolation kit 
(Ambion, Life Technologies; Grand Island, NY; #AM1560) according to the 
manufacturer's protocol, and RNA concentration and purity were determined by 
NanoDrop analysis. cDNA was prepared from 100 ng total RNA using SuperScript III 
(Invitrogen, Life Technologies; #18080-400). Primers designed to detect the 3’UTR of 
intact and truncated Met are as follows: F1: 5’ CTG AAC TCG GTT AGC CTC CCA 3’, 
F2: 5' CTC TGG GAG CTC ATG ACG AGA 3', R1: 5’ AGT TGG ACT TAC ACT TCG 
GGC 3’, R2: 5' TCA CAG TAT ACA AGA TGT TAC GTC A 3', R3: 5’ AGG AAG GGG 
GTC TTA AAT GCT TCA 3’. PCR fragments were cloned using pGEM-T Vector System 
(Promega; Madison, WI; #A3600) according to the manufacturer's protocol. DNA 
sequencing was done by Cornell Genomics Facility, Biotechnology Resource Center. 
 
Statistical analysis. Statistical analyses were performed with InStat 3.10 and Prism 6 
software (GraphPad). A Two-tailed unpaired t-test, direct Fisher's tests, and a log-rank 
Mantel-Haenszel test were used as appropriate.  
 
2.4 Results 
 
2.4.1 Mice with mir-34 conventional knockout have only minor developmental 
alterations 
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By using gene targeting of mir-34a and mir-34b/c loci and subsequent crosses of mice 
we prepared mice with conventional triple knockout (mir-34a-/-mir-34b/c-/-) and 
conditional (floxed, mir-34aloxP/loxPmir-34b/cloxP/loxP) triple alleles (Figure 2.1), and 
designated them as mir-34-/- and mir-34L/L, respectively.  
Consistent with a previous report (Concepcion et al., 2012), our findings indicate 
that germ line genetic inactivation of mir-34 has only a minor effect on normal 
development (Figure 2.2). mir-34-/- mice are viable and fertile. There was no difference 
in body size, growth pattern, and life span compared to age- and sex-matched wild-type 
mice up to 18 months of age (data not shown). After extensive histological evaluation of 
all major organs and systems the only consistent observation was focal irregular 
arrangement and increased cell number of Purkinje neurons in the cerebellum. This 
phenotype was particularly pronounced in males, where the distance between Purkinje 
neurons was significantly shorter than that of wild-type controls matched by age, sex, 
and genetic background (Figures 2.2A-2.2D). Consistent with this observation, miR-34a, 
miR-34b, and miR-34c are highly expressed in Purkinje neurons of wild-type mice 
according to in situ hybridization (Figures 2.2E and 2.2F). This raises the possibility that 
miR-34 plays a role in cerebellar development. Increased number of Purkinje neurons 
has been reported in Bcl-2 transgenic mice (Zanjani et al., 1996) and BCL-2 is one of 
the miR-34 targets (Ji et al., 2009). Thus it is tempting to speculate that miR-34 
deficiency results in increased BCL-2 expression, and subsequently causes increased 
number of Purkinje neurons. According to several tests, such as hanging wire test, 
rotarod, and foot print analysis there were no prominent locomotor abnormalities (data 
not shown). However, more in depths study of Purkinje neuron-related phenotype in 
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Figure 2.1 Generation and characterization of conditional (floxed) and 
conventional targeted mutations of mir-34 genes. (A) The schematic drawings of 
floxed and conventional knockout alleles of mir-34a and mir-34b/c prepared by 
homologous recombination. Neomycin resistance cassette (Neo) is flanked by FRT 
sites and is excised by flippase (FLP). mir-34 (red box) is flanked by two loxP sites 
(white triangles) and is excised by Cre recombinase. Colored arrows indicate PCR 
primers used for genotyping. (B) PCR genotyping of mice carrying conditional (floxed, L) 
and conventional knockout (null) alleles. Neg, negative control; WT, wild-type. (C) 
Levels of miR-34a, miR-34b, and miR-34c from the brain and the prostate of age-
matched WT and mir-34-/- mice (n=3). RU, relative units. Error bars denote SD. 
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Figure 2.2 mir-34-/- mice display increase in number and irregular arrangement of 
Purkinje neurons. (A, B) Purkinje neurons in the cerebellum of wild-type (WT; A) and 
mir-34-/- (B) mice. The arrows indicate normal (A) and irregular (B) arrangement of 
Purkinje neurons, respectively (C, D). Distance between Purkinje neurons in mixed (C) 
and separate (D) gender WT (male, n=6; female, n=8) and mir-34-/- (male, n=14; female, 
n=9) mice. (E, F) Expression (dark blue/purple) of miR-34a (E, arrow) and miR-34b and 
miR-34c (F, arrow) in Purkinje neurons of the cerebellum of WT mice. (A, B) 
Hematoxylin and eosin. (E, F) In situ hybridization, digoxigenin method. Methyl green (E) 
and nuclear fast red (F) counterstain. Scale bar, 25 µm for all histological images. 
**P<0.01. Error bars denote SD.  
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mice lacking all mir-34 genes could be merited. On the other hand, we also have not
observed any significant pathological phenotypes, including cancers, in mir-34-/- mice 
(n=19) between 15 and 18 months of age. 
 
2.4.2 miR-34 cooperates with p53 in suppression of prostate carcinogenesis  
 
To rule out the possibility that mice somehow physiologically compensate for germline 
mir-34 deficiency, we performed prostate epithelium-specific mir-34 deletion. This was 
accomplished by using a PB-Cre4 transgene, in which a modified probasin promoter 
drives postnatal expression of Cre recombinase in the prostate epithelium (Chen et al., 
2005; Zhou et al., 2006). Consistent with previous reports and our findings in mir-34-/- 
mice, mice lacking all mir-34 genes in the prostate epithelium cells (mir-34PE-/- mice) did 
not show any atypical lesions by 15 months of age (Figures 2.3A, 2.3B, and 2.4A; Table 
2.1).  
 To test if miR-34 may have p53-independent function, we determined the 
expression levels of miR-34 family after p53 deletion in FACS-purified p53L/L prostate 
epithelium cells exposed to Ad-Cre. Significant levels of miR-34 expression were still 
detected after p53 inactivation (Figures 2.4B and 2.4C).  
 To test if p53 and miR-34 may cooperate in suppressing prostate carcinogenesis 
we generated p53PE-/- and p53PE-/-mir-34PE-/- mice by crossing p53L/L mice with mir-34L/L 
and PB-Cre4 mice. Consistent with previous reports on lack or low frequency of 
neoplastic lesions in mice with prostate epithelium-specific p53 inactivation (Chen et al., 
2005; Zhou et al., 2006), only 1 out of 11 p53PE-/- mice (9%) showed PIN1 by 9 months 
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of age in the distal regions of prostatic ducts. By 15 months of age more of p53PE-/- mice 
developed PINs. However, all of them were of low-grade (PIN1 or PIN2; Figures 2.3A, 
2.3B, and 2.4A; Table 2.1). No significant changes were observed in the proximal 
regions of prostatic ducts, where are known to encompass a prostate epithelium stem 
cell compartment (Leong et al., 2008; Tsujimura et al., 2002). 
 In contrast, beginning at 3 months of age p53PE-/-mir-34PE-/- mice showed 
dysplastic lesions characterized by varying degree of nuclear atypia and loss of normal 
cellular arrangement in the proximal regions of prostatic ducts (Figures 2.3A and 2.4A; 
Table 2.1). From 9 months of age mice majority of mice had advanced dysplastic 
lesions which frequently filled up expanded ducts and 15% and 36% of mice developed 
early invasive adenocarcinomas at 9 and 15 months, respectively (Figures 2.3A and 
2.4A; Table 2.1). In the distal regions of prostatic ducts, the first PIN1 lesions were 
detected already by 3 months of age (Figures 2.3B and 2.4A; Table 2.1). High-grade 
PIN lesions (PIN3 and 4) have been observed by 9 months of age and 64% (9 out of 14) 
of mice had such lesions at 15 months of age. Consistent with these findings, 
adenocarcinomas and high-grade PIN lesions of the proximal and distal regions of 
prostatic ducts, respectively, characterized by elevated expression of such markers of 
early prostate cancer as AMACR and EZH2, and increased number of K5 and p63 
positive cells (Figure 2.3C). Similarly, higher proliferative activity has been observed in 
both proximal and distal regions of prostatic ducts of p53PE-/-mir-34PE-/- mice (Figures 
2.3D and 2.3E). In summary, these results show that miR-34 and p53 cooperate in 
suppression of prostate carcinogenesis.  
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Figure 2.3 miR-34 and p53 cooperate in suppression of prostate carcinogenesis. 
(A and B) A quantitative analysis of the frequency of neoplastic lesions in proximal (A) 
and distal (B) regions of prostatic ducts. N, normal; PRD, proximal dysplastic lesions; 
AC, adenocarcinoma; LG, low-grade PIN; HG, high-grade PIN. (C) Proximal (left two 
columns) and distal (right two columns) regions of prostatic ducts in 15-month-old WT 
and p53PE-/-mir-34PE-/- mice. Adenocarcinomas invading the surrounding stroma (arrows) 
and filling up the lumen (arrowheads) in the proximal regions of the prostatic ducts of 
p53PE-/-mir-34PE-/- mice are shown. PIN4 (arrows) in the distal regions of the prostatic 
ducts of p53PE-/-mir-34PE-/- mice is shown. As compared to the prostate epithelium of WT 
mice, both adenocarcinomas and PIN4 (arrows) show higher expression levels of 
AMACR and EZH2 and an increased number of CK5 and p63-positive cells. HE, 
hematoxylin and eosin staining. The ABC Elite method with hematoxylin (AMACR, CK5) 
or methyl green (EZH2, and p63) counterstaining was performed. Scale bar, 100 mm for 
all images. (D and E) A quantitative analysis of the proliferation rate in proximal (D) and 
distal (E) regions of prostatic ducts. *P<0.05; **P<0.01. Error bars denote SD. 
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Figure 2.4 miR-34 has p53-independent function in suppression of prostate 
carcinogenesis. (A) Proximal and distal regions of prostatic ducts in 3, 9, and 15-
month-old mir-34PE-/-, p53PE-/- and p53PE-/-mir-34PE-/- mice. Dysplastic lesions (3 months, 
arrow) and adenocarcinomas (9 and 15 months) invading surrounding stroma (arrows) 
and filling up the lumen (arrowheads) in the proximal regions of prostatic ducts of p53PE-
/-mir-34PE-/- mice. Low-grade prostatic intraepithelial neoplasia (PIN1, 9 months; PIN2, 
15 months, arrows) in the distal regions of prostatic ducts of p53PE-/- mice. PIN1 (3 
months, arrow) and high-grade PINs (PIN3, 9 months; PIN4, 15 months, arrows) in the 
distal regions of prostatic ducts of p53PE-/-mir-34PE-/- mice. Note densely fibrotic stroma 
surrounding PIN4. Hematoxylin and eosin. Scale bar, 100 µm for all images. (B) qRT-
PCR of miR-34 expression in Ad-blank or Ad-Cre-infected p53L/L and mir-34-/- prostate 
epithelium cells. ***P<0.001. Error bars denote SD. (C) PCR analysis of p53 gene 
structure in p53L/L prostate epithelium cells infected with Ad-blank (lane 2) or Ad-Cre 
(lane 3), and in mir-34-/- prostate epithelium cells (lane 4). Control samples include WT 
(lane 5), floxed (L, lane 6); and homozygous recombinant (R, lane 7) p53. 316, 198, and 
163 bp fragments are diagnostic for floxed, excised, and WT alleles of the p53 gene, 
respectively. M (lanes 1 and 8), DNA marker. 
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Table 2.1 Prostatic Lesions in Mice with Prostate Epithelium Specific Inactivation of mir-
34a, b/c (mir-34PE-/-), p53 (p53PE-/-) and Their Combination (p53PE-/-mir-34PE-/-). 
Strain Prostatic 
region 
Lesion* Age (months) 
   3 9 15 
mir-34PE-/- 
Proximal 
    
None 100 (9/9)# 100 (7/7) 100 (4/4) 
Dysplasia 0 (0/9) 0 (0/7) 0 (0/4) 
Adenocarcinoma    
    
Distal 
    
None 100 (0/9) 100 (7/7) 0 (0/4) 
PIN1 0 (0/9) 0 (0/7) 0 (0/4) 
PIN2 0 (0/9) 0 (0/7) 0 (0/4) 
PIN3 0 (0/9) 0 (0/7) 0 (0/4) 
PIN4 0 (0/9) 0 (0/7) 0 (0/4) 
      
p53PE-/- 
Proximal 
    
None 100 (9/9) 100 (11/11) 100 (12/12) 
Dysplasia 0 (0/9) 0 (0/11) 0 (0/12) 
Adenocarcinoma 0 (0/9) 0 (0/11) 0 (0/12) 
    
Distal 
    
None 100 (9/9) 91 (10/11) 17 (2/12) 
PIN1 0 (0/9) 9 (1/11) 66 (8/12) 
PIN2 0 (0/9) 0 (0/11) 17 (2/12) 
PIN3 0 (0/9) 0 (0/11) 0 (0/12) 
PIN4 0 (0/9) 0 (0/11) 0 (0/12) 
      
p53PE-/- 
mir-34PE-/- 
Proximal     None 87 (7/8) 31 (4/13) 7 (1/14) 
 Dysplasia 13 (1/8) 54 (7/13) 57 (8/14) 
 Adenocarcinoma 0 (0/8) 15 (2/13) 36 (5/14) 
     
Distal 
    
None 75 (6/8) 0 (0/13) 0 (0/14) 
PIN1 25 (2/8) 31 (4/13) 0 (0/14) 
PIN2 0 (0/8) 61 (8/13) 36 (5/14) 
PIN3 0 (0/8) 8 (1/13) 43 (6/14) 
PIN4 0 (0/8) 0 (0/13) 21 (3/14) 
      
 
*Lesions of the distal region of prostatic duct can be additionally classified as low-grade (PIN1 
and PIN2) and high-grade (PIN3 and PIN4). 
#% (number of mice with lesion out of total number of mice). 
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2.4.3 p53 and miR-34 cooperate in control of prostate stem/progenitor cell activity 
 
According to our pathological evaluation, stem/progenitor cell-enriched proximal regions 
of prostatic ducts were specifically affected in p53PE-/-mir-34PE-/- mice. To test if 
combined p53 and miR-34 deficiency affects functional properties of prostate 
stem/progenitor cells, we isolated such cells by fluorescence-activated cell sorting 
(FACS) based on their CD49fhi/Sca-1+ profile. Mice with prostate-specific deletions of 
either mir-34 or p53 had slightly more stem/progenitor cells than background-matched 
wild-type (WT) mice (Figure 2.5A). However, the pool of CD49fhi/Sca-1+ cells deficient 
for both miR-34 and p53 increased by 39% and constituted 7.1% of the prostate 
epithelium versus 5.1% in WT. Notably, the CD49fhi/Sca-1+ fraction isolated from 
prostates of p53PE-/-mir-34PE-/- mice formed prostaspheres far more efficiently and of 
larger size (Figures 2.5B and 2.5C). Both higher frequency and size of spheres formed 
by p53 and miR-34-deficient CD49fhi/Sca-1+ stem cells were maintained over multiple 
passages (dissociation and clonal formation), suggesting a role for these genes in the 
control of self-renewal. At the same time, no difference among genotypes was observed 
in CD49flo/Sca-1- luminal cells (Figure 2.5D). These cells formed very few spheres after 
first plating and no spheres were observed after first passage. Thus, miR-34 and/or p53 
deficiency are unlikely to reprogram differentiated cells towards stem cell state. 
 To test whether observed properties represent direct effects of p53 and/or miR-
34 on prostate stem/progenitor cells, we have isolated CD49fhi/Sca-1+ stem/progenitor 
cells and CD49flo/Sca-1- luminal cells from prostates of WT, mir-34L/L, p53L/L, and p53 L/L 
mir-34L/L mice and, followed by infection with Ad-Cre or Ad-blank, subjected them to the  
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Figure 2.5 Deletions of both p53 and mir-34 promote prostate stem/progenitor cell 
expansion and sphere-forming capacity. (A) A quantitative analysis of distribution of 
CD49fhi/Sca-1+ stem/progenitor cells and CD49flo/Sca-1- luminal cells from 3-month-old 
WT, mir-34PE-/-, p53PE-/-, and p53PE-/-mir-34PE-/- mice (n=3). Red and blue frames 
represent stem/progenitor cell and luminal cell populations, respectively. (B-D) The 
frequency (B and D) and size (C) of spheres formed by CD49fhi/Sca-1+ stem/progenitor 
cells (B and C) and CD49flo/Sca-1- (D) luminal cells from 3-month-old WT, mir-34PE-/-, 
p53PE-/-, and p53PE-/-mir-34PE-/- mice (n=3). P0-P3, passages 0–3. (E and F) The relative 
frequency of sphere formation by CD49fhi/Sca-1+ stem/progenitor cells (E) and 
CD49flo/Sca-1- luminal cells (F) isolated from WT, mir-34L/L, p53L/L, and p53L/Lmir-34L/L 
mice followed by Ad-Cre infection (n=3). Sphere counts were normalized to the Ad-
blank-infected spheres of each passage. **P < 0.01; ***P < 0.001. Error bars denote SD. 
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prostasphere formation experiments (Figures 2.5E and 2.5F). Consistently, the lack of 
both p53 and miR-34 had the most pronounced effect on frequency of stem/progenitor 
cells in consecutive passages.  
 
2.4.4 p53 and miR-34 regulation of stem/progenitor cells depends on MET 
 
In addition to invasive growth of cells in the prostate stem cell compartment of p53PE-/-
mir-34PE-/- mice, we have noted that some of the cells from the p53 and miR-34-deficient 
prostaspheres were spreading into surrounding matrix (Figure 2.6A). Because MET 
plays a crucial role in regulation of cell motility and invasion (Trusolino et al., 2010) and 
is a known target of p53 (Hwang et al., 2011) and miR-34 (Corney et al., 2010; He et al., 
2007; Hwang et al., 2011), we have tested its expression in FACS-isolated populations 
of the prostate epithelium. CD49fhi/Sca-1+ prostate stem/progenitor cells had far higher 
levels of expression as compared to CD49flo/Sca-1-luminal cells (Figure 2.6B). 
Deficiency for either miR-34 or p53 slightly increased MET levels in stem/progenitor 
cells, whereas such cells from p53PE-/-mir-34PE-/- showed the highest MET expression 
(Figures 2.6B and 2.6C). Consistently, CD49fhi/Sca-1+ prostate stem/progenitor cells 
deficient for both miR-34 and p53 had the highest motility in migration assay (Figure 
2.6D) and some trend, albeit not statistically significant, towards increased invasive 
activity (Figure 2.6E). To the contrary, CD49flo/Sca-1- luminal cells deficient for p53 
and/or miR-34 had no significant differences in their motility (Figure 2.6F) and invasion 
(Figure 2.6G). Consistent with ex vivo results, we also observed elevated levels of MET 
expression in cells of the proximal regions of prostatic ducts of p53PE-/-mir-34PE-/- mice, 
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Figure 2.6 MET expression is essential for the increased growth, sphere-forming 
capacity, motility, and invasion of p53 and miR-34-deficient prostate 
stem/progenitor cells. (A-H) Prostasphere formation (A), western blot (B), and qRT-
PCR (C) of Met expression, migration (D and F), and invasion (E and G) by 
CD49fhi/Sca-1+ stem/progenitor cells (A-E) and CD49flo/Sca-1- luminal cells (B, F, and G) 
of 3-month-old WT, mir-34PE-/-, p53PE-/-, and p53PE-/-mir-34PE-/- mice (n=3). (A) Note the 
outgrowth of cells from prostaspheres prepared from p53PE-/-mir-34PE-/- mice (arrow). (H) 
MET expression in the cells of proximal and distal regions of prostatic ducts of 3- and 
15-month-old WT, mir-34PE-/-, p53PE-/-, and p53PE-/-mir-34PE-/- mice is shown. MET 
expression (arrows) is detected in the proximal regions of the prostatic ducts of 3- and 
15-month-old p53PE-/-mir-34PE-/- mice and in the PIN4 of the distal region in 15-month-old 
p53PE-/-mir-34PE-/- mice. PIN1 (arrowheads) in the distal regions of prostatic ducts lacks 
MET expression in both p53PE-/- and p53PE-/-mir-34PE-/- mice. The ABC Elite method with 
hematoxylin counterstaining was performed. Scale bars, 100 mm. (I–N) qRT-PCR (I) 
and western blot (J) of Met expression, prostasphere size (K), sphere-forming capacity 
(L), migration (M), and invasion (N) of CD49fhi/Sca-1+ stem/progenitor cells isolated 
from 3-month-old WT, p53PE-/-mir-34PE-/-, and p53PE-/-mir-34PE-/-MetPE-/- mice (n=3). *P < 
0.05; **P < 0.01; ***P < 0.001. Error bars denote SD. 
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as compared to WT mice and mice with inactivation of either mir-34 or p53 (Figure 
2.6H). MET expression was below detectable levels in the epithelium of the distal 
regions of prostatic ducts in all strains. The only exception was elevated MET 
expression in high-grade PINs in p53PE-/-mir-34PE-/- mice, suggesting a possible increase 
in the number of stem cell-like cells in such lesions. 
To test if MET overexpression is essential for the observed phenotypes, Met was 
inactivated using a conditional MetL/L allele. Met inactivation abrogated growth, sphere-
forming capacity, cell motility, and invasion of p53 and miR-34-deficient CD49fhi/Sca-1+ 
prostate stem/progenitor cells (Figures 2.6I-2.6N). Effects of MET downregulation on 
growth, sphere-forming capacity, cell motility, and invasion of WT prostate stem/ 
progenitor cells were less prominent (Figures 2.7A–2.7G), consistent with the lower 
levels of MET expression in such cells. However, 2-fold induction of MET expression by 
hypoxia resulted in a comparable increase of all the above parameters (Figures 2.7A–
2.7G). Similar to p53/mir-34-inactivation experiments, this phenotype was reversed after 
MET knockdown, indicating a critical role for MET in prostate stem/progenitor cell 
regulation.   
Previously it has been shown that p53 may negatively regulate MET expression by 
the miR-34-mediated targeting of MET (Corney et al., 2007; He et al., 2007; Hwang et 
al., 2011). Supporting these observations, we have observed the preserved 3'UTR 
carrying two binding sites for miR-34 in prostate stem/progenitor cells (Figure 2.8). We 
have also reported that p53 also represses MET expression by miR-34-independent 
inhibition of SP1 binding to Met promoter in the ovarian surface epithelium cells (Hwang 
et al., 2011). Consistent with this mechanism, MET reciprocal coimmunoprecipitation 
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Figure 2.7 MET is essential for the growth, sphere-forming capacity, motility, and 
invasion of WT prostate stem/progenitor cells and is partially regulated by SP1 
interacting with p53. (A-G) qRT-PCR (A) and western blot (B and C) of Met expression, 
prostasphere size (D), sphere-forming capacity (E), migration (F), and invasion (G) of 
CD49fhi/Sca-1+ stem/progenitor cells isolated from 3-month-old WT mice (n = 3) and 
cultured under normoxic (20% O2, A, B, and D-G) and hypoxic (0.2% O2, A-G) 
conditions. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars denote SD. Very similar 
results were obtained in separate experiments with two different Met small interfering 
RNAs (siRNAs). (H and I) Coimmunoprecipitation of cell lysates with SP1 (H) or p53 (I) 
antibodies followed by western blot with p53 or SP1 antibodies, respectively (upper 
panels). Samples of the same lysates were used for western blot with p53 or SP1 
antibodies before immunoprecipitation (lower panels). CD49fhi/Sca-1+ stem/progenitor 
cells isolated from 3-month-old WT mice (n = 3) were used. IP, immunoprecipitation. 
BIP, before immunoprecipitation. (J) The effect of mithramycin A (100 nM) on MET 
expression of CD49fhi/Sca-1+ stem/progenitor cells isolated from 3-month-old WT, 
p53PE-/-mir-34PE-/-, and p53PE-/-mir-34PE-/-MetPE-/- mice (n=3). 
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Figure 2.8 Two miR-34 binding sites of Met 3’UTR are intact in p53- and/or mir-34-
deficient prostate stem/progenitor cells. (A) Experimental design. (B) Schematic 
diagrams of the intact Met mRNA containing miR-34 binding sites (upper) and truncated 
Met mRNA (lower). Primers (F1, F2, R1, R2, R3) are used for detecting the Met 3’ UTR. 
CDS, coding sequence. (C) Detection of 3’UTR of the truncated Met gene (494 bp) and 
internal fragment of the intact Met gene (675 bp) by F1/R1/R3 primer set. Only 675 bp is 
detected in all samples. (D) Detection of 3’UTR of the intact Met gene (2487 bp) by 
F2/R2 primer set. (C, D) WT (lane 2), mir-34PE-/-(lane 3), p53PE-/- (lane 4), and p53PE-/-
mir-34PE-/- (lane 5) prostate stem/progenitor cells. DNA marker (lanes 1 and 6). (E) 
Sequencing results of two miR-34 binding sites of Met 3’UTR in WT, p53- and/or mir-34-
deficient prostate stem/progenitor cells. 
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experiments have shown that p53 physically interacts with endogenous SP1 in the 
prostate stem/progenitor cells (Figures 2.7H and 2.7I). Furthermore, SP1 inhibition 
results in reduction of MET expression in prostate stem/progenitor cells deficient for 
either p53 or both miR-34 and p53, but not for miR-34 alone (Figure 2.7J). 
 
2.5 Discussion 
 
Our study provides a direct genetic proof that miRNAs of the miR-34 family may act as 
tumor suppressors in concert with other genes, such as p53. These findings offer a solid 
physiological basis for rational design of diagnostic and therapeutic approaches. 
Because the lack of mir-34 genes alone is insufficient for cancer initiation, their 
downregulation is likely to occur at some point during tumor progression. However, the 
preexistence of mir-34 methylation in some normal cells cannot be excluded. Further 
genomic studies in conjunction with animal modeling should be able to address this 
question. Although our current studies have been focused on prostate cancer, tissue-
specific inactivation of mir-34 and p53 in other tissues will address likely interactions of 
these genes in other cell lineages.  
Our observations confirm the earlier findings that p53 may negatively regulate MET 
expression by miR-34-mediated targeting of MET and by miR-34-independent inhibition 
of SP1 binding to the MET promoter. Notably, according to our previous ex vivo studies, 
inactivation of both mechanisms is required to achieve the highest MET overexpression, 
cell motility, and invasion (Hwang et al., 2011). Our present study supports this 
possibility in an autochthonous model of cancer. Our findings also show that miR-34 
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effects on MET regulation occur both in a p53-dependent and -independent manner. 
Specific mechanisms for p53-independent miR-34 regulation remain to be determined.  
 Previous studies have shown that p53 and miR-34 affect induced pluripotent 
stem cell reprogramming (Choi et al., 2011; Krizhanovsky and Lowe, 2009). p53 
mediates the onset of senescence of endothelial progenitor cells (Rosso et al., 2006) 
and negatively regulates proliferation and survival of neural stem cells (Meletis et al., 
2006). Constitutive p53 activation results in depletion of adult stem cells in bone marrow, 
brain and testes (Liu et al., 2010). It has been reported that ectopic expression of miR-
34a may inhibit prostate cancer-propagating cells (also known as cancer stem cells or 
cancer-initiating cells) and metastasis by directly repressing CD44 (Liu et al., 2011a). 
However, the role of miR-34 in regulation of normal adult stem cell has been unclear. 
Our study fills this gap by showing that miR-34 regulates prostate stem/progenitor cells 
in cooperation with p53. It will be of interest to see if similar cooperation of miR-34 and 
p53 may play role in stem cell compartments of other cell lineages. 
 It has been previously reported that prostate cancer-propagating cells express 
MET, and depletion of MET results in a decrease in prostasphere formation (Rajasekhar 
et al., 2011). However, the direct role of MET in regulation of normal prostate 
stem/progenitor cells and mechanisms controlling its expression have been uncertain. 
Our studies on prostate cells collected either in the early stages of carcinogenesis or 
immediately after mir-34 and p53 inactivation provide a missing link between normal 
biological functions of MET and promotion of aberrant expansion of the stem/progenitor 
cell pool, which may eventually lead to cancer. Considering that MET is particularly 
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overexpressed in stem/progenitor cells lacking both p53 and miR-34, its therapeutic 
targeting may be especially effective in p53 and miR-34-deficient cancer cases.  
Some cancers arise from stem/progenitor cells (Flesken-Nikitin et al., 2013; 
Schepers et al., 2012), while others may originate from more differentiated cells 
(Friedmann-Morvinski et al., 2012). In our study, we have observed that neoplastic 
lesions in the distal regions of prostatic ducts, which are mainly populated by transit-
amplifying and differentiated cells, never progress to frank invasive adenocarcinomas. 
These findings support observations in other models that cancers arising from stem cell 
compartments are more aggressive (Flesken-Nikitin et al., 2013). Our autochthonous 
mouse model of prostate cancer based on prostate epithelium-specific inactivation of 
p53 and mir-34 should provide a valuable tool for further elucidation of the role of 
individual cell subpopulations in prostate cancer pathogenesis. 
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3.1 Abstract 
 
The role of cells of the diffuse neuroendocrine system in development and maintenance 
of individual organs and tissues remains poorly understood. Here we identify a 
regulatory region sufficient for accurate in vivo expression of synaptophysin (SYP), a 
common marker of neuroendocrine differentiation, and report generation of Tg(Syp-
EGFPloxP-DTA)147Ayn (SypELDTA) mice suitable for flexible organ-specific ablation of 
neuroendocrine cells. These mice express EGFP and diphtheria toxin fragment A (DTA) 
in SYP positive cells before and after Cre-loxP mediated recombination, respectively. 
As a proof of principle, we have crossed SypELDTA mice with EIIA-Cre and PB-Cre4 
mice. EIIA-Cre mice express Cre recombinase in a broad range of tissues, while PB-
Cre4 mice specifically express Cre recombinase in the prostate epithelium. Double 
transgenic EIIA-Cre; SypELDTA embryos exhibited massive cell death in SYP positive 
cells. At the same time, PB-Cre4; SypELDTA mice showed a substantial decrease in 
the number of neuroendocrine cells and associated prostate hypotrophy. As no increase 
in cell death and/or Cre-loxP mediated recombination was observed in non-
neuroendocrine epithelium cells, these results suggest that neuroendocrine cells play 
an important role in prostate development. High cell type specificity of Syp locus-based 
cassette and versatility of generated mouse model should assure applicability of these 
resources to studies of neuroendocrine cell functions in various tissues and organs. 
 
3.2 Introduction 
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Neuroendocrine (NE) cells have both neuronal and endocrine phenotypes (Montuenga 
et al., 2003). The diffuse neuroendocrine system (DNES) is composed of NE cells 
scattered throughout the entire body either as single cells or clusters, such as solitary 
pulmonary NE cells (PNECs) and neuroepithelial bodies (NEBs) (Linnoila, 2006), the 
islets of Langerhans in the pancreas (Ahren, 2000; Koh et al., 2012), gastrointestinal NE 
cells (Dockray, 2003; Kuliczkowska-Plaksej et al., 2012), dermal NE cells (so-called 
Merkel cells) (Tachibana, 1995), adrenal medullary NE cell (de Diego et al., 2008; 
Douglas et al., 2010; Mravec, 2005), and prostate NE cells (Abrahamsson, 1999). 
PNECs are implicated in regulation of lung maturation and growth, function as oxygen-
sensing chemoreceptors and are likely important for lung stem cell niches (Linnoila, 
2006). Gastrointestinal NE cells are known to control gastrointestinal secretion, motility, 
growth, immune cell function and food intake (Dockray, 2003). Though there has been 
progress in understanding the function of NE cells, the physiological role of NE cells in 
most other organs is not well understood. 
Cells with NE differentiation are also present in many cancer types, with their 
representation ranging from being the major component in small cell carcinomas of the 
lung (Linnoila, 2006) and prostate (Sun et al., 2009), as well as NE tumors of  
gastrointestinal tract (Gustafsson et al., 2008), to more limited quantity in other cancers, 
such as adenocarcinomas of the lung (Linnoila, 2006) and prostate (Sun et al., 2009). 
Unfortunately, the cell of origin of neoplastic NE cells and their contribution to cancer 
progression remain insufficiently elucidated (Cheng and Nikitin, 2011; Linnoila, 2006; 
Montuenga et al., 2003; Sun et al., 2009). 
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NE cells are detected by a number of markers, such as chromogranin A (CgA) 
(Gazdar et al., 1988), neuron-specific enolase (NSE) (Schmechel et al., 1978), neural 
cell adhesion molecules (NCAMs, so-called CD56) (Jin et al., 1991), calcitonin gene-
related peptide (CGRP) (Cadieux et al., 1986) and SYP (Wiedenmann et al., 1986). 
However, the use of NSE (Haimoto et al., 1985; Schmechel, 1985; Seshi et al., 1988) or 
CD56 (Kaufmann et al., 1997; Lantuejoul et al., 1998) is limited because of their poor 
specificity and/or sensitivity. CgA reactivity is strongly dependent on the number of 
neurosecretory vesicles per cell and is frequently lost in neoplastic NE cells (Jensen et 
al., 1990), while only subset of NE cells expresses CGRP (Weichselbaum et al., 2005). 
In contrast, SYP is expressed in a broad-spectrum of normal and neoplastic NE and 
neural cells (Gould et al., 1987; Wiedenmann et al., 1986). 
SYP is a major integral membrane protein of small synaptic vesicles and belongs to 
a family of proteins that includes synaptogyrin (SYG) and synaptoporin (Sudhof et al., 
1987). It has been reported that in cell culture transfection experiments the 1.2 kb 
upstream region of rat Syp promoter is insufficient to confer cell type specific expression 
(Bargou and Leube, 1991). It has also been suggested that NE cell specific silencer 
elements lay within the 2.6 kb upstream fragment of Syp (Bargou and Leube, 1991). At 
the same time, other cell culture studies have reported that neuron-restrictive silencer 
element (NRSE), a binding site for RE-1 silencing transcription factor (REST), a.k.a. 
neuron-restrictive silencer factor (NRSF), is located within the first intron of Syp gene 
(Lietz et al., 2003). However, the regulatory region sufficient for accurate in vivo 
expression of SYP remains unknown, thereby preventing development of genetic 
constructs allowing Syp-specific gene expression. 
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Since SYP is among the most reliable markers for NE cells, we generated mice 
with Syp locus-based Bacterial Artificial Chromosome (BAC) cassettes. We show that in 
combination with the preserved NRSE in the first intron, only the 121 kb upstream and 
36 kb downstream regions, but not the 3 kb upstream region, allow for accurate 
expression of reporter gene in SYP expressing cells in the mouse. We also show that 
SYP positive cells can be accurately ablated in either the embryo or in the postnatal 
adult prostate after induction of DTA expression (Ivanova et al., 2005) by Cre-loxP 
mediated recombination in crosses of SypELDTA mice with EIIA-Cre (Lakso et al., 1996) 
or PB-Cre4 (Wu et al., 2001) mice, respectively. The Syp containing BAC cassette and 
generated mice should provide useful tools for studies of NE cell biological roles in 
development and maintenance of various tissues and organs.  
 
3.3 Materials and Methods 
 
Ethics statement. This study was carried out in strict accordance with the 
recommendations of the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Laboratory 
Animal Use and Care Committee at Cornell University (Permit Number: 2000-0116). All 
efforts were made to minimize animal suffering. 
 
Bioinformatics analyses. Analysis of sequence and species comparisons were 
performed by using the University of California Santa Cruz Genome Browser (UCSC, 
http://genome.ucsc.edu/). 
91 
 
Generation of SypELDTA mice. A BAC clone containing approximately 121 kb and 36 
kb of 5' and 3' DNA flanking the Syp locus was modified by insertion of a loxP-EGFP-
Neo cassette-Stop-loxP-DTA-bpA cassette to replace the sequence spanning intron 1 
downstream of NRSE to exon 7 of Syp locus by homologous recombination. The BAC 
constructs were microinjected into male pronuclei of fertilized oocytes from FVB/N mice 
to generate the SypELDTA mice. EIIA-Cre (FVB/N-Tg(EIIa-cre)C5379Lmgd/J) 
transgenic mice (The Jackson Laboratory, Bar Harbor, ME, stock number #003314) 
(Lakso et al., 1996), Rosa26StoploxPLacZ (B6;129S4-Gt(ROSA)26Sortm1Sor/J) reporter 
mice (The Jackson Laboratory, stock number #003309) (Soriano, 1999), and ARR2PB-
Cre transgenic male mice on FVB/N (PB-Cre4) (Wu et al., 2001) were described 
previously. Details about generation of the targeting construct and BAC recombineering 
are described in the Generation of the targeting construct and BAC recombineering. 
 
Generation of the targeting construct and BAC recombineering. The components of the 
BAC targeting vector were as follows: pBS302 ((Sauer, 1993), plasmid 11925), 
pcDNA3-EGFP (D. Golenbock, plasmid 13031), and PGKDTAbpA ((Soriano, 1997), 
plasmid 13440), all from Addgene (Cambridge, MA), and PL452 (Liu et al., 2003), 
National Cancer Institute - Frederick, Bethesda, MD). The ApaI-NotI DNA fragment of 
loxP-EGFP-Neocassette-Stop-loxP-DTA-bpA was made by cloning from DNA 
fragments of loxP-Stop-loxP (pBS302), EGFP (pcDNA3-EGFP), Neo cassette (PL452), 
and DTA-bpA (PGKDTAbpA), and inserted into the backbone of PGKDTAbpA to 
generate the final BAC targeting vector pBS-loxP-EGFP-Neo cassette-Stop-loxP-DTA-
bpA. BAC clone (RP23-267C15), which contains Syp locus, was purchased from 
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"BACPAC Resource Center" (BPRC, Oakland, CA). Syp homologous arms were 
amplified and inserted upstream and downstream of loxP-EGFP-Neo cassette-Stop-
loxP-DTA-bpA sequence in plasmid pBS-loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA. 
5' arm was a 510 bp fragment, containing exon 1 and NRSE of intron 1 within Syp locus, 
upstream of the middle of intron 1. It was generated by PCR that used forward primer 
(KpnI-F1) 5'-CCG TTG GGT ACC TTG CTG GCA CTG CTG CTG GCA GAC A-3' and 
reverse primer (ApaI-R1) 5'-CCG TTG GGG CCC GCT CCG GGG GTG AAA GGG 
TCG TC-3'. To avoid possible interference of transgene expression by start codon ATG 
in exon 1 of Syp locus, we changed ATG to GCA (alanine) in forward primer of 5' arm 
fragment. 3' arm was a 500 bp PCR product downstream of exon 7 of Syp locus that 
was generated by the forward primer (NotI-F1) 5'-TGC CGT TGG CGG CCG CGT CCC 
GGC TCT TTT TCT CAG TGC GC-3', and the reverse primer (SacII-R2) 5'-CCG TTG 
CCG CGG AGA CAG GCC TTT CAT CTT GGG CGC C-3'. The homology arms were 
inserted after KpnI/ApaI (5' arm) and NotI/SacII (3' arm) digestion and the targeting 
cassette was released from the plasmid by KpnI/SacII. EL350 bacteria carrying RP23-
267C15 were electroporated with the targeting cassette DNA and selected with 
kanamycin and chloramphenicol. Homologous recombination was verified by 
sequencing of PCR products obtained using primers flanking the homology arms and 
loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA fragment. The primer sets were BAC 
upstream: forward primer 5'-ACT GAG CGG TCC TCT TAC CAC CC-3' and reverse 
primer 5'-CCT GCA CGA CGC GAG CTG C-3'; and BAC downstream: forward primer 
5'-CTC CAC ACA GGC ATA GAG TGT CTG C-3' and reverse primer 5'-CCC ACT   
GCA CCT CTG CCC AAA GA-3' (Figure S1A). 
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The RP23-267C15 was cloned into pBACe3.6 vector, which has a wild type loxP 
site. In order to eliminate potential mis-recombination between the transgene cassette 
and an endogenous loxP site in the pBACe3.6 vector, we replaced the vector-derived 
loxP site with a β-lactamase sequence from pGEM-T vector (Promega, Madison, WI, 
#A3600) using homologous recombination (Figure S1B). The modified BAC construct 
was named SypELDTA (Figure 3A). Furthermore, to evaluate applicability of the shorter 
upstream sequence of Syp for cell type specific expression, we used the same 
homologous recombination strategy and retrieved the sequence SypP-loxP-EGFP-Neo 
cassette-Stop-loxP-DTA-bpA from SypELDTA into pGEM-T vector. The modified BAC 
construct used in cell culture study was named sSypELDTA (Figure 3B). SypELDTA 
and sSypELDTA constructs were purified (QIAGEN Plasmid Midi Kit, Valencia, CA, 
#12143) and microinjected into pronuclei of fertilized oocytes of FVB/N mice in the 
Cornell Transgenic Mouse Core facility.  
 
Genotyping. PB-Cre4 transgenic mice were identified by primers Cre5' (5'-GGA CAT 
GTT CAG GGA TCG CCA GGC G-3') and Cre3' (5'-GCA TAA CCA GTG AAA CAG 
CAT TGC TG-3’). PCR amplification of Cre resulted in 296 bp DNA fragment. 
Endogenous Rb was identified by primers Rb5' (5'-CGG AAG AAG AAC GTT TGT CCA 
TTC A-3') and Rb3' (5'-CGC TGC TAT ACG TAG CCA TTA CAA C-3'). PCR 
amplification of Rb resulted in 196 bp DNA fragment. EGFP was identified by primers 
EGFP5' (5'-CCT CGT GAC CAC CCT GAC CTA CGG C-3') and EGFP3' (5'-GCC GTC 
CTC GAT GTT GTG GCG GAT C-3'). PCR amplification of EGFP resulted in 346 bp 
DNA fragment. Neomycin was identified by primers Neo5' (5'-GCC GCC GTG TTC 
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CGG CTG TCA GCG C-3') and Neo3' (5'-CCG AGT ACG TGC TCG CTC GAT GCG A-
3'). PCR amplification of Neomycin resulted in 342 bp DNA fragment. DTA was 
identified by primers DTA5' (5'-AGC TTG GGC TGC AGG TCG AGG GAC C-3') and 
DTA3' (5'-ACG TCA CTT TGA CCA CGC CTC CAG C-3'). PCR amplification of DTA 
resulted in 348 bp DNA fragment. The PCR temperature profile was 35 cycles for 94°C 
for 30 seconds, 60°C for 1 minute, and 72°C for 2 minutes with extension of the last 
cycle for 10 minutes at 72°C (Nikitin and Lee, 1996).  
 
Cell culture experiments. Mouse p53 and Rb double deficient prostate adenocarcinoma 
cell lines PCN1 and PCN3 were established from prostate carcinomas of PB-Cre4; 
p53loxP/loxPRbloxP/loxP mice (Zhou et al., 2006). They were maintained in the Dulbecco's 
Modification of Eagle's Medium (DMEM, Cellgrow, Manassas, VA, #15-018-CV), 
supplementary with fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, #16000-044), L-
Glutamine (Cellgrow, #25-005-Cl), Na-Pyruvate (Cellgrow, #25-000-Cl), and Penicillin-
Streptomycin (Cellgrow, #30-002-Cl).  
 For EGFP detection experiment, PCN1 and PCN3 cells were seeded in triplicate 
in 12-well plates and transfected the next day with sSypELDTA using Lipofectamine 
2000 (Invitrogen, #11668019). 48 hours after transfection, EGFP signal was observed 
via fluorescent microscopy.  
 For DTA detection, cells were transfected with plasmids PGKDTAbpA, 
sSypELDTA, and SypDTA. sSypELDTA transfected cells were infected by Adenovirus-
Cre (Ad-Cre) 48 hours post-transfection. 24 hours after infection, RT-PCR was carried 
out for all groups. RNA was isolated using mirVana miRNA Isolation Kit (Ambion, Austin, 
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TX, #AM1561) according to the manufacturer's protocol. RNA concentration and purity 
were determined by NanoDrop. cDNA was prepared from 100 ng total RNA using 
SuperScript III (Invitrogen, Carlsbad, CA, #18080-051) and amplified with DTA forward 
primer 5'-ATG GAT CCT GAT GAT GTT GTT GAT TCT TCT AAA TC-3' and a reverse 
primer 5'-TTA GAG CTT TAA ATC TCT GTA GGT AGT TTG TCC AA-3', yielding a 657 
bp PCR product. The PCR temperature profile was 30 cycles for 95ºC for 45 seconds, 
60ºC for 45 seconds, and 72ºC for 1 minute with the extension of last cycle for 1 minute 
at 72ºC.  
 For detection of Cre-loxP mediated recombination, EL350 cells were cultured in 
10 ml of LB broth at 32°C overnight. 10 ml EL350 was divided into two 5 ml EL350 vials. 
One EL350 vial was treated with 100 μl 10% arabinose and other EL350 vial served as 
a control without arabinose induction. After one hour culture at 32°C, EL350 cells were 
electroporated with sSypELDTA and selected with ampicillin on LB plate. After 16 hours 
incubation at 32°C, colonies were picked, and Cre-loxP mediated recombination was 
verified by sequencing of PCR products obtained using forward primer (F1) 5'-CTC ACT 
GCC GCA GAG GGG GCC TCC A-3', forward primer (F2) 5'-ATG GAT CCT GAT GAT 
GTT GTT GAT TCT TCT AAA TC-3' and a reverse primer (R1) 5'-ACG TCA CTT TGA 
CCA CGC CTC CAG C-3'. Combination of F1 and R1 primers and that of F2 and R1 
yielded 617 bp and 256 bp PCR products, respectively.  
 
Transgene copy number quantification. Transgene copy number was carried out by 
Southern blotting and qPCR. Genomic DNA was isolated with a Gentra Puregene 
Tissue Kit (Qiagen, #158667). Genomic DNA from the sSypELDTA mouse (line 141) 
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was digested by restriction enzymes AflII, AscI, and PacI (New England Biolabs, 
Ipswich, MA), and detected by Southern blotting with 32P-labeled EGFP probe. 1117 bp 
EGFP probe was prepared by PCR using primers 5'EGFP (5'-ATG GTG AGC AAG 
GGC GAG GAG C-3') and 3'EGFP (5'-CCT GCA CGA CGC GAG CTG C-3'). The copy 
number of sSypELDTA transgene was estimated by densitometric analysis with Image J 
software (NIH, Bethesda, MD). To perform qPCR, 60 ng DNA was amplified with 
custom TaqMan real time EGFP probe (forward primer: 5'-CAC ATG AAG CAG CAC 
GAC TT-3'; reverse primer: 5'-GTG CGC TCC TGG ACG TA-3'), followed by 
normalization to the endogenous β-actin. All PCR reactions were performed in triplicate 
on AB 7500 Real Time PCR system (Applied Biosystems Inc, Foster City, CA). After 
getting relative quantification among each line, copy number was estimated by 
normalizing to copy number of sSypELDTA transgene in line 141.  
 
Microdissection-polymerase chain reaction. For laser microdissection, 4-μm-thick 
paraffin sections were prepared on PET (polyethylene terephthalate)-membrane slides 
for laser microdissection (Leica microsystems, Buffalo Grove, IL, #11505151) and 
stained with hematoxylin and eosin. Prostate cells from different areas (proximal region, 
ventral lobe, dorsolateral lobe, anterior lobe, muscular layer) were microdissected using 
a blue laser (Laser Microdissection System, Leica AS, Heidelberg, Germany), collected 
into caps of 0.6 ml Eppendorf tubes filled with lysis buffer, digested in proteinase K, 
divided equally among tubes for detection of recombination and used for subsequent 
PCR amplification following previously described protocol (Nikitin and Lee, 1996). EGFP 
was identified by primers EGFP5' (5'-CCT CGT GAC CAC CCT GAC CTA CGG C-3') 
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and EGFP3’ (5'-GCC GTC CTC GAT GTT GTG GCG GATC-3'). PCR amplification of 
EGFP resulted in 346 bp DNA fragment. 
 
Histotechnology. Mice euthanized according to schedule were subjected to cardiac 
perfusion by phosphate-buffered 4% paraformaldehyde. After digital camera 
photography during necropsy, collected tissues were processed for embedding in 
paraffin. Histological evaluations were done on 4-μm-thick sections stained with 
hematoxylin (Mayer's haemalum) and eosin. Transverse sections of the whole prostate 
were scanned by ScanScope (Aperio Technologies, Vista, CA) with 40X objective 
followed by lossless compression and assessment of all alterations in identical anatomic 
regions. 
 
Immunohistochemical analyses. Immunoperoxidase staining of paraffin sections of 
paraformaldehyde-fixed tissue was performed by a modified avidin-biotin-peroxidase 
(ABC) technique (Nikitin and Lee, 1996). Antigen retrieval was done by boiling the 
slides in 10 mM citric buffer (pH 6.0) for 10 minutes. The primary antibodies to 
cytokeratin-8 (CK8), cytokeratin-5 (CK5), SYP and cleaved Caspase-3 were incubated 
with deparaffinized sections at 4°C overnight. After incubation with methanol (Fisher 
Scientific, Bohemia, NY, #A454-4) containing 0.3% hydrogen peroxide (Sigma, St. Louis, 
MO, #H1009), sections were subsequently incubated with biotinylated secondary 
antibody for 30 minutes at room temperature and subsequently detected with the ABC 
Elite kit (Vector Laboratories, Burlingame, CA, #PK-6100) and 3,3-diaminobenzidine 
(DAB; Sigma, #D4418) as substrate. Hematoxylin was used as the counterstain in 
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immunoperoxidase stainings. Double immunofluorescence staining was performed by 
incubation of SYP and EGFP, or β-galactosidase primary antibody at 4°C overnight, 
followed by Alexa-Fluor 594-conjugated and Alexa-Fluor 488- conjugated secondary 
antibodies. To stain cell nuclei, sections were incubated with a 10 μg/ml solution of 4',6-
diamidino-2-phenylindole (DAPI; Sigma, #D9542) for 3 min. Antibody sources and 
dilutions are listed in the Immunohistochemical analyses - antibody sources and 
dilutions.  
 
Immunohistochemical analyses - antibody sources and dilutions. Primary antibody: rat 
anti-CK8 (Develop-mental Studies Hybridoma Bank, University of Iowa, IA, #TROMA-I, 
1:10), rabbit anti-CK5 (Covance, NJ, # PRB-160P, 1:1000), mouse anti-SYP (BD 
Biosciences, San Jose, CA, #611880, 1:200), rabbit anti-cleaved Caspase-3 (Cell 
Signaling, Danvers, MA, #9661, 1:200), rabbit anti-GFP (NOVUS biological, Littleton, 
CO, #NB600-303, 1:1000), rabbit anti-β-galactosidase (abcam, Cambridge, MA, 
#ab616-1, 1:200). Secondary antibody: biotinylated goat anti-mouse (Vector 
Laboratories, Burlingame, CA, # BA-9200, 1:200), biotinylated goat anti-rabbit (Vector 
Laboratories, #BA-1000, 1:200), biotinylated goat anti-rat (Vector Laboratories, # BA-
9400, 1:200), donkey Alexa-Fluor 594-conjugated anti-mouse (Invitrogen, Carlsbad, CA, 
#A21203, 1:200), donkey Alexa-Fluor 488-conjugated anti-rabbit (Invitrogen, #A21206, 
1:200), donkey Alexa-Fluor 594-conjugated anti-rabbit (Invitrogen, #404239, 1:200), 
donkey Alexa-Fluor 488-conjugated anti-mouse (Invitrogen, #A21202, 1:200). 
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Morphometric quantitative analyses. Five digital images of serial sections scanned by 
ScanScope with 40X objective were captured for each slide and transferred to Image J 
for manual counting of all epithelial cells (at least 1,000 cells) and SYP positive cells 
among them. The sizes of prostate lobes were determined by measuring the distance 
from the edge of each lobe to the urethra. The size of each prostatic duct was 
determined by measuring its diameter. 
 
Western blot analyses. PCN1, PCN2, and PCN3 cell lysates were prepared using RIPA 
buffer (Tris-HCl 50 mM, pH 7.4; Nonidet P-40 1%; Na-deoxicholate 0.25%; NaCl 150 
mM; EDTA 1 mM; PMSF 1 mM; Aprotinin, leupeptin, pepstatin: 1 μg/mL each; Na3VO4 1 
mM; NaF 1 mM), separated by 12% SDS-PAGE and transferred to PVDF membrane 
(Millipore). The membrane was incubated overnight at 4°C with antibodies to detect 
SYP (Dako, CA, #A0010, 1:100), followed by incubation for 1 hour at room temperature 
with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz 
Biotechnology, CA, #sc-2301, 1:2000) and developed using chemiluminescent 
substrate (Thermo scientific, Rockford, IL, #34077). 
 
Statistical analyses. Statistical analyses were performed with InStat 3.10 and Prism 
5.01 software. (GraphPad, Inc., San Diego, CA). Two-tailed unpaired t-test was used in 
all calculations. 
 
3.4 Results 
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3.4.1 Genomic structure of Syp locus and BAC engineering for the generation of 
SypELDTA constructs  
 
To identify the region containing all transcriptional cis-elements sufficient for accurate 
SYP expression in vivo, we have analyzed the genomic Syp locus by using the UCSC 
Genome Browser. The Syp locus is located on mouse chromosome X and contains 7 
exons and 6 introns. Locations of Syp locus and other surrounding genes are preserved 
among different species, such as rat and human (Figure 3.1A). Notably, NRSE within 
the first intron of Syp is highly conserved among closely related mammalian species 
(Figure 3.1B). Furthermore, comparison of the Syp upstream region also displays high 
conservation in proximal (approximate 0 to -600 bp) and distal (approximate -2000 to -
3000 bp) regions relative to transcription start site (Figure 3.2). It may imply that not only 
NRSE but also the sequences of those conserved regions are involved in conferring the 
cell type specific expression of SYP. Therefore, for molecular engineering we have 
decided to use mouse BAC clone RP23-267C15 because it encompasses the entire 
Syp locus and, thus, is likely to contain all transcriptional cis-elements required for 
recapitulation of the endogenous cell specific gene expression. 
First, loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA sequence was constructed to 
replace the sequence between 3' NRSE and exon 7 of Syp locus in BAC (Figure 3.3A). 
As a result, the Syp promoter specifically drives EGFP expression to label the SYP 
expressing cells. Following Cre-loxP mediated recombination, DTA can be expressed to 
ablate the SYP expressing cells. Second, the loxP site in the backbone of RP23-
267C15 was also replaced with β-lactamase sequence to avoid unintended Cre- 
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Figure 3.1 Genomic structure of the Syp gene. (A) Location of the Syp locus on 
mouse, rat, and human chromosome X. Mouse Syp contains 7 exons (black boxes). 
The translation initiation codon, ATG, is located in the first exon. The NRSE is located 
within the first intron of Syp. (B) Sequence comparison of the NRSE derived from Syp 
across species. 
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Figure 3.2 Sequence comparison of upstream region of Syp across species. Black 
lines and boxes represent highly conserved areas of the Syp upstream region. The 
position of upstream sequence is relative to the Syp transcription start site (0 bp). The 
assembly dates of the upstream regions are July 2007 (Mus musculus), November 
2004 (Rattus norvegicus), February 2009 (Homo sapiens), October 2010 (Pan 
troglodytes), January 2006 (Macaca mulatta), July 2007 (Pongo pygmaeus abelii), and 
March 2009 (Callithrix jacchus). 
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Figure 3.3 Generation of the BAC targeting construct. (A) The targeting strategy 
was to replace exon region of the Syp locus with loxP-EGFP-Neo cassette-Stop-loxP-
DTA-bpA by homologous recombination. Exon 1 and intron 1 have been preserved 
because of the NRSE sequence, which is essential for silencing activity in non-neuronal 
cells. Start codon ATG in exon 1 was mutated to alanine codon GCA. SypP: 
synaptophysin promoter. NRSE: neuro-restrictive suppressor element. (B) The 
backbone of RP23-267C15 (pBACe3.6 vector) contains a loxP site which has been 
replaced with β-lactamase sequence by homologous recombination. The modified BAC 
construct was named SypELDTA. 
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Figure 3.4 BAC transgenic constructs. (A) SypELDTA construct. The purple bar 
represents the EGFP probe. Restriction enzyme sites for Southern blot are indicated. (B) 
sSypELDTA construct. The fragment SypP-loxP-EGFP-Neo cassette-Stop-loxP-DTA-
bpA from SypELDTA was cloned into pGEM-T vector. 3 kb upstream fragment of Syp 
was used to drive downstream gene expression. 
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mediated recombination due to multiple loxP sites (Figure 3.3B). The modified BAC 
construct is named SypELDTA (173 kb) (Figure 3.4A). It contains 121 kb and 36 kb 
upstream and downstream DNA sequences flanking the Syp gene, respectively. To 
evaluate applicability of shorter upstream sequence of Syp for cell type specific 
expression, the sequence SypP-loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA from 
SypELDTA was retrieved into pGEM-T vector. The retrieving BAC construct is named 
sSypELDTA (12 kb; Figure 3.4B). It contains a 3 kb upstream fragment of the Syp 
promoter region. 
 
3.4.2 BAC transgene function in mammalian and bacterial cell culture  
 
Functionality of BAC construct was tested in cultured prostate cells and bacteria. 
sSypELDTA was transfected into the mouse p53 and Rb deficient prostate 
adenocarcinoma cell lines PCN1 and PCN3, which were established from prostate 
carcinomas of PB-Cre4; p53loxP/loxPRbloxP/loxP mice (Zhou et al., 2006). Consistent with 
our observation that PCN3 cells but not PCN1 cells express SYP (Figure 3.5A), EGFP 
positive cells have been observed only in PCN3 cells (Figures 3.5B-G) after transfection 
of sSypELDTA. Thus, 3 kb upstream fragment of Syp promoter region was sufficient to 
drive the transgene expression specifically in NE cells. 
To test for Cre-loxP mediated recombination, sSypELDTA was electroporated into 
the Escherichia coli (E. coli) EL350 system, which contains a tightly controlled 
arabinose-inducible Cre gene. As shown by PCR, successful Cre-loxP mediated 
recombination of sSypELDTA in bacterial system was observed after arabinose  
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Figure 3.5 Functional testing of sSypELDTA in cultured prostate NE cells and E. 
coli. (A) SYP expression in PCN1-PCN3 cells by western blotting. GAPDH, internal 
control. (B-G) Detection of EGFP expression by BAC transgene in prostate cancer cell 
line with NE differentiation (PCN3, C, E, G, arrows), but not in line without NE 
differentiation (PCN1, B, D, F). (B, C) Light microscopy, (D, E) green fluorescence, (F, 
G) merged images. Calibration bar: 200 μm (B-G). (H) Detection of Cre-loxP mediated 
recombination in sSypELDTA transgenic construct in the bacterial system EL350. 
EL350 bacteria, which contain endogenous arabinose-inducible Cre, were transformed 
with sSypELDTA transgenic construct and induced with arabinose. PCR genotyping 
was performed with F1/F2/R1 primers without (lane 2) and with (lane 3) arabinose 
induction. 256 bp and 617 bp fragments are diagnostic for internal control (primer F2/R1) 
and Cre-mediated recombination (primer F1/R1), respectively. Lane 1: marker (M). (I) 
Detection of DTA expression by sSypELDTA transgenic construct in the prostate cancer 
cell lines by RT-PCR. Lane 1: marker (M); Lane 2 (without RT) and Lane 3 (with RT): no 
transfection; Lane 4 (without RT) and Lane 5 (with RT): PGKDTAbpA transfection; Lane 
6 (without RT) and Lane 7 (with RT): sSypELDTA transfection; Lane 8 (without RT) and 
Lane 9 (with RT): sSypELDTA transfection followed by Ad-Cre infection; Lane 10 
(without RT) and Lane 11 (with RT): SypDTA transfection. 657 bp fragment is diagnostic 
for DTA mRNA; RT, reverse transcriptase. 
  
108 
 
induction (Figure 3.5H). The construct resulting from Cre-loxP mediated recombination 
was named SypDTA. To confirm that DTA expression driven by Syp promoter could be 
detected after Cre-loxP mediated recombination in mouse cells, reverse transcriptase 
PCR (RT-PCR) was performed with different constructs transfected into PCN1 and 
PCN3 after Adenovirus-Cre (Ad-Cre) infection. DTA expression could be detected in 
SypDTA-infected PCN3 cells and sSypELDTA-infected PCN3 cells followed by Ad-Cre 
infection. Conversely, no DTA expression could be detected in PCN1 cells. Thus, DTA 
was expressed specifically in NE cells after Cre-loxP mediated recombination (Figure 
3.5I). 
 
3.4.3 BAC transgene expression in SypELDTA transgenic mice 
 
To test transgene expression in vivo, sSypELDTA and SypELDTA DNA were used to 
generate transgenic lines 141-143 and 144-148, respectively (Table 3.1). Based on 
Southern blotting and quantitative PCR (qPCR), all mice of lines 144-148 carried a 
single copy of transgene, while copy number of sSypELDTA transgene was variable 
among lines 141-143 (Figure 3.6, Table 3.1).  
To confirm the specificity of transgene expression in transgenic mice, co- 
localization of transgene-derived EGFP and endogenous SYP has been determined by 
double immunofluorescence staining in prostate NE cells (Figure 3.7A). sSypELDTA 
transgenic mice had expression of transgene in non-NE epithelium cells of the prostate 
(Figure 3.8, Table 3.1). In contrast, no EGFP expression was detected in SYP negative 
cells (Figure 3.9, Table 3.2) of SypELDTA mice. Among 5 tested transgenic lines, the  
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 Table 3.1 Characterization of Transgenic Lines 141-148 
Transgene Line Male germ line transmission 
Copy 
number 
Transgene 
expression in 
prostate NE cells 
(%)* 
Transgene 
expression 
in prostate 
non-NE cells 
sSypELDTA 
141 Yes 11 72 Yes 
142 Yes 2 81 Yes 
143 Yes ND# ND Yes 
SypELDTA 
144 No 1 ND ND 
145 Yes 1 88 No 
146 No ND ND ND 
147 Yes 1 90 No 
148 Yes 1 83 No 
*Percentage of EGFP; SYP double positive cells within total number of SYP positive cells was 
determined by double immunofluorescence staining.  
#Not done  
  
110 
 
 
Figure 3.6 The transgene copy number in mice of sSypELDTA lines 141-143 and 
SypELDTA lines 144-148. (A) Experimental design. (B) Southern blot analysis of 
transgenic line 141. Genomic DNA digested with restriction enzymes AscI (Lane 2), 
PacI (Lane 3), and AscI, PacI and AflII (Lane 4). Lane 1: DNA marker (M). AflII but not 
AscI and PacI restriction sites are present within the transgene. 8,466 bp band in lane 4 
is diagnostic for multiple transgene copies integrated into a single genomic site, 
whereas top band (arrow) is  diagnostic for single copy of transgene. EGFP, DNA probe. 
(C) Quantification of transgene copy number in transgenic lines by quantitative PCR. 
Transgenic line 141 carrying 11 copies of transgene was used as a reference to 
estimate copy number of other lines. (D) Genotyping analysis of transgenic line 147. 
The upper bands are diagnostic for EGFP (lane 2, E, 346 bp), Neomycin (lane 3, N, 342 
bp), and DTA (lane 4, D, 348 bp) fragments of transgene. 196 bp band in lanes 2-4 is 
internal control (endogenous Rb). Lane 1: DNA marker (M). 
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Figure 3.7 SypELDTA transgene expression is highly specific for SYP expressing 
cells. (A-E) Co-expression of EGFP (green) and SYP (red) in prostate NE cells (A), 
lung NE cells (B; inset: high magnification), medulla of adrenal gland (C), pancreatic 
islets of Langerhans (D), and brain (E) of SypELDTA transgenic mice. Yellow color 
(arrows) indicates co-localization of EGFP and SYP fluorescent signals. Counterstaining 
with DAPI, blue. Calibration bar: 18 μm (A), 37 μm (B), 50 μm (C-E), 8 μm (inset).  
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Figure 3.8 Transgene expression in sSypELDTA lines 141-143. (A-H) Detection of 
EGFP (B, D, F, H, green) and SYP (C, D, G, H, red) expression (arrows) in non-NE (A-
D) and NE cells (E-H) of the prostate epithelium. Yellow color in overlay (D, H) indicates 
co-localization of EGFP and SYP fluorescent signals. Counterstaining with DAPI (A, D, 
E, H, blue). Calibration bar: 50 μm (A-D), 18 μm (E-H). 
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Figure 3.9 SypELDTA transgene expression has high specificity in SYP 
expressing cells. (A-T) Detection of EGFP (B, D, F, H, J, L, N, P, R, T, green) and 
SYP (C, D, G, H, K, L, O, P, S, T, red) expression (arrows) in prostate NE cells (A-D), 
lung NE cells (E-H), medulla of adrenal gland (I-L), islets of Langerhans in pancreas (M-
P), and brain (Q-T) of SypELDTA line 147 transgenic mice. Yellow color in overlay (D, H, 
L, P, T) indicates co-localization of EGFP and SYP fluorescent signals. Counterstaining 
with DAPI (A, D, E, H, I, L, M, P, Q, T, blue). Calibration bar: 25 μm (A-D), 50 μm (E-T). 
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Table 3.2 Transgene Expression in SypELDTA Line 147 
Tissue 
Transgene expression in 
SYP expressing cells 
(%)* 
Transgene expression 
in non-SYP expressing 
cells 
Brain 100 0 
Lung 92 0 
Medulla of adrenal gland 98 0 
Islets of Langerhans 100 0 
*Percentage of EGFP; SYP double positive cells within total number of SYP positive cells was 
determined by double immunofluorescence staining. 
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line 147 had the highest frequency (90%) of SYP positive NE cells co-expressing EGFP 
(Table 3.1). Furthermore, co-expression of EGFP and SYP in line 147 has also been 
observed in the lung NE cells (Figure 3.7B), medulla of adrenal gland (Figure 3.7C), 
islets of Langerhans in pancreas (Figure 3.7D), and brain (Figure 3.7E). 
 
3.4.4 DTA expression in EIIA-Cre; SypELDTA embryo 
 
To confirm that DTA expression driven by Syp promoter is able to ablate SYP positive 
cell lineage, DTA expression was examined by crossing the male SypELDTA mice of 
line 147 with female EIIA-Cre transgenic mice, following collection of embryos on 
gestational day (GD) 10.5 (Figure 3.10A). Adenoviral EIIA promoter targets expression 
of Cre recombinase to the early mouse embryo and Cre-mediated recombination occurs 
in a wide range of tissues, thereby allowing assessing effects of transgene expression 
in multiple organs and tissues (Lakso et al., 1996). EIIA-Cre; SypELDTA embryos had 
rare SYP positive cells in the brain and dorsal root ganglia (Figures 3.10B, D, F). 
Consistent with induction of apoptosis pathway by DTA (Chang et al., 1989a; Chang et 
al., 1989b), a significant number of cleaved Caspase-3 positive cells were detected in 
the same structures (Figures 3.10C, E, G). The brain and dorsal root ganglia of EIIA-
Cre littermates had abundant SYP positive cells (Figures 3.10H, J, L), but almost no 
cleaved Caspase-3 positive cells (Figures 3.10I, K, M). Thus, our construct was 
effective in conditional ablation of SYP expressing cells by DTA in vivo. 
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Figure 3.10 EIIA-Cre; SypELDTA embyros exhibit massive cell death in SYP 
positive cells. (A) Design of crosses between male SypELDTA and female EIIA-Cre 
transgenic mice. (B-M) SYP (B, D, F, H, J, L) and cleaved Caspase-3 (C, E, G, I, K, M) 
expression (arrows) in serial sections of EIIA-Cre; SypELDTA (B-G) and EIIA-Cre (H-M) 
embryos collected on gestational day 10.5. High (D-G, J-M) magnification images of 
brain (D, E, J, K) and dorsal root ganglion (F, G ,L, M) regions shown as rectangles in 
low magnification images (B, C, H, I). b, brain, g, dorsal root ganglia. ABC Elite method. 
Hematoxylin counterstaining. Calibration bar: 950 μm (B, C, H, I), 50 μm (D-G, J-M). 
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3.4.5 Effect of prostate epithelium-specific NE cell ablation  
 
Modified probasin promoter drives expression of Cre recombinase in the prostate 
epithelium of postnatal mouse prostate of PB-Cre4 transgenic mice (Chen et al., 2005; 
Wu et al., 2001). By using PB-Cre4 mice we have previously determined that deletion of 
tumor suppressor genes p53 and Rb results in prostate carcinomas with NE 
differentiation (Zhou et al., 2006; Zhou et al., 2007). We have also reported that 
expansion of NE cells is observed in prostate adenocarcinomas in PB-Cre4; PtenloxP/loxP 
mice, particularly after castration (Liao et al., 2007). To verify that Cre recombinase 
under the control of probasin promoter is expressed in NE cells, which are concentrated 
in the prostate proximal region (Figure 3.11), Cre-mediated recombination in prostate 
NE cells was examined by crossing PB-Cre4 transgenic mice (Wu et al., 2001) with 
R26R reporter mice (Soriano, 1999). The expression of β-galactosidase is possible only 
after Cre-mediated deletion of a stop codon flanked by loxP sites. Double 
immunofluorescence staining showed co-localized expression of β-galactosidase and 
SYP in the proximal region of prostatic ducts of PB-Cre4; R26R mice. Thus, Cre-loxP 
mediated recombination occurs in NE cell lineage after Cre expression directed by 
probasin promoter (Figure 3.12).  
To evaluate whether prostate epithelium-specific NE cell ablation impacts prostate 
development and function, male PB-Cre4 transgenic mice have been crossed with 
female SypELDTA (lines 147 and 148) mice to get PB-Cre4; SypELDTA male offspring 
(Figure 3.13A). Both lines shown similar phenotypes and line 147 has been 
characterized to the fullest extent. As compared to wild-type (FVB/N) and SypELDTA 
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Figure 3.11 NE cells are mostly located in the proximal region of prostatic ducts. 
(A, B) SYP expression in NE cells in proximal (A) and distal (B) regions of prostatic 
ducts of the prostate (n=6). NE cells and nerve terminals are indicated by arrows and 
arrowheads, respectively. Calibration bar: 50 μm (A), 100 μm (B). (C) Quantification of 
SYP positive NE cells. Distal regions of prostatic ducts contain no NE cells. Error bar 
denotes SD. 
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Figure 3.12 Cre recombinase under the control of probasin promoter is expressed 
in prostate NE cells. (A-D) Detection of SYP (B, D, green) and β-galactosidase (C, D, 
red, indicative of Cre-loxP mediated recombination) expression (arrows) in the prostate 
NE cells in PB-Cre4; R26R mice harboring Probasin-Cre and lacZ reporter gene. Yellow 
color in overlay (D) indicates co-localization of SYP and β-galactosidase fluorescent 
signals. Counterstaining with DAPI (A, D, blue). Calibration bar: 50 μm (A-D). 
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Figure 3.13 PB-Cre4; SypELDTA line 147 mice show decreased number of NE 
cells and prostate hypotrophy. (A) Design of crosses between male PB-Cre4 and 
female SypELDTA transgenic mice resulting in male PB-Cre4; SypELDTA offspring with 
prostate epithelium-specific NE cell ablation. (B) Gross images of the prostate from wild-
type FVB/N (FVB), SypELDTA (147), PB-Cre4; SypELDTA (AP147) mice. Calibration 
bar: 0.5 cm. (C, D) Detection of SYP positive NE cells (arrows) in the prostate proximal 
region of age-matched SypELDTA (C; n=4) and PB-Cre4; SypELDTA (D; n=4) mice. 
ABC Elite method. Hematoxylin counterstaining. Calibration bar: 50 μm. (E-G) 
Quantification of NE cells in the proximal regions of whole prostate (E), and in the 
proximal regions of ventral (F) and dorsolateral (G) lobes of prostates from age-
matched SypELDTA (147; n=4) and PB-Cre4; SypELDTA (AP147; n=4) mice. (H) 
Quantification of NE cells in proximal regions of dorsolateral and ventral lobes of the 
prostates from SypELDTA mice (n=4). *P<0.05. ***P<0.001. All error bars denote SD. 
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(147) age-matched controls and littermates, the size of prostate of PB-Cre4; SypELDTA 
(AP147) was smaller (Figures 3.13B and 3.14). In agreement with earlier reports of 
broad PB-Cre4 transgene expression in the prostate epithelium (Wu et al., 2001), loss 
of floxed EGFP was reproducibly observed in all prostate lobes according to 
microdissection-PCR genotyping of AP147 (Figure 3.15). However, only the NE cell 
population was diminished by 60% in AP147 mice as compared to controls according to 
immunostaining for SYP in the proximal regions of prostatic ducts (147 vs. AP147: 
1.19±0.34% vs. 0.5±0.19%, P<0.0001; Figures 3.13C-E). The decrease was observed 
consistently in various areas of the proximal region, such as ventral (1.07±0.22% vs. 
0.55±0.18%, P<0.0001; Figure 3.13F) and dorsolateral (1.42±0.39% vs. 0.44±0.19%, 
P<0.0001; Figure 3.13G) lobes. In addition, the average diameter of prostatic ducts in 
distal regions was decreased, especially in the dorsolateral lobe (Figure 3.16). 
Interestingly, more NE cells were observed (1.42±0.39% vs. 1.07±0.22%, P=0.0252; 
Figure 3.13H) and higher percentage of NE cells was ablated (70% vs. 49%; Figures 
3.13F, G) in the proximal regions of prostatic ducts of dorsolateral lobes, as compared 
to those of ventral lobes, which could be associated with the smaller diameter of 
prostatic ducts in dorsolateral lobes. 
Except for the size of lumens, there were no significant changes in overall 
morphology of prostatic ducts in the ventral and dorsolateral lobes of AP147 mice, or in 
either the proximal or distal regions of prostatic ducts (Figure 3.16). NE cell ablation did 
not result in any detectable changes to the extent of luminal (CK8) and basal (CK5) 
differentiation in the proximal and distal regions of ducts (Figure 3.17). No significant 
cell death was observed in luminal and basal cells in any of the regions (Figure 3.18),  
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Figure 3.14 Reduced sizes of prostate lobes in PB-Cre4; SypELDTA mice. (A-D) 
Quantification of size of anterior (A), dorsal(B), lateral (C), and ventral (D) lobes among 
age-matched FVB/N (FVB, n=4), SypELDTA (147; n=4), and PB-Cre4; SypELDTA 
(AP147; n=4) mice. *P<0.05. **P<0.01. Error bar denotes SD. 
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Figure 3.15 PB-Cre drives Cre-loxP recombination in the prostate of PB-Cre4; 
SypELDTA mice. (A-F) Microdissection-PCR. Proximal (A) and distal (ventral, B, 
dorsolateral, C, and anterior, D) regions of prostatic ducts and the muscular layer of the 
prostate (E) of age-matched SypELDTA (147) and PB-Cre4; SypELDTA (AP147) mice 
before and after microdissection. Hematoxylin and eosin. Calibration bar: 50 μm (A-E). 
(F) PCR design and detection of Cre-loxP mediated recombination in microdissected 
proximal region (P, lane 2 and 7), and ventral (V, lane 3 and 8), dorsolateral (DL, lane 4 
and 9), anterior (A, lane 5 and 10) distal regions, and muscular layer (ML, lane 6) of 
prostates from SypELDTA(lanes 2-5) and PB-Cre4; SypELDTA (lanes 6-10) mice. 346 
bp fragment is generated with primers F1and R1and is diagnostic for EGFP (present 
before Cre-loxP mediated recombination). 196 bp fragment (endogenous Rb) is internal 
control. Lane 1: marker (M). 
  
125 
 
 
Figure 3.16 NE cell ablation results in proportional reduction of prostatic duct 
diameters in distal regions. (A-I) Histology (A, B, D, E, G, H) and quantification of 
diameters (C, F, I) of proximal (A, B, C) and distal (ventral, D, E, F, and dorsolateral, G, 
H, I) regions of prostatic ducts of age-matched SypELDTA (147; n=6; A, D, G) and PB-
Cre4; SypELDTA (AP147, n=6; B, E, H) mice. Hematoxylin and eosin. Calibration bar: 
50 μm (A, B), 100 μm (D, E, G, H). *P<0.05. **P<0.01. All error bars denote SD. 
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Figure 3.17 NE cell ablation does not affect luminal (CK8+) or basal (CK5+) cell 
differentiation. (A-L) Detection of CK8 (A-F) and CK5 (G-L) expression (brown) in 
epithelial cells of proximal (A, D, G, J) and distal (ventral, B, E, H, K, and dorsolateral, C, 
F, I, L) regions of prostatic ducts in age-matched SypELDTA (147, A-C, G-I) and PB-
Cre4; SypELDTA (AP147, D-F, J-L) mice. ABC Elite method. Hematoxylin 
counterstaining. Calibration bar: 50 μm (A-L). 
 
  
127 
 
 
Figure 3.18 No significant cell death is observed in prostate epithelium non-NE 
cells in PB-Cre4; SypELDTA mice. (A-F) cleaved Caspase-3 expression in proximal 
(A, B), and distal (ventral, C, D, and dorsolateral, E, F) regions of prostatic ducts in age-
matched SypELDTA (147, A, C, E) and PB-Cre4; SypELDTA (AP147, B, D, F) mice. 
The staining of embryonic dorsal root ganglia (Figure 5) served as a positive control for 
cleaved Caspase-3 immunostaining. ABC Elite method. Hematoxylin counterstaining. 
Calibration bar: 50 μm (A-F). 
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which implies a tight regulation of Syp promoter in prostate non-NE epithelium cells. 
Taken together, these results support the notion that NE cells play an important role in 
prostate development.  
 
3.5 Discussion 
 
Previous report indicated that 2.6 kb but not 1.2 kb upstream fragment of Syp was 
sufficient to confer cell type specific expression (Bargou and Leube, 1991). Consistent 
with this observation, we have found high evolutionary conservation not only in the 
proximal (0 to -600 bp) but also distal (-2000 to -3000 bp) regions of the Syp gene. 
Based on this information, we have designed transgenic constructs preserving NRSE in 
the first intron of Syp gene and containing either 3 kb or 121 kb upstream regulatory 
sequence. While 3 kb sequence was sufficient for NE specific expression of transgene 
in cultured cells, it did not assure specificity of gene expression in the transgenic mice. 
At the same time, a longer promoter has been highly specific for NE cells. These results 
suggest that other cis-elements, farther than 3 kb upstream fragment, provide the cell 
type specific expression in the context of the whole organism. It is also possible that the 
36 kb 3' flanking region of Syp might play a role in regulating cell specificity as well, 
similarly to other genes, such as human tyrosine hydroxylase (Wong et al., 1995). Also, 
longer upstream and downstream regions of Syp locus may better insulate the Syp 
promoter from position effects by other genes at the site of transgene integration (Yang 
and Gong, 2005). However, given NE cell specific expression of 3 kb construct after its 
multi-copy integration in cell culture, the latter possibility is less likely. Identification of 
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environment driven mechanisms responsible for accurate gene expression should allow 
much better understanding of Syp regulation. 
It should be noted that in addition to NE cells, SYP is also expressed in neurons of 
the nervous system (Gould et al., 1987; Wiedenmann et al., 1986). Unlike other REST 
regulated genes, such as BDNF and GluR2 genes, Syp is similarly regulated in 
neuronal and NE cells (Hohl and Thiel, 2005). Consistently, we have observed broad 
expression of Syp driven EGFP and DTA in mouse neurons of the brain and spinal 
ganglia. Thus, our model can be used for targeted ablation of NE and/or neuronal cells 
depending on a particular Cre driving promoter. 
Some neuropeptides, such as calcitonin gene-related peptide (CGRP) and gastrin-
releasing peptide (GRP) are expressed only in subsets of NE cells (di Sant'Agnese et 
al., 1989; Sunday et al., 1988; Weichselbaum et al., 2005). Therefore, theoretically it is 
possible that some NE cells do not express SYP. Although we were unable to find any 
literature supporting this possibility, our SypELDTA mice should allow detection of such 
cells by using double immunofluorescence for various NE markers before and after Syp-
driven ablation in future. 
As a proof of the utility of our model, we performed prostate epithelium-specific 
ablation of NE cells. The mouse prostate is composed of a series of branching ducts, 
each containing distal, intermediate and proximal regions relative to the urethra 
(Sugimura et al., 1986). Each duct contains three differentiated cell types: luminal, basal 
and NE cells, with stem cells preferentially concentrated in the proximal region (Leong 
et al., 2008; Salm et al., 2005; Tsujimura et al., 2002; Wang et al., 2007). NE cells 
secrete a large number of neuropeptides which can be mitogenic and growth-promoting. 
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Receptors for some of the NE products have been found to be expressed in benign 
prostate and/or prostate cancer. It has been proposed that the NE cells may regulate 
the growth, differentiation and secretory activity of the prostatic epithelium, possibly 
through a paracrine mechanism (Abrahamsson, 1999). However, studies directly 
addressing role of NE cells in prostate development have been lacking.  
Based on co-detection of SYP and EGFP double immunofluorescence, as well as 
lack of Cre-mediated recombination and cell death in prostate non-NE epithelium cells 
of PB-Cre4; SypELDTA mice, expression of SypELDTA has been highly specific to SYP 
positive prostate NE cells. Consistent with the important role of NE cells in prostate 
biology, prostates with decreased number of NE cells were hypotrophic, with decreased 
sizes of prostate lobes and reduced average diameters of prostatic ducts. Notably, the 
most pronounced effect of NE ablation on prostate hypotrophy was in the dorsolateral 
prostate, where NE cells were ablated to the greatest extent. Our study also indicates 
that NE cells are located in the proximal regions of the prostatic ducts, the area of 
preferential stem cell location. Future in-depths studies should address the kinetics of 
NE cell ablation effects and explore if the effect of NE cells on prostate size can be 
explained by their proximity to prostate stem cells. 
It should be noted that in spite of 90% gene expression specificity in prostate NE 
cells of SypELDTA line 147 mice, we observed only 60% decrease in number of 
prostate NE cells in PB-Cre4; SypELDTA mice. Consistent with previous study 
describing compartmentalization of gene expression between prostate lobes (Abbott et 
al., 2003), our results support a possibility that efficiency of Cre-mediated homologous 
recombination is different in NE cells of a particular region. We also cannot exclude that 
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there are intrinsic differences in regulation of gene expression in individual NE cells, 
which may lead to the reduction of DTA expression in some of them. Thus, further 
improvements in design of constructs for highly efficient NE cell ablation may yield even 
more dramatic effect on prostate hypotrophy. 
NE cell differentiation is positively correlated with prostate cancer progression, 
castrate-resistance and poor prognosis (Debes and Tindall, 2004; Sun et al., 2009). 
Previous reports have indicated that NE cells can stimulate cell proliferation, invasion, 
and apoptosis resistance of cultured prostate cancer cells (Sun et al., 2009). However, 
specific mechanisms involved in the pathogenesis of NE differentiation are not well 
known. Crossing PB-Cre4; SypELDTA transgenic mice with Pten knockout mice (Liao et 
al., 2007; Wang et al., 2003) or other established mouse prostate cancer models with 
preferential NE differentiation, such as TRAMP or LADY (Kaplan-Lefko et al., 2003; 
Masumori et al., 2001), should decisively determine the role of NE cells in prostate 
carcinogenesis. More generally, SypELDTA mice should be useful for studying other NE 
neoplasms, such as small cell lung carcinoma and NE tumors in the gastrointestinal 
tract (Linnoila, 2006; Montuenga et al., 2003; Sun et al., 2009). 
Taken together, we have identified a region of Syp gene sufficient for faithful 
expression of genetic constructs. We have also successfully generated the SypELDTA 
mouse model suitable for flexible organ-specific detection and ablation of NE cells. This 
model system should provide an important tool for studies of NE cell functions in 
development and carcinogenesis in various tissues. 
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4.1 Abstract  
 
Membrane metallo-endopeptidase (MME) is responsible for the catalytic inactivation of 
neuropeptide substrates and is downregulated in a significant fraction of prostate 
cancers. Re-introduction of MME into MME-deficient neoplastic cells results in cancer 
suppression. However, mice lacking Mme do not develop prostatic neoplastic lesions, 
thereby placing in doubt MME's role as an authentic tumor suppressor. Here we report 
that MME cooperates with PTEN in the regulation of normal and neoplastic prostate 
stem/progenitor cells. In the mouse model of prostate carcinogenesis associated with 
PTEN deficiency, lack of MME results in expansion of prostate stem/progenitor cell pool 
and development of advanced adenocarcinomas with extensive vascular invasion. 
Effects of MME deficiency on prostate stem/progenitor cells and cancer propagating 
(aka stem) cells are recapitulated by addition of the main MME substrate, gastrin-
releasing peptide (GRP). Importantly, GRP receptor antagonist [Tyr4, D-Phe12]-
Bombesin abrogates those effects and delays tumor growth by reducing the pool of 
cancer propagating cells. Our study provides a definitive proof of tumor suppressive role 
of MME and uncovers an important function of the MME/GRP pathway in the control of 
prostate stem/progenitor cells. Furthermore, it identifies GRP receptor as a valuable 
target for therapies aimed at eradication of prostate cancer propagating cells. 
 
4.2 Introduction 
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Prostate cancer is the most frequently diagnosed cancer and is expected to remain the 
second leading cause of cancer-related death in men in 2014 (Siegel et al., 2014). 
Aberrations in neuroendocrine signaling frequently present in prostate cancer, and 
neuropeptides, such as gastrin-releasing peptide (GRP), have been reported to be 
associated with accelerated prostate cancer progression and poor prognosis (Amorino 
and Parsons, 2004; Gkonos et al., 1995; Sun et al., 2009; Uchida et al., 2006). GRP 
can promote cell proliferation and accelerate migration and invasion of PC-3, DU-145, 
TSU-pr1 and LNCaP prostate cancer cells (Aprikian et al., 1997; Hoosein et al., 1993; 
Nagakawa et al., 1998; Nagakawa et al., 2001; Sumitomo et al., 2000). Consistently, 
targeting of the GRP receptor has been reported to suppress the growth of human 
prostate cancer cells in cell culture and in xenografts (Hohla and Schally, 2010; Mansi 
et al., 2013; Stangelberger et al., 2008). However, specific mechanisms by which 
neuropeptide dysregulation may be involved in the pathogenesis of prostate cancer 
remain insufficiently elucidated.  
 Membrane metallo-endopeptidase (MME, aka Neutral endopeptidase, Neprilysin, 
Enkephalinase, CALLA, CD10, EC 3.4.24.11) is a cell-surface peptidase, which cleaves 
peptide bonds on the amino side of hydrophobic amino acids. MME is the key enzyme 
in the processing of a variety of physiologically active peptides including GRP (Erdos 
and Skidgel, 1989; Shipp and Look, 1993; Zheng et al., 2006). MME is downregulated 
in a large fraction of primary and metastatic prostate cancers, independently predicting 
an inferior prognosis (Freedland et al., 2003; Osman et al., 2004; Papandreou et al., 
1998). MME expression reduces growth, motility (Sumitomo et al., 2000), and survival 
(Sumitomo et al., 2001) of cancer cells in cell culture. Consistent with these 
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observations, both lentiviral and adenoviral replacements of MME inhibit prostate 
cancer tumorigenicity in xenograft experiments. (Horiguchi et al., 2007; Iida et al., 2012). 
However, mice lacking Mme show no cancer-related phenotype (Lu et al., 1995), raising 
a question about physiological relevance of MME's tumor suppressive effects.  
 To establish the role of MME in prostate carcinogenesis we used an 
autochthonous mouse model of prostate neoplasia associated with deficiency of the 
Pten tumor suppressor gene. In this model, prostate carcinogenesis is initiated by the 
prostate epithelium-specific inactivation of Pten driven by PB-Cre4 transgene (PtenPE-/- 
mice; Adisetiyo et al., 2013; Chen et al., 2005; Cheng et al., 2014; Liao et al., 2007; 
Trotman et al., 2003; Wang et al., 2003; Wu et al., 2001; Zhou et al., 2006). The 
majority of PtenPE-/- mice develop high-grade prostatic intraepithelial neoplasms (HG-
PINs) and a few animals show early adenocarcinomas characterized by stromal 
invasion. This model is particularly relevant to human disease because PTEN is 
frequently absent or downregulated in human prostate cancer (Cairns et al., 1997; Li et 
al., 1997). Previous cell culture studies have shown a potential cooperation between 
MME and PTEN (Sumitomo et al., 2004). Consistent with this possibility, the 
bioinformatics analysis of alterations via the cBioPortal for Cancer Genomics (Cerami et 
al., 2012; Gao et al., 2013) shows that downregulation of MME is observed in 42% and 
63% of PTEN-deficient cases of human primary and metastatic prostate cancers, 
respectively (Taylor et al., 2010). 
 It has been reported that Pten conditional deletion in the prostate epithelium 
leads to basal cell proliferation with concomitant expansion of the prostate 
stem/progenitor-like Sca-1+ and BCL-2+ subpopulation (Wang et al., 2006). CD49fhi/Sca-
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1+ Pten-deficient neoplastic cells exhibits cancer propagating cell properties, such as 
high sphere-forming capacity, sustained self-renewal, increased proliferation, and 
tumorigenic potential, as compared with other isogenic subpopulations (Mulholland et 
al., 2009). Prostate cancer propagating cells have also been shown to be regulated by 
the PTEN/PI3K/AKT pathway (Dubrovska et al., 2009).  
 In the current study we show that additional deficiency for MME facilitates 
expansion of the prostate/stem cell pool associated with Pten loss and leads to 
morphologically detectable neoplastic lesions of the prostate stem/progenitor cell 
compartment followed by the formation of aggressive prostate cancers manifesting 
frequent vascular invasion. We also show that effects of MME on normal prostate 
stem/progenitor cells and cancer propagating cells depend on its substrate, GRP, and 
can be abrogated by either GRP receptor (GRPR) antagonist or GRPR siRNA 
knockdown. These findings offer a new mechanism by which neuropeptide-mediated 
dysregulation may facilitate cancer progression. 
 
4.3 Materials and Methods 
 
Mice. ARR2PB-Cre transgenic male mice on FVB/N background (PB-Cre4) (Wu et al., 
2001) were crossed with PtenloxP/loxP (Lesche et al., 2002) female mice on the 
129/BALB/c background. Resulting PB-Cre4PtenloxP/loxP male mice were designated as 
PtenPE-/- mice. PtenPE-/- male mice were crossed with Mme null female mice on a 
C57BL6 background (Mme-/-) (Lu et al., 1995). Offspring with PB-Cre4 Mme-/- 
PtenloxP/loxP genotype were designated as Mme-/-PtenPE-/- mice. To minimize the 
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confounding effects of genetic background, PtenPE-/- and Mme-/-PtenPE-/- mice were 
backcrossed to FVB/N for at least 10 crosses and all control experiments were 
performed on age and sex-matched mice of the same background. All animal 
experiments were carried out in strict accordance with the recommendations of the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
The protocol was approved by the Institutional Laboratory Animal Use and Care 
Committee at Cornell University. All efforts were made to minimize animal suffering. 
 
Immunohistochemistry and quantitative image analysis. Immunoperoxidase staining of 
paraffin sections of paraformaldehyde-fixed tissue was performed by a modified Elite 
avidin-biotin-peroxidase (ABC) technique (Nikitin and Lee, 1996). Antigen retrieval was 
done by boiling the slides in 10 mM citric buffer (pH 6.0) for 10 min. The primary 
antibodies to MME (Santa Cruz; Dallas, TX; #sc-80021, 1:100), Ki67 (Leica 
Microsystems; Bannockburn, IL; #NCLKi67p, 1:1000), EZH2 (Cell Signaling Technology; 
Danvers, MA; #5246, 1:200), keratin 5 (CK5, Covance; Dallas, TX, #PRB-160P, 1:2500), 
keratin 8 (CK8, Developmental Studies Hybridoma Bank; Iowa City, IA; #TROMA-I, 
1:10), p63 (Santa Cruz, #sc-8431, 1:1000), PTEN (Cell Signaling Technology, #9559S, 
1:800), pAKT (Cell Signaling Technology, # 3787S, 1:50), SYP (BD Biosciences; 
#611880, 1:500), GRP (Santa Cruz, #sc-7788, 1:100), NT (Santa Cruz, #sc-20806, 
1:1000), and VIP (Abcam; Cambridge, MA; #ab8556, 1:200) were incubated with 
deparaffinized sections at 4ºC overnight, followed by incubation with secondary 
biotinylated antibody (1 hour, room temperature) and modified avidin-biotin-peroxidase 
(ABC) technique. Methyl green was used as the counterstain in immunoperoxidase 
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stainings. Slides were scanned by ScanScope CS (Leica Biosystems, Vista, CA) with a 
40X objective followed by lossless compression. Quantitative analysis of 
immunohistochemistry (IHC) was performed with the ImageJ software (W. Rasband, 
National Institutes of Health, Bethesda, MD). 
 
Tumorigenicity experiments. Human prostate cancer PC3 cells (5 x 106 cells) were 
suspended in the mixture of 200 µl PBS and 200 µl Matrigel (BD Biosciences, #356237) 
and injected subcutaneously into 5-week-old NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ4; 
The Jackson Laboratory, stock number #005557) male mice (Fridman et al., 2012; 
Shultz et al., 2005). Intra-peritoneal injection of GRPR antagonist (0.8 μg/g body 
weight/day in PBS) was started when the tumor size reached 10 mm3 (Chanda et al., 
2010; Pinski et al., 1993). After 26 days of treatment with GRPR antagonist, mice were 
euthanized and subjected to necropsy. Tumor xenografts were collected for pathological 
evaluation and ALDEFLUOR assay followed by FACS analysis 
 
Pathologic assessment. Moribund mice, as well as those sacrificed according to 
schedule, were anesthetized with avertin and, if necessary, subjected to cardiac 
perfusion at 90 mm Hg with PBS. After macroscopic evaluation during necropsy, lung, 
liver, prostate, and lymph nodes were fixed in phosphate-buffered 4% 
paraformaldehyde and embedded in paraffin. 4-μm-thick sections were stained with 
Hematoxylin (Mayer's haemalum) and eosin. Mouse prostatic intraepithelial neoplasia 
(PIN) and adenocarcinoma were defined according to earlier publications (Ittmann et al., 
2013; Park et al., 2002; Shappell et al., 2004; Zhou et al., 2006). Briefly, distal PIN 1 
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has 1 or 2 layers of atypical cells; PIN 2 has 3 or more layers of atypical cells, PIN 3 
occupies the near entire glandular lumen; and PIN 4 fills and distorts the glandular 
profile, and is frequently marked by pronounced desmoplastic reaction. In agreement 
with the recent consensus report (Ittmann et al., 2013), PIN1 and PIN2 represent low-
grade PIN (LG PIN) and PIN3 and 4 represent high-grade PIN (HG PIN). Due to 
different architecture of the proximal regions of prostatic ducts, current PIN classification 
cannot be carefully applied to atypical proliferative lesions found in those structures. 
Thus we named those lesions as proximal duct dysplasia to stress their dissimilarity to 
PIN of distal regions of prostatic ducts. Given the complexity and controversial nature of 
the interpretation of stromal microinvasion we used the term “early adenocarcinoma” 
only for neoplasms with invasive stromal growth confirmed by serial sections followed 
by 3D reconstruction. We used the term “advanced adenocarcinoma” for neoplasms 
invading blood and lymphatic vessels.  
 
Cell culture. DU145 and PC3 cell lines were obtained from the American Type Culture 
Collection (ATCC) and cultured in minimum essential medium (Cellgrow, #10-010-CV) 
and F-12K (Cellgrow, #10-025-CV), respectively, supplemented with 10% heat-
inactivated fetal bovine serum (FBS, GIBCO, #16141-079) and Penicillin-Streptomycin 
(Cellgrow, #30-002-Cl). The cultures were maintained at 37ºC in a 5 % CO2 incubator. 
Primary mouse prostate cells were isolated following described procedures 
(Lawson et al., 2010; Lukacs et al., 2010a). Lipofectamin 2000 reagent (Invitrogen; 
Carlsbad, CA, #11668-030) was used for the transfection following manufacturer’s 
recommendations. Control siRNA (Santa Cruz, #sc-37007) and two independent human 
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GRPR siRNAs (Santa Cruz, # sc-106924 and Life Technologies, #145216) and mouse 
Grpr siRNAs (Life Technologies, #157912 and #157914) were used for all knockdown 
experiments.  
5-bromo-2’deoxyuridine (BrdU) staining (Flesken-Nikitin et al., 2013), migration and 
invasion assays (Corney et al., 2010) were performed as previously described. 
 
ALDEFLUOR assay and Fluorescence Activated Cell Sorting. For detection of aldehyde 
dehydrogenase (ALDH) enzymatic activity, 106 cells were placed in ALDEFLUOR buffer 
and processed for staining with the ALDEFLUOR Kit (STEM CELL, #01700) according 
to the manufacturer's protocol. Unstained and ALDH inhibitor 
(diethylaminobenzaldehyde, DEAB)-treated cells served as controls. For detection of 
CD44-expressing cancer cells, prostate cancer cells were stained for CD44 (BD 
Bioscience, #553134) to sort CD44-positive and CD44-negative cells. Cell sorting and 
data analysis were performed on a FACS Aria II sorter equipped with the FACS DiVa 
software (BD Bioscience).  
 
Prostate sphere assay. The preparation of prostate epithelial cell suspensions, 
stem/basal cells, and luminal cells from male mice and the prostate sphere assay were 
performed as described previously (Cheng et al., 2014; Lawson et al., 2010; Lukacs et 
al., 2010a). Briefly, 104 mouse prostate stem/basal cells, mouse prostate luminal cells, 
human prostate cancer cells, and human prostate cancer propagating cells were 
resuspended in 120 µl of a 1:1 mixture of Matrigel (BD Biosciences, #354234) and 
PrEGM (Lonza, #CC-3166), and plated around the rim of a well of a 12-well tissue 
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culture plate. Matrigel mix was allowed to solidify at 37°C for 15 min, and 1 ml of PrEGM 
was added to each well. Media were changed every 3 days. To recover the spheres, 
each well was treated with enzyme mixture: 750 µl Collegenase/Dispase 4 mg/ml 
(Roche, #10269638001), 30 mg BSA (Sigma, #A3311), and 1 µl DNase1 10mg/ml 
(Sigma, D4513). This was followed by treatment with Trypsin 0.25% EDTA (Cellgrow, 
25-052-Cl) to make cell suspensions, which were ready for passage. 
 
GRP and GRPR antagonist treatment. 5 nM GRP (Gastrin-releasing peptide human, 
Sigma, #G8022) (Dai et al., 2002) and 4 μM GRPR antagonist ([Tyr4, D-Phe12]-
Bombesin, Sigma, #B0650) (Heinz-Erian et al., 1987) were used for cell culture 
experiments. Media were changed every 3 days. 
 
Western blot. For western blot, cell lysates were prepared using RIPA buffer (50 mM 
Tris-HCl, (pH 7.4), 1% Nonidet P-40, 0.25% Na-deoxicholate, 150 mM NaCl, 1 mM 
EDTA, 1 mM PMSF, Aprotinin, leupeptin, pepstatin: 1 μg/ml each, 1 mM Na3VO4, 1 
mM NaF), and 10 seconds of sonication on ice 5 times. Lysates were then separated by 
12% SDS-PAGE and transferred to PVDF membrane (Millipore #IPVH00010). The 
membrane was incubated overnight at 4ºC with antibodies to detect GRPR (Santa Cruz, 
#sc-32903, 1:1000) and GAPDH (Advanced Immunohistochemical Inc.; Long Beach, 
CA; #2-RGM2,1:5000), followed by incubation for 1 hour at room temperature with 
corresponding horseradish peroxidase-conjugated anti-rabbit secondary antibodies 
(Santa Cruz, #sc-2004, 1:2000) or anti-mouse secondary antibodies (Santa Cruz, #sc-
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2005, 1:2000), and developed using chemiluminescent substrate (Thermo Scientific, 
Rockford, IL, #34077). 
 
Statistical analysis. Statistical analyses were performed with InStat 3.10 and Prism 6 
software. (GraphPad, Inc., San Diego, CA). A two-tailed unpaired t-test, direct Fisher's 
tests, and a log-rank Mantel-Haenszel test were used as appropriate.  
 
4.4 Results 
 
4.4.1 MME cooperates with PTEN in suppression of prostate cancer in 
autochthones mouse model 
 
To test potential cooperation of Mme and Pten genes in suppression of prostate cancer, 
we evaluated MME expression in HG-PINs and early invasive adenocarcinomas typical 
for PtenPE-/- mice. While irregular MME expression was observed in the majority of 
neoplastic lesions, MME was absent in the areas of stromal invasion (Figure 4.1). No 
significant alterations in MME expression were detected in the proximal regions of 
prostatic ducts, consistent with the lack of neoplastic lesions in that part of the prostate 
in PtenPE-/- mice (Figures 4.1 and 4.2A, Table 4.1). 
  Next we crossed Mme-/- and PtenPE-/- mice, and evaluated prostates of age-
matched wild-type (WT), Mme-/-, and PtenPE-/- and Mme-/-PtenPE-/- strains (Figures 4.2 
and 4.3, Table 4.1). Consistent with previous observations, Mme-/- mice did not develop 
any neoplastic lesions by 16 months of age, while PtenPE-/- mice showed low- and high-
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grade PINs at 3 months and onwards. At 16 months, 33% of PtenPE-/- mice developed 
early invasive adenocarcinomas, characterized by separate nests of neoplastic cells in 
the desmoplastic stroma (Figure 4.3A). All neoplastic lesions were in the distal regions 
of prostatic ducts. Unlike PtenPE-/- mice, Mme-/-PtenPE-/- mice developed dysplastic 
lesions followed by adenocarcinomas in the proximal regions of the prostatic ducts 
(Figure 4.2A). Furthermore, some adenocarcinomas have shown distinct vascular 
invasion, a feature not characteristic of prostatic lesions in PtenPE-/- mice (Figures 4.2A 
and 4.3A). Consistent with these histological observations, the prostatic epithelium of 
Mme-/-PtenPE-/- mice was characterized by a significantly higher proliferative rate 
according to Ki67 staining (Figures 4.2A, 4.2B, 4.3A, and 4.3B), expressed higher 
amounts of a marker of early prostate cancer, EZH2, and showed an increased number 
of CK5 and p63 positive cells as compared to prostatic lesions in PtenPE-/- mice. 
Prostatic epithelium lesions of Mme-/-PtenPE-/- mice also showed higher levels of pAKT, 
suggesting the existence of additional MME-dependent mechanisms of regulation of this 
downstream target of PTEN. Also, consistent with our previous observation (Liao et al., 
2007), prostatic neoplastic lesions of PtenPE-/- mice had an increased number of 
synaptophysin-positive neuroendocrine cells in the distal regions of prostatic ducts 
(Figures 4.3A and 4.3C). However, this number was not additionally elevated in Mme-/-
PtenPE-/- mice. In sum, lack of both MME and PTEN not only promoted lesions typically 
observed in the prostates of PtenPE-/- mice but also resulted in distinct, additional 
neoplasms located in the proximal regions of prostatic ducts. 
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Figure 4.1 Alterations of MME expression in prostate adenocarcinoma of PtenPE-/- 
mice. MME expression (arrows) in the proximal and distal regions of prostatic ducts of 
wild-type (WT) and PtenPE-/- mice. Note that area of stromal invasion (arrowhead) by 
early adenocarcinoma lacks MME expression in PtenPE-/- mice. The ABC Elite method 
with hematoxylin counterstaining was performed. Scale bar, 60 μm. Immunostainings 
are representative of four WT and two PtenPE-/- mice, respectively. 
  
151 
 
 
152 
 
Figure 4.2 Mme and Pten cooperate in suppression of prostate carcinogenesis in 
the proximal regions of prostatic ducts of the mouse. (A) Proximal regions of 
prostatic ducts in 16-month-old WT (n=5), Mme-/- (n=15), PtenPE-/- (n=9) and Mme-/-
PtenPE-/- (n=12) mice. The arrows indicate adenocarcinoma (HE) in Mme-/-PtenPE-/- mice 
or positive immunostained cells. As compared to the prostate epithelium of WT, Mme-/-, 
and PtenPE-/- mice, adenocarcinomas of Mme-/-PtenPE-/- mice show higher expression 
levels of EZH2 and pAKT, and an increased number of Ki67, CK5, and p63 positive 
cells, but no differences in number of synaptophysin (SYP) positive cells. HE, 
hematoxylin and eosin staining. The ABC Elite method with hematoxylin (CK5, CK8, 
PTEN, pAKT, and SYP) or methyl green (Ki67, EZH2, and p63) counterstaining was 
performed. Scale bar, 60 µm for all images. (B and C) A quantitative analysis of the 
proliferation rate (B) and frequency of SYP positive cells (C) in proximal regions of 
prostatic ducts. *P<0.05; **P<0.01; ***P<0.001. Error bars denote SD. (A-C) All results 
are representative of at least three mice per genotype. 
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Figure 4.3 Lack of MME promotes carcinogenesis associated with PTEN 
deficiency in the distal regions of prostatic ducts. (A) Distal regions of prostatic 
ducts in 16-month-old WT (n=5), Mme-/- (n=15), PtenPE-/- (n=9), and Mme-/-PtenPE-/- 
(n=12) mice. The arrows indicate invasive adenocarcinomas in Mme-/-PtenPE-/- mice (HE, 
PTEN) or positive immunostained cells, and the arrowheads indicate vascular invasion 
in Mme-/-PtenPE-/- mice. As compared to the prostate epithelium of PtenPE-/- mice, 
adenocarcinomas of Mme-/-PtenPE-/- mice show higher expression levels of EZH2 and 
pAKT and a trend in increased number of Ki67 positive cells, but no difference in 
number of SYP positive cells. HE, hematoxylin and eosin staining. The ABC Elite 
method with hematoxylin (CK5, CK8, PTEN, pAKT, and SYP) or methyl green (Ki67, 
EZH2, and p63) counterstaining was performed. Scale bar, 60 µm for all images. (B and 
C) A quantitative analysis of the proliferation rate (B) and frequency of SYP positive 
cells (C) in distal regions of prostatic ducts. *P<0.05; **P<0.01. Error bars denote SD. 
(A-C) All results are representative of at least three mice per genotype. 
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Table 4.1 Prostatic Lesions in Mme-/-, PtenPE-/- and Mme-/-PtenPE-/- Mice 
Strain Prostatic 
region 
Lesion Age (months) 
   3 7 16 
Mme-/- 
Proximal 
None 100 (3/3)* 100 (7/7) 100 (15/15) 
Dysplasia 0 (0/3) 0 (0/7) 0 (0/15) 
Early adenocarcinoma 0 (0/3) 0 (0/7) 0 (0/15) 
Advanced adenocarcinoma# 0 (0/3) 0 (0/7) 0 (0/15) 
Distal 
None 100 (3/3) 100 (7/7) 100 (15/15) 
Low-grade PIN 0 (0/3) 0 (0/7) 0 (0/15) 
High-grade PIN 0 (0/3) 0 (0/7) 0 (0/15) 
Early adenocarcinoma 0 (0/9) 0 (0/7) 0 (0/15) 
Advanced adenocarcinoma 0 (0/9) 0 (0/7) 0 (0/15) 
PtenPE-/- 
Proximal 
None 100 (16/16) 100 (11/11) 100 (0/9) 
Dysplasia 0 (0/16) 0 (0/11) 0 (0/9) 
Early adenocarcinoma 0 (0/16) 0 (0/11) 0 (0/9) 
Advanced adenocarcinoma 0 (0/16) 0 (0/11) 0 (0/9) 
Distal 
None 100 (0/16) 0 (0/11) 0 (0/9) 
Low-grade PIN 6 (1/16) 0 (0/11) 0 (0/9) 
High-grade PIN 94 (15/16) 100 (11/11) 67 (6/9) 
Early adenocarcinoma 0 (0/16) 0 (0/11) 33 (3/9) 
Advanced adenocarcinoma 0 (0/16) 0 (0/11) 0 (0/9) 
Mme-/- 
PtenPE-/-  
Proximal 
None 83 (5/6) 0 (0/8) 0 (0/12) 
Dysplasia 17 (1/6) 87 (7/8) 50 (6/12) 
Early adenocarcinoma 0 (0/6) 13 (1/8) 42 (5/12) 
Advanced adenocarcinoma 0/(0/6) 0 (0/8) 8 (1/12) 
Distal 
None 0 (0/6) 0 (0/8) 0 (0/12) 
Low-grade PIN 0 (0/6) 0 (0/8) 0 (0/12) 
High-grade PIN 100 (6/6) 100 (8/8) 17 (2/12) 
Early adenocarcinoma 0 (0/6) 0 (0/8) 58 (7/12) 
Advanced adenocarcinoma 0 (0/6) 0 (0/8) 25 (3/12) 
 
*% (number of mice with lesion out of total number of mice). 
#Advanced adenocarcinoma is defined as adenocarcinoma with vascular invasion 
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4.4.2 MME loss promotes activities of PTEN-deficient mouse prostate 
stem/progenitor cells 
 
The proximal regions of prostatic ducts are particularly enriched in prostate epithelium 
stem/progenitor cells (Leong et al., 2008; Salm et al., 2005; Tsujimura et al., 2002; 
Wang et al., 2007; Zhou et al., 2007). Thus, we evaluated potential effects of MME and 
PTEN deficiency on prostate stem/progenitor cells, isolated as the CD49fhi/Sca-1+ 
fraction by fluorescence-activated cell sorting (FACS) (Figure 4.4A). Mme-/- mice had 
the same number of stem/progenitor cells as age-matched WT mice (5.7% vs 5.6%). In 
contrast, PtenPE-/- mice showed a significant increase of the stem cell pool (8.4%), 
consistent with previous reports, suggesting that PTEN is involvd in regulation of 
prostate stem/progenitor cells (Abou-Kheir et al., 2010; Dubrovska et al., 2009; 
Mulholland et al., 2009; Wang et al., 2006). The pool of CD49fhi/Sca-1+ cells deficient for 
both PTEN and MME constituted 12.1% of the prostate epithelium, representing an 
additional 44% increase compared to PTEN deficient CD49fhi/Sca-1+ cells (Figure 4.4A, 
P<0.0001).  
 Prostasphere formation is used as a functional cell culture test for presence, 
growth, and self-renewal potential of prostate stem/progenitor cells. Consistent with 
FACS results, CD49fhi/Sca-1+ cells isolated from prostates of Mme-/-PtenPE-/-mice 
showed the highest frequency of prostaspheres in multiple consecutive sphere 
dissociation and regeneration passages (Figure 4.4B). Furthermore, prostaspheres 
deficient for both genes were larger in size, compared to WT, MME-deficient or PTEN-
deficient stem/progenitor cells (Figure 4.4C). In all groups CD49flo/Sca-1- luminal cells  
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Figure 4.4 Lack of Mme promotes Pten-deficient prostate stem/progenitor cell 
expansion and sphere-forming capacity. (A) Quantitative analysis of distribution of 
CD49fhi/Sca-1+ stem/progenitor cells and CD49flo/Sca-1- luminal cells isolated from 3-
month-old WT, Mme-/-, PtenPE-/-, and Mme-/-PtenPE-/- mice (n=3 per genotype). Red and 
blue frames represent stem/progenitor cell and luminal cell populations, respectively. 
(B-D) Frequency (B, D) and size (C) of spheres formed by CD49fhi/Sca-1+ 
stem/progenitor cells (B, C) and CD49flo/Sca-1- (D) luminal cells from 3-month-old WT, 
Mme-/-, PtenPE-/-, and Mme-/-PtenPE-/- mice (n=3 per genotype). (E, F) Relative frequency 
of sphere formation by CD49fhi/Sca-1+ stem/progenitor cells (E) and CD49flo/Sca-1- 
luminal cells (F) isolated from 3-month-old WT, Mme-/-, PtenloxP/loxP, and Mme-/-
PtenloxP/loxP mice followed by Ad-Cre infection (n=3 per genotype). Spheres counts were 
normalized to the Ad-blank-infected spheres of each passage. P0-P3, passages 0-3. 
**P<0.01, ***P<0.001. Error bars denote SD. (A-F) Data represent three independent 
experiments. 
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formed very few spheres after the first plating and no spheres were observed after the 
first passage (Figure 4.4D). Thus, PTEN and/or MME deficiency are unlikely to 
reprogram differentiated cells towards stem cell state. 
 To test if the observed properties represent direct effects of MME and/or PTEN 
on prostate stem/progenitor cells we have isolated CD49fhi/Sca-1+ stem/progenitor cells 
and CD49flo/Sca-1- luminal cells from prostates of WT, Mme-/-, PtenloxP/loxP, and Mme-/-
PtenloxP/loxP mice and infected them with adenovirus expressing Cre recombinase (Ad-
Cre). Consistent with our previous experiments, lack of both Pten and Mme had the 
most pronounced effect on frequency of CD49fhi/Sca-1+ stem/progenitor cells in 
consecutive passages (Figure 4.4E). Luminal cells formed only a few spheres with the 
same frequency in all groups (Figure 4.4F). Taken together, these results showed that 
MME cooperates with PTEN in regulation of prostate stem/progenitor cell activity. 
 
4.4.3 GRP promotes activities of PTEN-deficient mouse prostate stem/progenitor 
cells 
 
To identify mechanisms by which MME may affect regulation of prostate 
stem/progenitor cells, we have tested expression of its main substrates, GRP, 
neurotensin (NT), and vasoactive intestinal peptide (VIP) in the prostates of WT, Mme-/-, 
PtenPE-/-, and Mme-/-PtenPE-/- strains. Strong GRP expression was detected only in 
prostates of Mme-/-PtenPE-/- mice, while NT and VIP were not detected in all cases 
(Figure 4.5).  
 To test if GRP recapitulates effects of MME deficiency, we isolated prostate cells 
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from Mme-/-PtenPE-/- mice, and either performed knockdown of the GRP receptor (GRPR, 
Figure 4.6A) or administered GRPR antagonist ([Tyr4, D-Phe12]-Bombesin) (Heinz-Erian 
et al., 1987). Both approaches reversed effects of MME deficiency on formation 
frequency and size of prostaspheres (Figures 4.6B and 4.6C).  
 Consistent with frequent vascular invasion by prostate adenocarcinomas in Mme-
/-PtenPE-/- mice, we have observed increased cell motility and invasion of prostate cells 
isolated from Mme-/-PtenPE-/- mice, compared to those prepared from PtenPE-/- mice 
(Figures 4.6D and 4.6E). Notably, both parameters were normalized by either GRPR 
knockdown or treatment with [Tyr4, D-Phe12]-Bombesin.  
To test if GRP directly affects function of PTEN-deficient prostate stem/progenitor 
cells, CD49fhi/Sca-1+ prostate stem cells isolated from PtenloxP/loxP were infected with 
Ad-Cre followed by treatment with GRP and/or [Tyr4, D-Phe12]-Bombesin. GRP addition 
reproduced the effects of MME deficiency on formation frequency and size of 
prostasphere, but these effects were abrogated by [Tyr4, D-Phe12]-Bombesin (Figures 
4.6F and 4.6G). In sum, these results showed that GRP may be a key MME target, 
responsible for its effects on prostate stem/progenitor cells and on progression of 
cancer associated with PTEN deficiency. 
 
4.4.4 GRP promotes expansion of human prostate cancer propagating cells 
 
To assess the relevance of our observations to human disease, we tested the effects of 
GRP and [Tyr4, D-Phe12]-Bombesin on human prostate cancer cells, DU145 and PC3 
(Figure 4.7). In both cell lines, GRP promoted cell proliferation, migration, and invasion.  
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Figure 4.5 GRP accumulation in mouse prostatic lesions deficient for Mme and 
Pten. GRP, NT, and VIP expression in the proximal and distal regions of prostatic ducts 
in 16-month-old WT (n=5), Mme-/- (n=15), PtenPE-/- (n=9), and Mme-/-PtenPE-/- (n=12) 
mice are shown. Arrows, prostatic lesions. The ABC Elite method with hematoxylin 
counterstaining was performed. Scale bar, 60 μm.  
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Figure 4.6 GRP promotes Pten-deficient mouse prostate stem/progenitor cell 
expansion and sphere-forming capacity. (A-E) Western blot of GRPR expression (A), 
prostasphere size (B), sphere-forming capacity (C), migration (D), and invasion (E) of 
prostate cells isolated from 3-month-old PtenPE-/- and Mme-/-PtenPE-/- mice (n=3 per 
genotype) were performed. (F, G) Frequency (F) and size (G) of prostaspheres formed 
by Ad-Cre-infected CD49fhi/Sca-1+ stem/progenitor cells isolated from 3-month-old 
PtenloxP/loxP mice (n=3) with treatments of GRP and/or [Tyr4, D-Phe12]-Bombesin were 
performed. P0-P3, passages 0-3. *P<0.05, **P<0.01, ***P<0.001. All error bars denote 
SD. (A-G) Data represent three independent experiments. 
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All these effects were negated by addition of [Tyr4, D-Phe12]-Bombesin, consistent with 
our observations on mouse prostate epithelium cells. Moreover, GRPR knockdown 
rescued the stimulating effects of GRP and inhibitory effects of [Tyr4, D-Phe12]-
Bombesin, suggesting a crucial role for GRP/GRPR in control of the above parameters.  
 Prostate cancer propagating cells can be identified by either high enzymatic 
activity of ALDH (ALDERFLUOR assay) (Burger et al., 2009; Li et al., 2010b) or by 
detection of CD44 expression (Leong et al., 2008; Patrawala et al., 2007; Patrawala et 
al., 2006). In both approaches, cancer propagating cells increased in number after GRP 
treatment (Figures 4.8A-4.8D). Cancer propagating cells treated with GRP also formed 
spheres in greater number and size. These changes were diminished by [Tyr4, D-
Phe12]-Bombesin and/or GRPR siRNA (Figures 4.8A-4.8G).  
 To study the effect of GRP on human prostate cancer in vivo, immunodeficient 
NSG mice were subcutaneously injected with PC-3 cells and then treated with [Tyr4, D-
Phe12]-Bombesin when the tumor size reached 10 mm3 (Figures 4.8H-4.8J). Daily 
intraperitoneal injections of [Tyr4, D-Phe12]-Bombesin reduced both tumor volume and 
weight by 70% by the time the animals were euthanized at 26 days after beginning 
treatment. Importantly, according to the ALDERFLUOR assay, a fraction of prostate 
cancer propagating cells was significantly reduced in tumors treated with [Tyr4, D-
Phe12]-Bombesin compared to controls treated with vehicle alone. Thus GRPR 
antagonist inhibits tumorigenicity of prostate cancer cells by diminishing a population of 
cancer propagating cells. 
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Figure 4.7 GRP promotes activities of human prostate cancer cells. (A-H) Western 
blot of GRPR expression (A, B) and BrdU positive cells (%) (C, D), migration (E, F), and 
invasion (G, H) of DU145 (A, C, E, and G) and PC3 (B, D, F, and H) human prostate 
cancer cells with treatments of GRP and/or [Tyr4, D-Phe12]-Bombesin are shown. 
*P<0.05, **P<0.01, ***P<0.001. All error bars denote SD. (A-H) Data represent three 
independent experiments. 
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Figure 4.8 GRP promotes activities of human prostate cancer propagating cells. 
(A-E) ALDEFLUOR assay (A), quantitative analysis of ALDH positive cancer 
propagating cells (%) of DU145 (B) and PC3 (C), CD44 positive cancer propagating 
cells (%) of DU145 (D), and sphere-forming capacity of DU145 (E) with treatment of 
GRP and/or [Tyr4, D-Phe12]-Bombesin were performed. (A) The number in each red 
frame represents the percentage of ALDH positive cancer propagating cells. (F, G) 
Frequency (F) and size (G) of prostaspheres formed by FACS-purified CD44 positive 
cancer propagating cells of DU45 with treatments of GRP and/or [Tyr4, D-Phe12]-
Bombesin are shown. P0-P3, passages 0-3. (H) Average volume of PC3 tumor 
xenografts at indicated time points. Red arrow indicates the starting day of i.p. injection 
of [Tyr4, D-Phe12]-Bombesin or PBS. (I) Average weight of PC3 tumor xenografts at 
sacrifice (day 34). (J) ALDH positive cancer propagating cells (%) of PC3 tumor 
xenografts. *P<0.05, **P<0.01, ***P<0.001. All error bars denote SD. Data represent 
three independent experiments (A-G), and two groups of five mice with injection of [Tyr4, 
D-Phe12]-Bombesin or PBS, respectively (H-J). 
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4.5 Discussion 
 
It is well established that cancer cells frequently acquire stem cell-like properties. In 
many cases, such properties are specifically associated with subpopulations of cancer 
cells known as cancer propagating or cancer stem cells (Greaves and Maley, 2012; 
Kreso and Dick, 2014; Visvader, 2011). Such cells are characterized by long-term self-
renewal, high potential for proliferation, high tumorigenicity, and capacity to generate 
the whole spectrum of heterogeneity of the original tumors. However, the cell of origin of 
cancer propagating cells remains far less elucidated and is likely to depend on specific 
cell lineages affected by carcinogenic events. Some cancer may originate from adult 
stem/progenitor cells (Cheng et al., 2014; Flesken-Nikitin et al., 2013; Schepers et al., 
2012), while others may originate from more differentiated cells (Friedmann-Morvinski et 
al., 2012; Schwitalla et al., 2013). As our study shows, alterations in specific genes 
involved in the maintenance of normal adult stem cells may also contribute to defining 
susceptibility of specific stages of lineage formation to transformation.  
 Until recently, studies of specific stem/progenitor populations mainly relied on 
approaches based on isolation of cells according to their display of stem cell-specific 
markers. However, it has become obvious that many stem cell niches are well defined 
anatomically (Blanpain et al., 2007; Clevers, 2013; Flesken-Nikitin et al., 2013), thereby 
allowing histopathological assessment of early neoplastic lesions and laying ground for 
development of stem cell pathology as a discipline. The mouse prostate represents an 
attractive subject of such studies. Each mouse prostatic duct consists of a proximal 
region attached to the urethra, an intermediate region, and a distal tip. Proliferating, 
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transit-amplifying cells are preferentially located in the distal region of the prostatic ducts, 
whereas cells with stem cell-like properties, such as low cycling rate, self-renewal, high 
ex vivo proliferative potential, and androgen withdrawal resistance, mainly reside in the 
proximal region of the prostatic ducts (Leong et al., 2008; Tsujimura et al., 2002; Wang 
et al., 2007; Zhou et al., 2007). 
 Our findings, based on conditional deletion of Pten in CD49fhi/Sca-1+ prostate 
stem/progenitor cells, are consistent with the earlier observations of the role of Pten in 
regulation of the prostate stem/progenitor cell compartment (Dubrovska et al., 2009; 
Mulholland et al., 2009; Wang et al., 2006). Interestingly, however, PTEN deficiency 
alone does not lead to pronounced dysplastic lesions in the proximal regions of prostatic 
ducts. However, combined lack of Mme and Pten leads to formation of dysplastic 
lesions and adenocarcinomas in such areas. Furthermore, malignant neoplasms 
deficient for both genes are more advanced as evidenced by frequent intravascular 
invasion. Taken together with the effects of Mme and Pten deficiency on increased 
number and growth potential of prostate stem/progenitor cells, our observations suggest 
a critical non-overlapping role of both genes in regulation of prostate stem/progenitor 
cells and suggests that dysregulation of MME functions may represent a critical step in 
cancer progression. 
 In addition to catalytic inactivation of neuropeptides, MME has other, non-
catalytic functions affecting cell growth and motility (Sumitomo et al., 2000) (Sumitomo 
et al., 2004). For example, the cytoplasmic domain of MME interacts with PTEN 
(Sumitomo et al., 2004). MME recruits endogenous PTEN to the cell membrane, leading 
to prolonged PTEN protein stability and increased PTEN phosphatase activity, resulting 
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in downregulation of AKT activity (Sumitomo et al., 2004). At the same time, MME 
interactions with PTEN may not completely explain MME tumor suppressive functions 
because levels of MME expression inversely correlate with tumorigenicity of some 
human prostate cancer cell lines mutant for PTEN. For example, low tumorigenic cell 
line LNCaP has a high level of MME, whereas highly tumorigenic PC3 expresses a low 
level of MME (Freedland et al., 2003; Witkowski et al., 1993). Furthermore, homozygous 
deletion of PTEN is observed in 33% of MME-deficient cases of human metastatic 
prostate cancers, according to bioinformatic analysis (Cerami et al., 2012; Gao et al., 
2013) of alterations reported in (Taylor et al., 2010). Future studies should determine 
whether or not non-catalytic functions of MME also play a role in regulation of prostate 
stem/progenitor cells.  
 Neuroendocrine cells are important for prostate development (Cheng et al., 
2013). However, it remains debatable if an increased number of neuroendocrine cells, 
as defined by their expression of neuroendocrine markers, such as synaptophysin and 
calcitonin gene-related peptide, is associated with accelerated progression of prostate 
adenocarcinoma (Bonkhoff and Berges, 2010; Debes and Tindall, 2004; Hansson and 
Abrahamsson, 2001, 2003; Sun et al., 2009). Our findings suggest the possibility that 
MME downregulation mitigates the requirement for neuroendocrine cell expansion in 
prostate cancers. Indeed, a significantly higher number of neuroendocrine cells was 
observed in prostate neoplastic lesions of PtenPE-/- mice, in agreement with our previous 
studies (Liao et al., 2007). However, no further increase in the number of such cells was 
observed in mice also lacking Mme. It is possible that accumulation of un-cleaved 
neuropeptides leads to a feedback inhibition of neuroendocrine cell differentiation. 
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Further studies should address this possibility, thereby allowing better delineation of the 
role of neuroendocrine cells in prostate cancer pathogenesis.  
 Our study provides direct genetic support to previous reports proposing the role 
of Mme as a tumor suppressor gene. Furthermore, it shows that effects of MME on 
prostate stem/progenitor cells depend on the presence of its downstream effector, GRP. 
GRP is the mammalian homologue of the amphibian bombesin, which regulates various 
physiological functions in gastrointestinal and central nervous systems. Its roles relevant 
to carcinogenesis such as mitosis, morphogenesis, angiogenesis, cell migration, and 
cell adhesion in different cancers have been reported (Mansi et al., 2013; Patel et al., 
2006; Rick et al., 2013). GRP binds with high affinity to GRPR (Jensen et al., 2008), 
which is one of three mammalian bombesin receptors (Fathi et al., 1993; Gorbulev et al., 
1992; Jensen et al., 2008). GRPR is detected in normal, malignant human prostate 
tissues and prostatic cancer cell lines (LNCaP, DU145, PC-3) and is the only bombesin 
receptor overexpressed in human prostate cancer (Bartholdi et al., 1998; Fleischmann 
et al., 2009; Maddalena et al., 2009; Markwalder and Reubi, 1999; Reile et al., 1994; 
Reubi et al., 2002; Sturzu et al., 2013; Sun et al., 2000; Weber, 2009).  
 Our study supports earlier observations of general effects of GRP on cell motility 
and invasion of cancer cells (Hohla and Schally, 2010; Mansi et al., 2013; 
Stangelberger et al., 2008). However, it also identifies a previously unknown role of 
GRP in regulation of the prostate stem cell niche and shows that abrogation of GRPR 
signaling may diminish the pool of cancer propagating cells. These findings offer new 
insights into the role of neuropeptide-mediated dysregulation in prostate cancer 
pathogenesis. Furthermore, they provide a rationale for using the MME/GRP pathway 
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for targeting of cancer propagating cells, perhaps as a part of combinatorial therapy 
approaches.  
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Summary 
 
In chapter 2, in order to dissect the precise role of miR-34 in vivo, we generated mice 
with mir-34 conventional and conditional targeted mutations. Unexpectedly, mice with 
conventional and prostate epithelium conditional inactivation of mir-34 did not give rise 
to neoplastic lesions up to 18 months old, consistent with the previous study by Ventura 
group (Concepcion et al., 2012). This observation also has shown that loss of miR-34 is 
not as critical as loss of p53 (Donehower et al., 1992; Jacks et al., 1994) in the initiation 
of carcinogenesis (Chapter 1.3.3). Various studies have suggested that miR-34 may be 
regulated by a p53-independent pathway (Chapter 1.3.4). To test this possibility, we 
conditionally deleted both p53 and mir-34 in the prostate epithelium in mice and found 
development of early invasive adenocarcinoma and high-grade prostatic intraepithelial 
neoplasia in the proximal and distal regions of prostatic ducts, respectively, whereas no 
such lesions were observed after inactivation of mir-34 or p53 genes alone. This piece 
of evidence not only clarified the tumor suppressor role of miR-34 but also p53-
indepentdent function of miR-34 in vivo. Consistent with our previous finding of a 
feedforward loop regulation of MET by a dual miR-34/p53 mechanism (Hwang et al., 
2011), combined deficiency of p53 and miR-34 leads to acceleration of MET-dependent 
growth, self-renewal, and motility of prostate stem/progenitor cells, and thus alterations 
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in joint regulation of stem cell compartment may lead to cancer. MET inhibitors may be 
an important component of targeting prostate CPCs, particularly in the context of 
combined p53 and miR-34 deficiency. Taken together, the miR-34-centered regulatory 
network independent of p53 emerges. It is of interest to further study the cooperative 
interaction of p53/miR-34/MET in stem/progenitor cells of other cell lineages. 
Furthermore, it would also be interesting to verify if any other targets are under 
p53/miR-34 dual regulation. Gaining insight into the p53-miR-34 circuit may bring value 
for clinical diagnosis and therapy in cancer prevention and treatment in future. 
The precise functions of NE cells in prostate development and carcinogenesis are 
not well understood. In chapter 3, we have generated the transgenic mice, Tg(Syp-
EGFPloxP-DTA)147Ayn (SypELDTA), in which DTA is driven by the Syp promoter, 
suitable for flexible tissue-specific ablation of NE cells. By crossing the SypELDTA 
mouse line with prostate epithelium-specific expressing Cre mice, PB-Cre4, we have 
shown a substantial decrease in the number of NE cells and associated prostate 
hypotrophy, suggesting that NE cells play an important role in prostate development. 
The Syp-containing BAC cassette and generated mice should provide useful tools for 
studies of NE cell biological roles in development and maintenance of various tissues 
and organs. Furthermore, this transgenic line can be used to study the role of NE cells 
in carcinogenesis by crossing with other established mouse cancer lines with 
preferential NE cell differentiation. 
To further study the role of NE cells and their secreted neuropeptides in prostate 
carcinogenesis, the Mme-null mouse model was chosen in chapter 4.  Deficiency of 
MME, the enzyme responsible for metabolism of neuropeptides, is associated with poor 
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prostate cancer prognosis (Freedland et al., 2003; Osman et al., 2004; Papandreou et 
al., 1998). However, mice deficient for Mme did not develop prostate cancer by 18 
months of age, and so its role in prostate carcinogenesis remains insufficiently 
elucidated. Here, we report that in the autochthonous mouse model of prostate cancer 
associated with Pten deficiency, lack of Mme leads to expansion of the neoplastic 
lesions with increased proliferation and accelerated carcinogenesis, especially in the 
prostate stem cell-enriched niche. The pathological lesions may result from aberrant 
regulation of prostate stem cell activities, such as stem cell pool expansion, growth, and 
self-renewal. To understand the mechanisms by which large MME deficiency may affect 
the regulation of stem cell activities, GRP, one of the main MME substrates, has been 
tested in mouse prostate stem cells and human prostate CPCs. Consistently, GRP can 
expand pool, growth, and self-renewal of mouse prostate Pten-deficient stem cells and 
human prostate CPCs and can be successfully blocked by GRP antagonist, [Tyr4, D-
Phe12]-Bombesin. Importantly, [Tyr4, D-Phe12]-Bombesin can inhibit growth of human 
xenografts and lead to decreased pool of CPCs in formed tumors. In summary, our 
results show a GRP-mediated effect of MME deficiency in control of prostate stem and 
CPCs, and suggest that GRPR antagonists may be an important component of 
targeting CPCs, particularly in the context of Pten deficiency.  
 
5.2 Future Directions 
 
5.2.1 p53/miR-34/Met pathway in stem cells and early carcinogenesis 
 
183 
 
MET plays an important role in growth, survival, motility, invasion, and metastasis in 
cancers (Birchmeier et al., 2003; Trusolino et al., 2010; Trusolino and Comoglio, 2002), 
and its overexpression is associated with poor prognosis in several different types of 
cancers, including prostate cancer (Di Renzo et al., 1994; Di Renzo et al., 1995a; Di 
Renzo et al., 1995b; Ferracini et al., 1995; Humphrey et al., 1995; Morello et al., 2001; 
Natali et al., 1996; Olivero et al., 1996; Takeo et al., 2001; Taniguchi et al., 1998). Our 
previous finding indicates that p53 has miR-34-dependent and miR-34-independent 
mechanisms to control MET expression by feedforward loop regulation (Hwang et al., 
2011). In Chapter 2, by using the autochthonous model of cancer, we also found that 
p53-dependent and p53-independent miR-34 functions may cooperate to inhibit MET 
expression in the stem cell compartment, jointly suppressing prostate carcinogenesis. 
Therefore, it would be of interest to further study differential MET expression and 
prognosis combined with p53 and mir-34 status in human prostate cancer specimens. In 
addition, given our findings and studies by others, it is becoming increasingly obvious 
that MET is also involved in regulation of stem/progenitor cells and CPCs in different 
tissues (Boccaccio and Comoglio, 2006; De Bacco et al., 2012; Forte et al., 2006; Joo 
et al., 2012; Li et al., 2011a; Li et al., 2011b; Nicoleau et al., 2009; Rajasekhar et al., 
2011; Son et al., 2006; Suzuki et al., 2004; Tesio et al., 2011; Vermeulen et al., 2010; 
Yoshioka et al., 2013). Therefore, it would be interesting to test if p53/miR-34 
feedforward loop regulation of the MET-dependent stem/progenitor cell pool is also 
present in other types of normal and neoplastic cells. Such study could be performed by 
tissue-specific inactivation of p53 and mir-34. It is also worth noting that our 
histopathological studies of the mouse model with prostate epithelium-specific 
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inactivation of p53 and mir-34 indicate that neoplastic lesions are already present during 
the early stages of carcinogenesis. Thus therapeutic targeting of MET in both p53 and 
miR-34 deficient cells might be effective from the earliest stages of prostate cancer. 
 
5.2.2 Generation of the knockin mouse model for NE cell ablation 
 
In Chapter 3, although we used the BAC construct, likely containing all the cis-elements 
of the Syp locus, to make the transgenic mouse model (Yang and Gong, 2005), the 
stochastic insertion of the transgene, which might affect functions of other genes, may 
become a concern for our mouse model. To avoid this problem, knockin mice would be 
a better option to study the exogenous expression of the given protein driven by the 
endogenous Syp promoter. In this way, the genetic environment surrounding the 
transgene can be controlled completely, and the transgene will not incorporate into 
random locations. Thus, we would be more certain that any resulting phenotype is due 
to the exogenous expression of the transgene because a targeted transgene is not 
interfering with any other critical loci. More importantly, site-specific knockin results in a 
more consistent level of expression of the transgene from generation to generation 
because the transgene is under the control of the endogenous Syp promoter.  
Another potential probelm with our mouse model is presence of DTA in the 
transgenic construct. It has been shown that one molecule of DTA is sufficient to kill the 
cell, indicating high toxicity of DTA (Yamaizumi et al., 1978). The advantage of high 
toxicity is that even low DTA expression can have efficient cell ablation. However, 
nonspecific leakage of DTA expression, even at a low level, may jeopardize mouse 
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embryogenesis and phenotype as well as the outcome of following experiments. 
Although we did not observe significant cell death in luminal and basal cells in any 
regions of the prostate due to a tight regulation of the Syp promoter in prostate non-NE 
epithelium cells (Figure 3.18), the issue cannot be completely ruled out in the prostate 
and/or other organs. Use of diphtheria toxin receptor (DTR) has become an alternative 
method (Buch et al., 2005; Cha et al., 2003; Saito et al., 2001). The advantage of this 
method is not only that DTR itself is not toxic, but also spatio-temporal cell ablation can 
be manipulated by injecting DT, leading to the death of the DTR positive cells in the 
given tissue by crossing with tissue-specific Cre-expressing mice. The DTR approach 
has been extensively applied to different mouse models (Luquet et al., 2005; Rother et 
al., 2012; Thorel et al., 2010; Tian et al., 2011; Tittel et al., 2012). However, there have 
been reports of DT toxicity in long-term mouse experiments (Tian et al., 2011). Thus, 
DTA and DTR approaches may complement each other. 
In our case, we can knockin the loxP-EGFP-Neo cassette-Stop-loxP-DTR-bpA 
before exon 1 of the Syp locus by homologous recombination to generate Cre-inducible 
DTR knockin mice in which Cre-mediated excision of a Stop cassette renders SYP-
positive cells sensitive to DT (Figure 5.1). Thus, ablating prostate NE cells can be 
achieved by crossing newly generated knockin mice with ARR2PB-Cre mice (Wu et al., 
2001) or tamoxifen-inducible ARR2PB-Cre-ER(T2) mice (Birbach et al., 2009; Luchman 
et al., 2008), allowing us to study the role of NE cells in prostate development 
accurately. Furthermore, crossing these knockin mice with prostate cancer mouse 
models with preferential NE differentiation, such as Pten knockout mice (Chen et al., 
2005; Liao et al., 2007; Trotman et al., 2003; Wang et al., 2003), TRAMP mice (Gingrich 
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et al., 1996; Kaplan-Lefko et al., 2003), or LADY mice (Kasper et al., 1998; Masumori et 
al., 2001), could also allow us to examine the role of NE cells in prostate carcinogenesis. 
 
5.2.3 Cell origin of NE cell lineage and NE cell differentiated prostate cancer 
 
Lineage tracing is a tool to study stem cell hierarchy. Recent studies of cell fate based 
on lineage tracing have revealed the existence of multipotent basal stem/progenitor 
cells, unipotent basal cells, and luminal stem/progenitor cells (Choi et al., 2012; Liu et 
al., 2011b; Ousset et al., 2012; Wang et al., 2009a; Wang et al., 2013). Although some 
evidence supports the notion that NE cells originate from basal stem/progenitor cells 
(Leong et al., 2008; Ousset et al., 2012; Wang et al., 2013) or luminal stem/progenitor 
cells (Wang et al., 2009a), whether or not there are unipotent or even multipotent NE 
stem/progenitor cells residing in the prostate stem cell hierarchy is still an open question. 
Inspired by the studies above, we can generate the NE cell-specific inducible Cre mice 
(Syp-CreERT2) in which CreER is driven by the promoter of Syp, a NE cell marker. In 
addition, the mTmG mouse line is a double fluorescent reporter line that replaces the 
expression of a membrane-targeted Tomato-Red (mT) protein with a membrane-
targeted enhanced green fluorescence protein (mG) upon Cre-loxP-mediated 
homologous recombination (Muzumdar et al., 2007). After breeding of the double 
fluorescent reporter line mTmG with Syp-CreER mice to generate Syp-CreER; mTmG 
mice, NE cell lineage can be traced by GFP expression after a tamoxifen pulse. Thus, 
to determine the fate of prostate NE cells, we are able to induce prostate epithelial 
turnover by the regression-regeneration assay as schematically illustrated in  
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Figure 5.1 Generation of the Cre-inducible DTR knockin mouse model. (A) The 
targeting strategy was to knockin the loxP-EGFP-Neo cassette-Stop-loxP-DTR-bpA 
before the exon 1 of Syp locus by homologous recombination. SypP: synaptophysin 
promoter. NRSE: neuro-restrictive suppressor element. DTR: diphtheria toxin receptor.  
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Figure 5.2 Schematic illustration of the lineage-tracing strategy. (A) After crosses 
of Syp-CreERT2 mice and mTmG reporter mice, NE cell lineage can be traced by GFP 
expression after tamoxifen administration in Syp-CreERT2; mTmG mice. (B) Timeline 
for androgen deprivation and replacement experiments. 
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Figure 5.2. In response to fluctuating serum testosterone levels, epithelial cell turnover 
is induced after cycles of prostate regression-regeneration. Immunofluorescence 
analyses of luminal (K8), basal (K5), as well as NE (SYP) cells can be applied to 
examine co-expression of GFP with these three markers, which may illustrate the 
hierarchy of NE cell lineage. 
Likewise, the cell of origin of prostate cancer with NE differentiation remains to be 
established. Previously, it has been proposed that NE cells are the result of trans-
differentiation from predominant luminal cells within prostate adenocarcinoma. For 
example, clinical genetic analysis showed that prostate cancer cells with NE 
differentiation have allelic profiles identical to non-NE prostate cancer cells but distinct 
from those of the normal prostatic epithelium or normal NE cells (Sauer et al., 2006). 
Two human prostatic small cell carcinoma cell lines, NCI-H660 (Carney et al., 1985) 
and PSK-1 (Kim et al., 2000), in which NE cells are the predominant cell type, express 
K8/18 (luminal cell markers) but not K5/14 (basal cell markers) (van Bokhoven et al., 
2003). Our lab also detected co-expression of luminal cell marker (K8, AR) and NE cell 
marker (SYP, CgA) in neoplastic cells of the mouse model with prostate epithelium-
specific deletion of p53 and Rb (Zhou et al., 2007) and Pten (Liao et al., 2007). 
Moreover, accumulating cell culture studies showed that luminal cells in prostate cancer 
cell lines can acquire NE phenotype under certain conditions (Chapter 1.4.2). 
Collectively, these results suggest that luminal cells could trans-differentiate into NE 
cells in prostate cancer. However, some studies using cell lineage-specific Cre lines did 
not show that prostate cancer arising from luminal cells (Nkx3-1CreERT2/+; Ptenflox/flox, K8-
CreERT2Tg/wt; Ptenflox/flox) or basal cells (K14-CreERTg/Tg; Ptenflox/flox) with Pten deletion 
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could trans-differentiate to the NE phenotype (Choi et al., 2012; Wang et al., 2009a; 
Wang et al., 2013). Since those results are inconsistent with findings of NE cells in 
prostatic neoplasms in ARR2PB-Cre; Ptenflox/flox mice (Liao et al., 2007), additional 
lineage tracing studies of prostate stem cell fate with particular attention to the proximal 
regions of prostatic ducts are well-merited. Another possibility is that NE cells 
themselves could represent a target of oncogenic transformation in prostate cancer. To 
investigate these hypotheses, we may generate the mouse model with targeted deletion 
of the Pten in NE cells (Syp-CreERT2; Ptenflox/flox). Tamoxifen would be administered to 
8-week-old Syp-CreERT2; Ptenflox/flox mice so that Pten is specifically disrupted in 
prostate NE cells. The ARR2PB-Cre; Ptenflox/flox mouse model for prostate cancer can be 
used as a positive control, in which ARR2PB can drive Cre expression to ablate Pten in 
luminal, basal, and NE cells (Cheng et al., 2013; Lawson et al., 2010; Liao et al., 2007; 
Wang et al., 2006; Zhang et al., 2010). 
 
5.2.4 The role of neuropeptides in induction of senescence in Pten-deficient 
neoplasms 
 
Senescence is a hallmark of aging and opposing cancer progression (Campisi, 2013; 
Collado and Serrano, 2010; Prieur and Peeper, 2008; Rodier and Campisi, 2011). MME 
activity increases with age in the brain (Miners et al., 2010), and its expression is 
upregulated during the replicative senescence of human skin fibroblasts (Morisaki et al., 
2010) and in human lung fibroblasts (Kletsas et al., 1998), suggesting neuropeptides 
might play a role in senescence response.  
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Conditional inactivation of Pten in prostate epithelium caused cellular senescence, 
restricting carcinogenesis but was rescued by concomitant loss of p53 (Chen et al., 
2005). By p53 IHC (Figure 5.3A, E, I, M, Q), p53 expression is low in WT (Figure 5.3A) 
and Mme-/- (Figure 5.3E) prostates. Consistent with previous reports, p53 is upregulated 
after Pten inactivation, which has increased accumulation of p53 in the nuclei of 
prostate epithelial cells in the PtenPE-/- prostate (Figure 5.3I), but p53 is downregulated 
after MME loss in the Mme-/-PtenPE-/- prostate (Figure 5.3M). Expression status of 
senescence-associated markers, such as senescence-associated beta-galactosidase 
(SA-β-Gal) (Figure 5.3B, F, J, N, R), p16INK4a (Figure 5.3C, G, K, O, S), p27Kip1 (Figure 
5.3D, H, L, P, T), and p21Cip1 (Figure 5.4) was studied (Bringold and Serrano, 2000; 
Kuilman et al., 2010). Similar to p53 expression, expression level of SA-β-Gal (Figure 
5.3J, N, R), p16INK4a (Figure 5.3K, O, S), and p27Kip1 (Figure 5.3L, P, T) is upregulated 
in the PtenPE-/- (Figure 5.3J, K, L) prostate but downregulated with concomitant MME 
loss in the Mme-/-PtenPE-/- prostate (Figure 5.3N, O, P). Interestingly, p27Kip1 expression 
of the Mme-/- prostate is comparable to that of the PtenPE-/- prostate (Figure 5.3H, L, T), 
suggesting a synergistic effect of PTEN and MME loss on suppressing p27Kip1 
expression. However, cytoplasmic p21Cip1 expression increases in the Mme-/-PtenPE-/- 
prostate compared to the PtenPE-/- prostate (Figure 5.4). Taken together, MME loss can 
rescue the senescence in Pten-deficient tumors, possibly through suppressing the 
p16INK4a/Rb pathway and the PTEN/p27Kip1 pathway, but not the p53/p21Cip1 pathway 
(Bringold and Serrano, 2000), although p53 is downregulated in Mme-/-PtenPE-/- prostate 
(Figure 5.3M). Overexpression and associated cytoplasmic accumulation of p21Cip1 has 
been found in many human cancers and is correlated with aggressive tumors and poor 
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prognosis, including in prostate cancer (Abbas and Dutta, 2009). Thus, Mme-/-PtenPE-/- 
prostates exhibit prominent cytoplasmic expression of p21 in our model, which might be 
indicative of aggressive carcinogenesis. 
So far our preliminary results did not show significant differences in senescence 
after treatment with GRP and/or its antagonist, [Tyr4, D-Phe12]-Bombesin, on CD44-
positive DU145 human prostate CPCs (Figure 5.5). It may suggest that the senescent 
mechanism is important only in some types of neoplasms and/or at specific stages of 
cancer progression. Alternatively, other neuropeptides processed by MME or 
neuropeptide-catalysis-independent functions of MME play a role in senescence 
response. Therefore, it will be of interest to further investigate the effects of NE 
signaling on senescence in human cancers stratified according to their histological and 
molecular features and stage of progression. Such research may lead to identification of 
new therapeutic targets responsive to the effects of neuropeptides. 
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Figure 5.3 MME loss rescues cellular senescence in Pten-deficient prostate 
neoplastic lesions. (A-T) p53 (A, E, I, M), β-Gal (B, F, J, N), p16 (C, G, K, O), p27 (D, 
H, L, P) immunostaining and quantitative analysis of p53 (Q), β-Gal © p16 (S), p27 (T) 
positive cells in prostates of aged-matched WT (A-D), Mme-/- (E-H), PtenPE-/- (I-L) and 
Mme-/-PtenPE-/- (M-P) mice (n=3). (A, C, D, E, G, H, I, K, L, M, O, P) ABC Elite method, 
methyl green counterstain. (B, F, J, N) Nuclear fast blue counterstain. Arrows indicate 
p53 (I), β-Gal (J), p16 (K), and p27 (H, L) positive cells. Scale bar: 50 μm (A, C, D, E, G, 
H, I, K, L, M, O, P), 100 μm (B, F, J, N). *P<0.05, **P<0.01, ***P<0.001. All error bars 
denote SD. 
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Figure 5.4 Mme-/-PtenPE-/- prostate shows cytoplamic overexpression of p21. (A-D) 
p21 immunostaining of prostate from WT (A), Mme-/- (B), PtenPE-/- (C) and Mme-/-PtenPE-
/- (D) mice by 18 months of age (n=3). The arrow indicates p21 positive cells (D). (A-D) 
ABC Elite method, methyl green counterstain. Scale bar: 50 μm (A-D). 
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Figure 5.5 GRP has no effect on regulating senescence of CD44-positive DU145 
human prostate cancer propagating cells. β-Gal staining of CD44-positive DU145 
human prostate cancer propagating cells with GRP and/or GRPR antagonist [Tyr4, D-
Phe12]-Bombesin. All error bars denote SD. 
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Abstract 
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer deaths among 
women in the United States, but its pathogenesis is poorly understood. Some epithelial 
cancers are known to occur in transitional zones between two types of epithelium, 
whereas others have been shown to originate in epithelial tissue stem cells. The stem 
cell niche of the ovarian surface epithelium (OSE), which is ruptured and regenerates 
during ovulation, has not yet been defined unequivocally. Here we identify the hilum 
region of the mouse ovary, the transitional (or junction) area between the OSE, 
mesothelium and tubal (oviductal) epithelium, as a previously unrecognized stem cell 
niche of the OSE. We find that cells of the hilum OSE are cycling slowly and express 
stem and/or progenitor cell markers ALDH1, LGR5, LEF1, CD133 and CK6B. These 
cells display long-term stem cell properties ex vivo and in vivo, as shown by our serial 
sphere generation and long-term lineage-tracing assays. Importantly, the hilum cells 
show increased transformation potential after inactivation of tumour suppressor genes 
Trp53 and Rb1, whose pathways are altered frequently in the most aggressive and 
common type of human EOC, high-grade serous adenocarcinoma. Our study supports 
experimentally the idea that susceptibility of transitional zones to malignant 
transformation may be explained by the presence of stem cell niches in those areas. 
Identification of a stem cell niche for the OSE may have important implications for 
understanding EOC pathogenesis. 
  
209 
 
 
 
 
LOSS OF SURVIVIN IN THE PROSTATE EPITHELIUM IMPEDES CARCINOGENESIS 
IN A MOUSE MODEL OF PROSTATE ADENOCARCINOMA 
 
Helty Adisetiyo, Mengmeng Liang, Chun-Peng Liao, Ari Aycock-Williams, Michael B. 
Cohen, Shili Xu, Nouri Neamati, Edward M. Conway, Chieh-Yang Cheng, Alexander Yu. 
Nikitin, Pradip Roy-Burman, (2013). PLoS One. 8 (7): e69484. PMID: 23936028. 
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Abstract 
The inhibitor of apoptosis protein survivin is expressed in most cancers. Using the 
conditional PTEN deletion mouse model, we previously reported that survivin levels 
increase with prostate tumor growth. Here we evaluated the functional role of survivin in 
prostate tumor growth. First, we demonstrated that mice lacking the survivin gene in 
prostate epithelium were fertile and had normal prostate growth and development. We 
then serially, from about 10–56 weeks of age, evaluated histopathologic changes in the 
prostate of mice with PTEN deletion combined with survivin mono- or bi-allelic gene 
deletion. While within this time period most of the animals with wild-type or monoallelic 
survivin deletion developed adenocarcinomas, the most severe lesions in the biallelic 
survivin deleted mice were high-grade prostatic intra-epithelial neoplasia with distinct 
histopathology. Many atypical cells contained large hypertrophic cytoplasm and 
desmoplastic reaction in the prostatic intra-epithelial neoplasia lesions of this group was 
minimal until the late ages. A reduced proliferation index as well as apoptotic and 
senescent cells were detected in the lesions of mice with 
compound PTEN/survivin deficiency throughout the time points 
examined. Survivin deletion was also associated with reduced tumor expression of 
another inhibitor of apoptosis member, the X-linked inhibitor of apoptosis. Our findings 
suggest that survivin participates in the progression of prostatic intraepithelial neoplasia 
to adenocarcinoma, and that survivin interference at the prostatic intraepithelial 
neoplasia stages may be a potential therapeutic strategy to halt or delay further 
progression. 
 
